Excess Readmission vs Excess Penalties: Maximum Readmission Penalties as a Function of Socioeconomics and Geography

Article Type
Changed
Tue, 09/05/2017 - 14:20

INTRODUCTION

According to Centers for Medicare & Medicaid Services (CMS), approximately 1 in 5 patients discharged from a hospital will be readmitted within 30 days.1 The Hospital Readmission Reduction Program (HRRP) is designed to reduce readmission by withholding up to 3% of all Medicare reimbursement from hospitals with “excess” readmissions; however, absent from the HRRP is adjustment for socioeconomic status (SES), which CMS holds may undermine incentives to reduce health disparities and institutionalize lower standards for hospitals serving disadvantaged populations.2

Lack of SES adjustment has been criticized by those who point to evidence highlighting postdischarge environment and patient SES as drivers of readmission and suggest hospitals that serve low SES individuals will bear a disproportionate share of penalties.3-6 Single-center,3,7,8 regional,9,10 and nationwide6,11 studies highlight census tract level socioeconomic variables as predictive of readmission. Single-center studies, robust in controlling for confounders, including staffing, training, electronic medical record utilization, and transitional care processes, do not allow comparisons between hospitals, limiting utility in HRRP evaluation. Multicenter cohorts, on the other hand, allow for comparisons between high and low penalty hospitals, pioneered by Joynt et al12 after the first round of HRRP penalties; yet this technique may not account for confounding caused by extensive demographic, socioeconomic, and hospital characteristic heterogeneity inherent in a national cohort. Analysis of the 2015 HRRP penalty data by Sjoding et al.6 revealed higher chronic obstructive pulmonary disease (COPD) readmission rates in the Mid-Atlantic, Midwest, and South relative to other regions; however, the magnitude of small-area variation and its relationship to population SES have yet to be characterized.

Therefore, we conducted a matched case-control design, whereby each maximum penalty hospital was matched to a nonpenalty hospital using key hospital characteristics. We then used geographic matching to isolate SES factors predictive of readmission within specific geographies in an effort to control for regional population differences. We hypothesized that, among both matched and localized hospital pairs, the disparities in population SES are the most significant predictors of a maximum penalty. Now in the 3rd year of the HRRP with approximately 75% of eligible hospitals to receive penalties worth an estimated $428 million in the 2015 fiscal year,13 we offer a small-area analysis of bipolar extremes to inform debate surrounding the HRRP with evidence regarding the causes and implications of readmission penalties.

METHODS

Study Design and Sample

This study relies on a case-control design. The cases were defined as US hospitals to receive the maximum 3% HRRP penalty in fiscal year 2015. Controls were drawn from the cohort of hospitals potentially subject to HRRP penalties that received no readmission penalty in the 2015 fiscal year with at least 1 admission for any of the following conditions: heart failure (HF), acute myocardial infarction (AMI), pneumonia (PN), total knee arthroscopy or total hip arthroscopy (THA/TKA), or chronic obstructive pulmonary disease (COPD).

Data Sources

Penalty data were drawn from the 2015 master penalty file,14 which were accessed via CMS.gov. County-level demographic and socioeconomic data were gathered from the 2015 American Community Survey (ACS), a subsidiary of the US Census. Data on hospital characteristics, capacity, and regional healthcare utilization were drawn from 2012 Dartmouth Atlas,15 2012 Medicare Cost Report,16 2012 American Hospital Association Hospital Statistics Database, and 2014 Hospital Care Downloadable Database.

Hospital-level CMS data were linked to the master 2015 penalty file. Dartmouth Atlas data were subsequently linked to the file using the Dartmouth Atlas “Hospital to HSA/HRR Crosswalk” file (accessed via DartmouthAtlas.org.) Each hospital was assigned the profile of the hospital service area (HSA) and hospital referral region (HRR) in which it is located. An HSA is a geographic region defined by hospital admissions; the majority, but not entirety, of residents of a given HSA utilize the corresponding hospital. Similarly, an HRR is a geographic region defined by referrals for major cardiovascular and neurosurgery procedures. County-level socioeconomic data were linked to the dataset by county name; thus, hospital socioeconomic profiles are based on the county in which they are located.

 

 

Case-Control Matching

In the primary analysis, coarsened exact matching (CEM) matched controls to cases by potential confounding hospital characteristics, including the following: ownership, number of beds, case mix index (measure of acuity), ambulatory care visit rates within 14 days of discharge, and total number of penalty-eligible cases, including HF, AMI, COPD, PN, and THA/TKA.

In the secondary analysis, hospitals were geocoded by zip code. Geographic Information Systems mapping software (ESRI ArcGIS, Redlands, CA) relied upon Euclidean allocation distance spatial analysis17,18 to match each maximum-penalty hospital to the nearest nonpenalty hospital. Each case was matched to a distinct control; duplicate controls were replaced with the nearest unmatched no-penalty hospital.

Statistical Analysis

Univariate analyses utilized unpaired Student t tests (primary analysis) and paired Student t tests (secondary analysis). The CEM algorithm matches by strata rather than pairs, precluding paired Student t tests in the primary analysis. Statistical analyses were conducted using STATA (StataCorp. 2013. Stata Statistical Software: Release 13. College Station, TX).

RESULTS

Maximum Penalty and Nonpenalty Hospital Matching

Of 3383 hospitals eligible for the HRRP, 39 received the maximum penalty and 770 received no penalty. Thirty-eight control hospitals were identified using CEM algorithm; 1 maximum-penalty hospital could not be matched and was excluded from primary analy

sis.

Hospital Characteristics

Case and control profiles are presented in Table 1. Cases and controls were matched by characteristics which may impact readmission rates (Table 1). CEM yielded cohorts similar across a spectrum of metrics, and identical in terms of matching criteria including ownership, beds (quartile), case mix index (above median), ambulatory care visit within 14 days of discharge (above median), and total number of penalty-eligible cases (above median). Relative to no-penalty hospitals, maximum-penalty hospitals were more likely rural (n = 9 vs n = 2, P = 0.022) and have a less profitable operating margin (0.1% vs 6.9%), and location within HSAs with higher age, sex, and race adjusted hospital-wide mortality rate (5.3% vs 4.9%, P = 0.009) and higher rates of discharge for ambulatory care sensitive conditions (108 vs 63 discharges per 1000 Medicare enrollees).

Demographic and Socioeconomic Characteristics

As presented in Table 2, cases a

nd controls are in counties with similar age, sex, and ethnicity profiles. Per capita income was similar between cohorts. However, relative to non-penalty hospitals, maximum-penalty hospitals are in counties with a larger percentage of individuals below the poverty line (19.1% vs 15.5%, P = 0.015), a larger percentage of individuals qualifying for food stamp benefits (16.8% vs 12.7%, P = 0.005), lower rates of labor force participation (57.0% vs 63.6%), and lower rates of high school graduation (82.2% vs 87.5%, P = 0.0011).

Secondary Analysis: Geographical Matching

Secondary analysis matched each maximum-penalty hospital to the nearest no-penalty hospital using a global information system vector analysis algorithm. As shown in the Figure, median distance between the case and the control was 42.5 miles (interquartile range: 25th percentile, 15.4 miles; 75th percentile, 98.4 miles). Seventeen pairs (44%) were in the same HRR, 6 of which were in the same HSA. Seven pairs (18%) were within the same county

.

Secondary Analysis: Economic and Demographic Profiles of Geographically Matched Pairs

Demographic and socioeconomic profiles are presented in Table 3. The cases and controls are in counties with similar age, sex, and ethnicity distributions. Relative to no-penalty hospitals, maximum-penalty hospitals are in counties with lower socioeconomic profiles, including increased rates of poverty (15.6% vs 19.2%, P = 0.007) and lower rates of high school (86.4% vs 82.1%, P = 0.005) or college graduation (22.3% vs 28.1%, P = 0.002). Seven pairs were in the same county; a sensitivity analysis excluding these hospitals revealed similarly lower SES profile in cases relative to controls (Supplementary Table 1).

DISCUSSION

Our analysis reveals that county-level socioeconomic profiles are predictors of maximum HRRP penalties. Specifically, after matching cases and controls on 5 hospital characteristics that may influence readmission, maximum-penalty hospitals were more likely to be in rural counties with higher rates of poverty and lower rates of education relative to no-penalty hospitals. We observed no difference between cases and controls with respect to age, sex, or ethnicity.

Our study complement

s that of Joynt et al.,12 whose analysis of the first year of the HRRP revealed safety net hospitals (top quartile in disproportionate share index) had nearly double the odds to receive a high penalty (highest 50% of penalties). We add to current literature with evidence that national and regional variation in readmission penalties is associated with income and education but not race and ethnicity. Others have shown racial and ethnic disparities in readmission rates even after adjusting for income and disease severity,19,20 leading the American Hospital Association to call for race and ethnicity adjustments of HRRP penalties.21 In contrast, we offer evidence that maximum penalties are not a function of race or ethnicity.

 

 

Maximum Penalties as a Function of Population Health

The Dartmouth Atlas of Healthcare measures health outcomes, which are regionally aggregated among local hospitals by either HSA or HRR; see Methods. Such small-area aggregation does not precisely reflect outcomes from a specific hospital, but rather it describes the health status of localities. Disparities in health outcomes exist between maximum-penalty and no-penalty HSAs. Complication rates were slightly higher in maximum penalty HSAs, consistent with studies highlighting complications as drivers of surgical readmissions.22,23 Moreover, hospital-wide mortality rates were higher in maximum-penalty areas relative to nonpenalty HSAs (5.3 vs 4.9, P = 0.009).

Using national data, Krumholz et al. found no correlation between rates of readmission and mortality for HF, AMI, and PN24, which is a phenomenon acknowledged by the Medicare Payment Advisory Commission (MedPac) in a 2013 report titled, “Refining the hospital readmission reduction program.”25 In large national studies, others have shown low SES to be associated with elevated readmission but not mortality.10,11 In contrast, we restricted our analysis to matched cohorts and are, to our knowledge, the first to present evidence of an association between readmission and hospital-wide mortality adjusted for age, sex, and ethnicity.

Our results suggest maximum readmission penalties are a function of population health and public health capacity. The rates of ambulatory care sensitive condition (ACSC) discharges were substantially higher in HSAs of maximum penalty hospitals relative to nonpenalty hospitals (108 vs 63 per 1000 Medicare enrollees, P < 0.001). ACSC discharges have been used to measure primary care quality for 30 years, with the assumption being that admission for chronic conditions, such as HF, can be prevented with effective primary care.26,27 Moreover, patients discharged from maximum-penalty hospitals were more likely to have an emergency room visit within 30 days of discharge (20.8% vs 18.4%, P < 0.001). Higher rates of ACSCs and postdischarge emergency department visits suggest outpatient resources in maximum-penalty service areas struggle to manage the disease burden of high-risk populations. Geography may be a contributor; maximum-penalty hospitals were more likely to be rural than no-penalty hospitals (24% vs 5%, P = 0.022).

Our findings suggest hospitals providing care to vulnerable communities (defined by low income, low education, and high rates of ambulatory sensitive discharges) are disproportionately penalized. McHugh et al. revealed high nurse staffing levels to be protective against readmission penalties28, yet high penalties to low-margin hospitals may encourage reduced rather than increased staff. It may be better policy to direct resources rather than penalties to underserved communities; our findings echo others with concern about disproportionate penalties to hospitals serving low SES patients.2,5,6,29

Secondary Analysis: Geographic Matching

Geographic matching paired each maximum-penalty hospital to the nearest no-penalty hospital in an attempt to control for unmeasured regional factors that may confound an association between socioeconomic profile and health outcomes. For example, cost of living 30, 31 and obesity 32,33 vary regionally. Our study was unequipped to assess potential regional confounders; we attempted to control for them with geographical matching.

Median distance between maximum-penalty and no-penalty hospitals was 42.5 miles. Seven pairs were located within the same county, thus both case and control were assigned the same socioeconomic profile. Despite close proximity and identical SES profile in 7 of 39 pairs, maximum-penalty hospitals were in counties with lower income and lower rates of education, strengthening the association between SES and maximum readmission penalties.

Implications and Future Directions

In response to criticism surrounding the HRRP, the National Quality Forum endorsed the general concept of SES adjustment for hospital quality measures.34 Subsequently, in a briefing dated March 24, 2015, MedPAC, a government agency which provides Medicare policy analysis to Congress, proposed an SES adjustment methodology of “dividing hospitals into peer groups based on their overall share of low-income Medicare patients, and then setting a benchmark readmissions target for each peer group”;35 in other words, lower standards for hospitals that serve low-income populations. MedPAC’s proposal will reduce penalties to “safety net” institutions, which is progress but not a solution. Although the HRRP appears to be working, according to the US Department of Health and Human Services, readmissions fell by 150,000 between January 2012 and February 2013,36 we are concerned neither the HRRP nor the MedPac revision proposal considers geographic and environmental components of readmission. The HRRP promotes national improvement in exchange for regional regression.

Fair quality measures are key to value-based reimbursement models; yet, implicit in penalties for excess readmissions is the assumed ability to calculate hospital performance targets. Benchmarks for safety, timely care, and patient satisfaction can be uniform; rates of central line infections should not be influenced by patient mix. However, 9 of the 39 maximum-penalty hospitals under the HRRP are in rural Kentucky; one could hypothesize many reasons why rural Kentucky is a hotbed for excess readmission, including the regional production of tobacco and bourbon.

The fundamental question raised by our study is whether poor performance on quality measures is a function of underperforming hospitals or a manifestation of underserved communities. Moving forward, we encourage data systems and study designs that focus research on geospatial distribution of population health within the context of social and behavioral health determinants.37 Small-area studies of factors that drive health outcomes will inform rational alignment of healthcare policies and resources (including penalties and incentives) with underlying population needs.

 

 

Strengths and Weaknesses

Matching is a strength of the study. Primary analysis matched case and controls by hospital characteristics, generating cohorts similar across a spectrum of hospital metrics. Therefore, variation in readmission rates was less likely confounded by hospital characteristics. The secondary analysis was matched by geography in an effort to adjust for unmeasured, regional factors, including obesity and cost of living that may confound an association between SES and health outcomes. Geographic matching adds strength to our assertion that SES drives distinction between maximum-penalty hospitals and nonpenalty hospitals.

One weakness was the regional unit of analysis for socioeconomic and Dartmouth Atlas data, which is not a precise profile of the corresponding hospital. Each hospital was assigned a county-level socioeconomic profile. A more robust methodology would analyze patient-level SES data; this was impractical given a cohort of 78 hospitals. Regional health outcomes data limits analysis of readmission penalties as a function of hospital quality. Instead, regional data facilitated associations between readmission and population health, consistent with the aim of our study.

We analyzed 116 of 3668 hospitals eligible for the HRRP (3.2%), limiting the generalizability of our findings. Eighty-four percent of hospitals in the primary analysis have below the median number of beds, and none of them are teaching hospitals. Our analysis, restricted to maximum-penalty and no-penalty cohorts, does not address potential association between submaximal readmission penalties and socioeconomics.

Both matching techniques potentially controlled for similar SES factors and skewed our results towards null, especially in terms of race and ethnicity. Geographic matching generated 7 pairs (18%) within in the same county; both maximum-penalty and no-penalty hospitals were assigned the same socioeconomic profile, as well as 6 pairs (15%) within the same HSA, and both cases and controls had identical Dartmouth Atlas health outcomes profiles. We retained these pairs in our analysis to avoid artificially inflating SES and population health differences between cohorts.

Thirty-nine hospitals received a maximum penalty in the 3rd year of the HRRP. Relative to geographically matched no-penalty hospitals, maximum-penalty hospitals were more likely to be rural and located in counties with less educational attainment, more poverty and more poorly controlled chronic disease. In contrast to nationwide studies, a matched analysis plan revealed no difference between the cohorts in terms of race and ethnicity and provided evidence that maximum penalty hospitals had higher rates of age-, sex-, and race-adjusted hospital-wide mortality.

Our results highlight potential consequences of nationally derived benchmarks for phenomena underpinned by social, behavioral, and environmental factors and raise the question of whether maximum HRRP penalties are a consequence of underperforming hospitals or a manifestation of underserved communities. We are encouraged by MedPAC’s proposal to stratify HRRP by SES, yet recommend further small-area geographic analyses to better align quality measures, penalties, and incentives with resources and needs of distinct populations.

Acknowledgments

The authors thank William Hisey, who laid the foundation for the analysis and without whom the project would not have been possible.

DISCLOSURE

The authors certify that none of the material in this manuscript has been previously published and that none of this material is currently under consideration for publication elsewhere. This project received no funding. None of the authors on this manuscript have any commercial relationships to disclose in relation to this manuscript. All authors have reviewed and approved this manuscript and have contributed significantly to the design, conduct, and/or analysis of the research. No authors have any financial interests to disclose. No authors have any potential conflicts of interest to disclose. No authors have financial or personal relationships with any of the subject material presented in the manuscript.

Files
References

1. Jencks SF, Williams MV, Coleman EA. Rehospitalizations among patients in the Medicare fee-for-service program. N Engl J Med. 2009;360(14):1418-1428. PubMed
2. Axon RN, Williams MV. Hospital readmission as an accountability measure. JAMA. 2011;305(5):504-505. PubMed
3. Amarasingham R, Moore BJ, Tabak YP, et al. An automated model to identify heart failure patients at risk for 30-day readmission or death using electronic medical record data. Med Care. 2010;48(11):981-988. PubMed
4. Calvillo-King L, Arnold D, Eubank KJ, et al. Impact of social factors on risk of readmission or mortality in pneumonia and heart failure: systematic review. J Gen Intern Med. 2013;28(2):269-282. PubMed
5. Feemster LC, Au DH. Penalizing hospitals for chronic obstructive pulmonary disease readmissions. Am J Respir Crit Care Med. 2014;189(6):634-639. PubMed
6. Sjoding MW, Cooke CR. Readmission penalties for chronic obstructive pulmonary disease will further stress hospitals caring for vulnerable patient populations. Am J Respir Crit Care Med. 2014;190(9):1072-1074. PubMed
7. Hu J, Gonsahn MD, Nerenz DR. Socioeconomic status and readmissions: evidence from an urban teaching hospital. Health Aff (Project Hope). 2014;33(5):778-785. PubMed
8. Mather JF, Fortunato GJ, Ash JL, et al. Prediction of pneumonia 30-day readmissions: a single-center attempt to increase model performance. Respir Care. 2014;59(2):199-208. PubMed
9. Philbin EF, Dec GW, Jenkins PL, et al. Socioeconomic status as an independent risk factor for hospital readmission for heart failure. Am J Cardiol. 2001;87(12):1367-1371. PubMed
10. Bikdeli B, Wayda B, Bao H, et al. Place of residence and outcomes of patients with heart failure: analysis from the telemonitoring to improve heart failure outcomes trial. Circ Cardiovasc Qual Outcomes. 2014;7(5):749-756. PubMed
11. Lindenauer PK, Lagu T, Rothberg MB, et al. Income inequality and 30 day outcomes after acute myocardial infarction, heart failure, and pneumonia: retrospective cohort study. BMJ. 2013;346:f521. PubMed
12. Joynt KE, Jha AK. Characteristics of hospitals receiving penalties under the Hospital Readmissions Reduction Program. JAMA. 2013;309(4):342-343. PubMed
13. Medicare Fines 2,610 Hospitals in Third Round of Readmission Penalties. Kaiser Health News. October 2, 2014, 2014. 
14. Centers for Medicare and Medicaid Services. Fiscal Year 2015 IPPS Hospital Readmission Reduction Program Supplemental Data File. https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/FY2015-IPPS-Final-Rule-Home-Page.html Last accessed July 10, 2017.
15. Atlas D. “Hospital and Post-Acute Care” and “Selected Hospital and Physician Capacity Measures”. In: Practice TDIfHPaC, ed. http://www.dartmouthatlas.org/tools/downloads.aspx. Last Accessed July 10, 2017.
16. Services CfMaM. Cost Reports by Year: 2014. https://www.cms.gov/Research-Statistics-Data-and-Systems/Downloadable-Public-Use-Files/Cost-Reports/Cost-Reports-by-Fiscal-Year.html. Last Accessed July 10, 2017.
17. Walsh SJ, Page PH, Gesler WM. Normative models and healthcare planning: network-based simulations within a geographic information system environment. Health Serv Res. 1997;32(2):243-260. PubMed
18. Emch M, Ali M, Root ED, et al. Spatial and environmental connectivity analysis in a cholera vaccine trial. Soc Sci Med. 2009;68(4):631-637. PubMed
19. Joynt KE, Orav EJ, Jha AK. Thirty-day readmission rates for Medicare beneficiaries by race and site of care. JAMA. 2011;305(7):675-681. PubMed
20. Vivo RP, Krim SR, Liang L, et al. Short- and long-term rehospitalization and mortality for heart failure in 4 racial/ethnic populations. J Am Heart Assoc. 2014;3(5):e001134. PubMed
21. Detailed comments on the Inpatient Prospective Payment System Proposed Rule for FY 2013 [press release]. http://www.aha.org/advocacy-issues/letter/2012/120619-cl-ipps.pdf. June 19, 2012. Last accessed July 10, 2017.
22. Dailey EA, Cizik A, Kasten J, et al.Risk factors for readmission of orthopaedic surgical patients. J Bone Joint Surg Am. 2013;95(11):1012-1019. PubMed
23. Tsai TC, Orav EJ, Joynt KE. Disparities in surgical 30-day readmission rates for Medicare beneficiaries by race and site of care. Ann Surg. 2014;259(6):1086-1090. PubMed
24. Krumholz HM, Lin Z, Keenan PS, et al. Relationship between hospital readmission and mortality rates for patients hospitalized with acute myocardial infarction, heart failure, or pneumonia. JAMA. 2013;309(6):587-593. PubMed
25. Committee MPA. Chapter 4: Refining the hospital readmissions reduction program. Report to the Congress: Medicare and the Health Care Delivery System. http://www.medpac.gov/docs/default-source/reports/jun13_ch04.pdf?sfvrsn=0 Last accessed July 10, 2017.
26. Rutstein DD, Berenberg W, Chalmers TC, Child CG, 3rd, Fishman AP, Perrin EB. Measuring the quality of medical care. A clinical method. N Engl J Med. 1976;294(11):582-588. PubMed
27. Purdy S, Griffin T, Salisbury C, Sharp D. Ambulatory care sensitive conditions: terminology and disease coding need to be more specific to aid policy makers and clinicians. Public Health. 2009;123(2):169-173. PubMed
28. McHugh MD, Berez J, Small DS. Hospitals with higher nurse staffing had lower odds of readmissions penalties than hospitals with lower staffing. Health Aff (Project Hope). 2013;32(10):1740-1747. PubMed
29. Joynt KE, Jha AK. Thirty-day readmissions--truth and consequences. N Engl J Med. 2012;366(15):1366-1369. PubMed
30. Bethell C, Simpson L, Stumbo S, Carle AC, Gombojav N. National, state and local disparities in childhood obesity. Health Aff. 2010; 29(3): 347-356. PubMed
31. Singh GK, Kogan MD, van Dyck PC. Changes in state-specific childhood obesity and overweight prevalence in the United States from 2003 to 2007. Arch Pediatr Adolesc Med. 2010;164(7):598-607. PubMed
32. Aten BH, Figueroa EB, Martin TB. Regional Price Parities for States and Metropolitan Areas, 2006–2010. Survey of Current Business 2012;92:229-242. 

33. Dubay L, Wheaton L, Zedlewski S. Geographic variation in the cost of living: implications for poverty guidelines and program eligibility. Urban Institute. 2013. https://aspe.hhs.gov/system/files/pdf/174186/UrbanGeographicVariation.pdf. Accessed on February 22, 2017. Last accessed July 10, 2017

34. National Quality Forum. Risk Adjustment for Socioeconomic Status or Other Sociodemographic Factors: a Technical Report. 2014. http://www.qualityforum. org/Publications/2014/08/Risk_Adjustment_for_Socioeconomic_Status_or_Other_Sociodemographic_Factors.aspx. Accessed July 10, 2017.

36. Services CfMaM. New HHS Data Shows Major Strides Made in Patient Safety, Leading to Improved Care and Savings. In: Services USDoHaH, ed. https://innovation.cms.gov/Files/reports/patient-safety-results.pdf. Accessed July 10, 2017.

 

 

37. Harrison KM, Dean HD. Use of data systems to address social determinants of health: a need to do more. Public Health Reports (Washington, DC:1974). 2011;126 Suppl 3:1-5. PubMed

Article PDF
Issue
Journal of Hospital Medicine 12 (8)
Topics
Page Number
610-617
Sections
Files
Files
Article PDF
Article PDF

INTRODUCTION

According to Centers for Medicare & Medicaid Services (CMS), approximately 1 in 5 patients discharged from a hospital will be readmitted within 30 days.1 The Hospital Readmission Reduction Program (HRRP) is designed to reduce readmission by withholding up to 3% of all Medicare reimbursement from hospitals with “excess” readmissions; however, absent from the HRRP is adjustment for socioeconomic status (SES), which CMS holds may undermine incentives to reduce health disparities and institutionalize lower standards for hospitals serving disadvantaged populations.2

Lack of SES adjustment has been criticized by those who point to evidence highlighting postdischarge environment and patient SES as drivers of readmission and suggest hospitals that serve low SES individuals will bear a disproportionate share of penalties.3-6 Single-center,3,7,8 regional,9,10 and nationwide6,11 studies highlight census tract level socioeconomic variables as predictive of readmission. Single-center studies, robust in controlling for confounders, including staffing, training, electronic medical record utilization, and transitional care processes, do not allow comparisons between hospitals, limiting utility in HRRP evaluation. Multicenter cohorts, on the other hand, allow for comparisons between high and low penalty hospitals, pioneered by Joynt et al12 after the first round of HRRP penalties; yet this technique may not account for confounding caused by extensive demographic, socioeconomic, and hospital characteristic heterogeneity inherent in a national cohort. Analysis of the 2015 HRRP penalty data by Sjoding et al.6 revealed higher chronic obstructive pulmonary disease (COPD) readmission rates in the Mid-Atlantic, Midwest, and South relative to other regions; however, the magnitude of small-area variation and its relationship to population SES have yet to be characterized.

Therefore, we conducted a matched case-control design, whereby each maximum penalty hospital was matched to a nonpenalty hospital using key hospital characteristics. We then used geographic matching to isolate SES factors predictive of readmission within specific geographies in an effort to control for regional population differences. We hypothesized that, among both matched and localized hospital pairs, the disparities in population SES are the most significant predictors of a maximum penalty. Now in the 3rd year of the HRRP with approximately 75% of eligible hospitals to receive penalties worth an estimated $428 million in the 2015 fiscal year,13 we offer a small-area analysis of bipolar extremes to inform debate surrounding the HRRP with evidence regarding the causes and implications of readmission penalties.

METHODS

Study Design and Sample

This study relies on a case-control design. The cases were defined as US hospitals to receive the maximum 3% HRRP penalty in fiscal year 2015. Controls were drawn from the cohort of hospitals potentially subject to HRRP penalties that received no readmission penalty in the 2015 fiscal year with at least 1 admission for any of the following conditions: heart failure (HF), acute myocardial infarction (AMI), pneumonia (PN), total knee arthroscopy or total hip arthroscopy (THA/TKA), or chronic obstructive pulmonary disease (COPD).

Data Sources

Penalty data were drawn from the 2015 master penalty file,14 which were accessed via CMS.gov. County-level demographic and socioeconomic data were gathered from the 2015 American Community Survey (ACS), a subsidiary of the US Census. Data on hospital characteristics, capacity, and regional healthcare utilization were drawn from 2012 Dartmouth Atlas,15 2012 Medicare Cost Report,16 2012 American Hospital Association Hospital Statistics Database, and 2014 Hospital Care Downloadable Database.

Hospital-level CMS data were linked to the master 2015 penalty file. Dartmouth Atlas data were subsequently linked to the file using the Dartmouth Atlas “Hospital to HSA/HRR Crosswalk” file (accessed via DartmouthAtlas.org.) Each hospital was assigned the profile of the hospital service area (HSA) and hospital referral region (HRR) in which it is located. An HSA is a geographic region defined by hospital admissions; the majority, but not entirety, of residents of a given HSA utilize the corresponding hospital. Similarly, an HRR is a geographic region defined by referrals for major cardiovascular and neurosurgery procedures. County-level socioeconomic data were linked to the dataset by county name; thus, hospital socioeconomic profiles are based on the county in which they are located.

 

 

Case-Control Matching

In the primary analysis, coarsened exact matching (CEM) matched controls to cases by potential confounding hospital characteristics, including the following: ownership, number of beds, case mix index (measure of acuity), ambulatory care visit rates within 14 days of discharge, and total number of penalty-eligible cases, including HF, AMI, COPD, PN, and THA/TKA.

In the secondary analysis, hospitals were geocoded by zip code. Geographic Information Systems mapping software (ESRI ArcGIS, Redlands, CA) relied upon Euclidean allocation distance spatial analysis17,18 to match each maximum-penalty hospital to the nearest nonpenalty hospital. Each case was matched to a distinct control; duplicate controls were replaced with the nearest unmatched no-penalty hospital.

Statistical Analysis

Univariate analyses utilized unpaired Student t tests (primary analysis) and paired Student t tests (secondary analysis). The CEM algorithm matches by strata rather than pairs, precluding paired Student t tests in the primary analysis. Statistical analyses were conducted using STATA (StataCorp. 2013. Stata Statistical Software: Release 13. College Station, TX).

RESULTS

Maximum Penalty and Nonpenalty Hospital Matching

Of 3383 hospitals eligible for the HRRP, 39 received the maximum penalty and 770 received no penalty. Thirty-eight control hospitals were identified using CEM algorithm; 1 maximum-penalty hospital could not be matched and was excluded from primary analy

sis.

Hospital Characteristics

Case and control profiles are presented in Table 1. Cases and controls were matched by characteristics which may impact readmission rates (Table 1). CEM yielded cohorts similar across a spectrum of metrics, and identical in terms of matching criteria including ownership, beds (quartile), case mix index (above median), ambulatory care visit within 14 days of discharge (above median), and total number of penalty-eligible cases (above median). Relative to no-penalty hospitals, maximum-penalty hospitals were more likely rural (n = 9 vs n = 2, P = 0.022) and have a less profitable operating margin (0.1% vs 6.9%), and location within HSAs with higher age, sex, and race adjusted hospital-wide mortality rate (5.3% vs 4.9%, P = 0.009) and higher rates of discharge for ambulatory care sensitive conditions (108 vs 63 discharges per 1000 Medicare enrollees).

Demographic and Socioeconomic Characteristics

As presented in Table 2, cases a

nd controls are in counties with similar age, sex, and ethnicity profiles. Per capita income was similar between cohorts. However, relative to non-penalty hospitals, maximum-penalty hospitals are in counties with a larger percentage of individuals below the poverty line (19.1% vs 15.5%, P = 0.015), a larger percentage of individuals qualifying for food stamp benefits (16.8% vs 12.7%, P = 0.005), lower rates of labor force participation (57.0% vs 63.6%), and lower rates of high school graduation (82.2% vs 87.5%, P = 0.0011).

Secondary Analysis: Geographical Matching

Secondary analysis matched each maximum-penalty hospital to the nearest no-penalty hospital using a global information system vector analysis algorithm. As shown in the Figure, median distance between the case and the control was 42.5 miles (interquartile range: 25th percentile, 15.4 miles; 75th percentile, 98.4 miles). Seventeen pairs (44%) were in the same HRR, 6 of which were in the same HSA. Seven pairs (18%) were within the same county

.

Secondary Analysis: Economic and Demographic Profiles of Geographically Matched Pairs

Demographic and socioeconomic profiles are presented in Table 3. The cases and controls are in counties with similar age, sex, and ethnicity distributions. Relative to no-penalty hospitals, maximum-penalty hospitals are in counties with lower socioeconomic profiles, including increased rates of poverty (15.6% vs 19.2%, P = 0.007) and lower rates of high school (86.4% vs 82.1%, P = 0.005) or college graduation (22.3% vs 28.1%, P = 0.002). Seven pairs were in the same county; a sensitivity analysis excluding these hospitals revealed similarly lower SES profile in cases relative to controls (Supplementary Table 1).

DISCUSSION

Our analysis reveals that county-level socioeconomic profiles are predictors of maximum HRRP penalties. Specifically, after matching cases and controls on 5 hospital characteristics that may influence readmission, maximum-penalty hospitals were more likely to be in rural counties with higher rates of poverty and lower rates of education relative to no-penalty hospitals. We observed no difference between cases and controls with respect to age, sex, or ethnicity.

Our study complement

s that of Joynt et al.,12 whose analysis of the first year of the HRRP revealed safety net hospitals (top quartile in disproportionate share index) had nearly double the odds to receive a high penalty (highest 50% of penalties). We add to current literature with evidence that national and regional variation in readmission penalties is associated with income and education but not race and ethnicity. Others have shown racial and ethnic disparities in readmission rates even after adjusting for income and disease severity,19,20 leading the American Hospital Association to call for race and ethnicity adjustments of HRRP penalties.21 In contrast, we offer evidence that maximum penalties are not a function of race or ethnicity.

 

 

Maximum Penalties as a Function of Population Health

The Dartmouth Atlas of Healthcare measures health outcomes, which are regionally aggregated among local hospitals by either HSA or HRR; see Methods. Such small-area aggregation does not precisely reflect outcomes from a specific hospital, but rather it describes the health status of localities. Disparities in health outcomes exist between maximum-penalty and no-penalty HSAs. Complication rates were slightly higher in maximum penalty HSAs, consistent with studies highlighting complications as drivers of surgical readmissions.22,23 Moreover, hospital-wide mortality rates were higher in maximum-penalty areas relative to nonpenalty HSAs (5.3 vs 4.9, P = 0.009).

Using national data, Krumholz et al. found no correlation between rates of readmission and mortality for HF, AMI, and PN24, which is a phenomenon acknowledged by the Medicare Payment Advisory Commission (MedPac) in a 2013 report titled, “Refining the hospital readmission reduction program.”25 In large national studies, others have shown low SES to be associated with elevated readmission but not mortality.10,11 In contrast, we restricted our analysis to matched cohorts and are, to our knowledge, the first to present evidence of an association between readmission and hospital-wide mortality adjusted for age, sex, and ethnicity.

Our results suggest maximum readmission penalties are a function of population health and public health capacity. The rates of ambulatory care sensitive condition (ACSC) discharges were substantially higher in HSAs of maximum penalty hospitals relative to nonpenalty hospitals (108 vs 63 per 1000 Medicare enrollees, P < 0.001). ACSC discharges have been used to measure primary care quality for 30 years, with the assumption being that admission for chronic conditions, such as HF, can be prevented with effective primary care.26,27 Moreover, patients discharged from maximum-penalty hospitals were more likely to have an emergency room visit within 30 days of discharge (20.8% vs 18.4%, P < 0.001). Higher rates of ACSCs and postdischarge emergency department visits suggest outpatient resources in maximum-penalty service areas struggle to manage the disease burden of high-risk populations. Geography may be a contributor; maximum-penalty hospitals were more likely to be rural than no-penalty hospitals (24% vs 5%, P = 0.022).

Our findings suggest hospitals providing care to vulnerable communities (defined by low income, low education, and high rates of ambulatory sensitive discharges) are disproportionately penalized. McHugh et al. revealed high nurse staffing levels to be protective against readmission penalties28, yet high penalties to low-margin hospitals may encourage reduced rather than increased staff. It may be better policy to direct resources rather than penalties to underserved communities; our findings echo others with concern about disproportionate penalties to hospitals serving low SES patients.2,5,6,29

Secondary Analysis: Geographic Matching

Geographic matching paired each maximum-penalty hospital to the nearest no-penalty hospital in an attempt to control for unmeasured regional factors that may confound an association between socioeconomic profile and health outcomes. For example, cost of living 30, 31 and obesity 32,33 vary regionally. Our study was unequipped to assess potential regional confounders; we attempted to control for them with geographical matching.

Median distance between maximum-penalty and no-penalty hospitals was 42.5 miles. Seven pairs were located within the same county, thus both case and control were assigned the same socioeconomic profile. Despite close proximity and identical SES profile in 7 of 39 pairs, maximum-penalty hospitals were in counties with lower income and lower rates of education, strengthening the association between SES and maximum readmission penalties.

Implications and Future Directions

In response to criticism surrounding the HRRP, the National Quality Forum endorsed the general concept of SES adjustment for hospital quality measures.34 Subsequently, in a briefing dated March 24, 2015, MedPAC, a government agency which provides Medicare policy analysis to Congress, proposed an SES adjustment methodology of “dividing hospitals into peer groups based on their overall share of low-income Medicare patients, and then setting a benchmark readmissions target for each peer group”;35 in other words, lower standards for hospitals that serve low-income populations. MedPAC’s proposal will reduce penalties to “safety net” institutions, which is progress but not a solution. Although the HRRP appears to be working, according to the US Department of Health and Human Services, readmissions fell by 150,000 between January 2012 and February 2013,36 we are concerned neither the HRRP nor the MedPac revision proposal considers geographic and environmental components of readmission. The HRRP promotes national improvement in exchange for regional regression.

Fair quality measures are key to value-based reimbursement models; yet, implicit in penalties for excess readmissions is the assumed ability to calculate hospital performance targets. Benchmarks for safety, timely care, and patient satisfaction can be uniform; rates of central line infections should not be influenced by patient mix. However, 9 of the 39 maximum-penalty hospitals under the HRRP are in rural Kentucky; one could hypothesize many reasons why rural Kentucky is a hotbed for excess readmission, including the regional production of tobacco and bourbon.

The fundamental question raised by our study is whether poor performance on quality measures is a function of underperforming hospitals or a manifestation of underserved communities. Moving forward, we encourage data systems and study designs that focus research on geospatial distribution of population health within the context of social and behavioral health determinants.37 Small-area studies of factors that drive health outcomes will inform rational alignment of healthcare policies and resources (including penalties and incentives) with underlying population needs.

 

 

Strengths and Weaknesses

Matching is a strength of the study. Primary analysis matched case and controls by hospital characteristics, generating cohorts similar across a spectrum of hospital metrics. Therefore, variation in readmission rates was less likely confounded by hospital characteristics. The secondary analysis was matched by geography in an effort to adjust for unmeasured, regional factors, including obesity and cost of living that may confound an association between SES and health outcomes. Geographic matching adds strength to our assertion that SES drives distinction between maximum-penalty hospitals and nonpenalty hospitals.

One weakness was the regional unit of analysis for socioeconomic and Dartmouth Atlas data, which is not a precise profile of the corresponding hospital. Each hospital was assigned a county-level socioeconomic profile. A more robust methodology would analyze patient-level SES data; this was impractical given a cohort of 78 hospitals. Regional health outcomes data limits analysis of readmission penalties as a function of hospital quality. Instead, regional data facilitated associations between readmission and population health, consistent with the aim of our study.

We analyzed 116 of 3668 hospitals eligible for the HRRP (3.2%), limiting the generalizability of our findings. Eighty-four percent of hospitals in the primary analysis have below the median number of beds, and none of them are teaching hospitals. Our analysis, restricted to maximum-penalty and no-penalty cohorts, does not address potential association between submaximal readmission penalties and socioeconomics.

Both matching techniques potentially controlled for similar SES factors and skewed our results towards null, especially in terms of race and ethnicity. Geographic matching generated 7 pairs (18%) within in the same county; both maximum-penalty and no-penalty hospitals were assigned the same socioeconomic profile, as well as 6 pairs (15%) within the same HSA, and both cases and controls had identical Dartmouth Atlas health outcomes profiles. We retained these pairs in our analysis to avoid artificially inflating SES and population health differences between cohorts.

Thirty-nine hospitals received a maximum penalty in the 3rd year of the HRRP. Relative to geographically matched no-penalty hospitals, maximum-penalty hospitals were more likely to be rural and located in counties with less educational attainment, more poverty and more poorly controlled chronic disease. In contrast to nationwide studies, a matched analysis plan revealed no difference between the cohorts in terms of race and ethnicity and provided evidence that maximum penalty hospitals had higher rates of age-, sex-, and race-adjusted hospital-wide mortality.

Our results highlight potential consequences of nationally derived benchmarks for phenomena underpinned by social, behavioral, and environmental factors and raise the question of whether maximum HRRP penalties are a consequence of underperforming hospitals or a manifestation of underserved communities. We are encouraged by MedPAC’s proposal to stratify HRRP by SES, yet recommend further small-area geographic analyses to better align quality measures, penalties, and incentives with resources and needs of distinct populations.

Acknowledgments

The authors thank William Hisey, who laid the foundation for the analysis and without whom the project would not have been possible.

DISCLOSURE

The authors certify that none of the material in this manuscript has been previously published and that none of this material is currently under consideration for publication elsewhere. This project received no funding. None of the authors on this manuscript have any commercial relationships to disclose in relation to this manuscript. All authors have reviewed and approved this manuscript and have contributed significantly to the design, conduct, and/or analysis of the research. No authors have any financial interests to disclose. No authors have any potential conflicts of interest to disclose. No authors have financial or personal relationships with any of the subject material presented in the manuscript.

INTRODUCTION

According to Centers for Medicare & Medicaid Services (CMS), approximately 1 in 5 patients discharged from a hospital will be readmitted within 30 days.1 The Hospital Readmission Reduction Program (HRRP) is designed to reduce readmission by withholding up to 3% of all Medicare reimbursement from hospitals with “excess” readmissions; however, absent from the HRRP is adjustment for socioeconomic status (SES), which CMS holds may undermine incentives to reduce health disparities and institutionalize lower standards for hospitals serving disadvantaged populations.2

Lack of SES adjustment has been criticized by those who point to evidence highlighting postdischarge environment and patient SES as drivers of readmission and suggest hospitals that serve low SES individuals will bear a disproportionate share of penalties.3-6 Single-center,3,7,8 regional,9,10 and nationwide6,11 studies highlight census tract level socioeconomic variables as predictive of readmission. Single-center studies, robust in controlling for confounders, including staffing, training, electronic medical record utilization, and transitional care processes, do not allow comparisons between hospitals, limiting utility in HRRP evaluation. Multicenter cohorts, on the other hand, allow for comparisons between high and low penalty hospitals, pioneered by Joynt et al12 after the first round of HRRP penalties; yet this technique may not account for confounding caused by extensive demographic, socioeconomic, and hospital characteristic heterogeneity inherent in a national cohort. Analysis of the 2015 HRRP penalty data by Sjoding et al.6 revealed higher chronic obstructive pulmonary disease (COPD) readmission rates in the Mid-Atlantic, Midwest, and South relative to other regions; however, the magnitude of small-area variation and its relationship to population SES have yet to be characterized.

Therefore, we conducted a matched case-control design, whereby each maximum penalty hospital was matched to a nonpenalty hospital using key hospital characteristics. We then used geographic matching to isolate SES factors predictive of readmission within specific geographies in an effort to control for regional population differences. We hypothesized that, among both matched and localized hospital pairs, the disparities in population SES are the most significant predictors of a maximum penalty. Now in the 3rd year of the HRRP with approximately 75% of eligible hospitals to receive penalties worth an estimated $428 million in the 2015 fiscal year,13 we offer a small-area analysis of bipolar extremes to inform debate surrounding the HRRP with evidence regarding the causes and implications of readmission penalties.

METHODS

Study Design and Sample

This study relies on a case-control design. The cases were defined as US hospitals to receive the maximum 3% HRRP penalty in fiscal year 2015. Controls were drawn from the cohort of hospitals potentially subject to HRRP penalties that received no readmission penalty in the 2015 fiscal year with at least 1 admission for any of the following conditions: heart failure (HF), acute myocardial infarction (AMI), pneumonia (PN), total knee arthroscopy or total hip arthroscopy (THA/TKA), or chronic obstructive pulmonary disease (COPD).

Data Sources

Penalty data were drawn from the 2015 master penalty file,14 which were accessed via CMS.gov. County-level demographic and socioeconomic data were gathered from the 2015 American Community Survey (ACS), a subsidiary of the US Census. Data on hospital characteristics, capacity, and regional healthcare utilization were drawn from 2012 Dartmouth Atlas,15 2012 Medicare Cost Report,16 2012 American Hospital Association Hospital Statistics Database, and 2014 Hospital Care Downloadable Database.

Hospital-level CMS data were linked to the master 2015 penalty file. Dartmouth Atlas data were subsequently linked to the file using the Dartmouth Atlas “Hospital to HSA/HRR Crosswalk” file (accessed via DartmouthAtlas.org.) Each hospital was assigned the profile of the hospital service area (HSA) and hospital referral region (HRR) in which it is located. An HSA is a geographic region defined by hospital admissions; the majority, but not entirety, of residents of a given HSA utilize the corresponding hospital. Similarly, an HRR is a geographic region defined by referrals for major cardiovascular and neurosurgery procedures. County-level socioeconomic data were linked to the dataset by county name; thus, hospital socioeconomic profiles are based on the county in which they are located.

 

 

Case-Control Matching

In the primary analysis, coarsened exact matching (CEM) matched controls to cases by potential confounding hospital characteristics, including the following: ownership, number of beds, case mix index (measure of acuity), ambulatory care visit rates within 14 days of discharge, and total number of penalty-eligible cases, including HF, AMI, COPD, PN, and THA/TKA.

In the secondary analysis, hospitals were geocoded by zip code. Geographic Information Systems mapping software (ESRI ArcGIS, Redlands, CA) relied upon Euclidean allocation distance spatial analysis17,18 to match each maximum-penalty hospital to the nearest nonpenalty hospital. Each case was matched to a distinct control; duplicate controls were replaced with the nearest unmatched no-penalty hospital.

Statistical Analysis

Univariate analyses utilized unpaired Student t tests (primary analysis) and paired Student t tests (secondary analysis). The CEM algorithm matches by strata rather than pairs, precluding paired Student t tests in the primary analysis. Statistical analyses were conducted using STATA (StataCorp. 2013. Stata Statistical Software: Release 13. College Station, TX).

RESULTS

Maximum Penalty and Nonpenalty Hospital Matching

Of 3383 hospitals eligible for the HRRP, 39 received the maximum penalty and 770 received no penalty. Thirty-eight control hospitals were identified using CEM algorithm; 1 maximum-penalty hospital could not be matched and was excluded from primary analy

sis.

Hospital Characteristics

Case and control profiles are presented in Table 1. Cases and controls were matched by characteristics which may impact readmission rates (Table 1). CEM yielded cohorts similar across a spectrum of metrics, and identical in terms of matching criteria including ownership, beds (quartile), case mix index (above median), ambulatory care visit within 14 days of discharge (above median), and total number of penalty-eligible cases (above median). Relative to no-penalty hospitals, maximum-penalty hospitals were more likely rural (n = 9 vs n = 2, P = 0.022) and have a less profitable operating margin (0.1% vs 6.9%), and location within HSAs with higher age, sex, and race adjusted hospital-wide mortality rate (5.3% vs 4.9%, P = 0.009) and higher rates of discharge for ambulatory care sensitive conditions (108 vs 63 discharges per 1000 Medicare enrollees).

Demographic and Socioeconomic Characteristics

As presented in Table 2, cases a

nd controls are in counties with similar age, sex, and ethnicity profiles. Per capita income was similar between cohorts. However, relative to non-penalty hospitals, maximum-penalty hospitals are in counties with a larger percentage of individuals below the poverty line (19.1% vs 15.5%, P = 0.015), a larger percentage of individuals qualifying for food stamp benefits (16.8% vs 12.7%, P = 0.005), lower rates of labor force participation (57.0% vs 63.6%), and lower rates of high school graduation (82.2% vs 87.5%, P = 0.0011).

Secondary Analysis: Geographical Matching

Secondary analysis matched each maximum-penalty hospital to the nearest no-penalty hospital using a global information system vector analysis algorithm. As shown in the Figure, median distance between the case and the control was 42.5 miles (interquartile range: 25th percentile, 15.4 miles; 75th percentile, 98.4 miles). Seventeen pairs (44%) were in the same HRR, 6 of which were in the same HSA. Seven pairs (18%) were within the same county

.

Secondary Analysis: Economic and Demographic Profiles of Geographically Matched Pairs

Demographic and socioeconomic profiles are presented in Table 3. The cases and controls are in counties with similar age, sex, and ethnicity distributions. Relative to no-penalty hospitals, maximum-penalty hospitals are in counties with lower socioeconomic profiles, including increased rates of poverty (15.6% vs 19.2%, P = 0.007) and lower rates of high school (86.4% vs 82.1%, P = 0.005) or college graduation (22.3% vs 28.1%, P = 0.002). Seven pairs were in the same county; a sensitivity analysis excluding these hospitals revealed similarly lower SES profile in cases relative to controls (Supplementary Table 1).

DISCUSSION

Our analysis reveals that county-level socioeconomic profiles are predictors of maximum HRRP penalties. Specifically, after matching cases and controls on 5 hospital characteristics that may influence readmission, maximum-penalty hospitals were more likely to be in rural counties with higher rates of poverty and lower rates of education relative to no-penalty hospitals. We observed no difference between cases and controls with respect to age, sex, or ethnicity.

Our study complement

s that of Joynt et al.,12 whose analysis of the first year of the HRRP revealed safety net hospitals (top quartile in disproportionate share index) had nearly double the odds to receive a high penalty (highest 50% of penalties). We add to current literature with evidence that national and regional variation in readmission penalties is associated with income and education but not race and ethnicity. Others have shown racial and ethnic disparities in readmission rates even after adjusting for income and disease severity,19,20 leading the American Hospital Association to call for race and ethnicity adjustments of HRRP penalties.21 In contrast, we offer evidence that maximum penalties are not a function of race or ethnicity.

 

 

Maximum Penalties as a Function of Population Health

The Dartmouth Atlas of Healthcare measures health outcomes, which are regionally aggregated among local hospitals by either HSA or HRR; see Methods. Such small-area aggregation does not precisely reflect outcomes from a specific hospital, but rather it describes the health status of localities. Disparities in health outcomes exist between maximum-penalty and no-penalty HSAs. Complication rates were slightly higher in maximum penalty HSAs, consistent with studies highlighting complications as drivers of surgical readmissions.22,23 Moreover, hospital-wide mortality rates were higher in maximum-penalty areas relative to nonpenalty HSAs (5.3 vs 4.9, P = 0.009).

Using national data, Krumholz et al. found no correlation between rates of readmission and mortality for HF, AMI, and PN24, which is a phenomenon acknowledged by the Medicare Payment Advisory Commission (MedPac) in a 2013 report titled, “Refining the hospital readmission reduction program.”25 In large national studies, others have shown low SES to be associated with elevated readmission but not mortality.10,11 In contrast, we restricted our analysis to matched cohorts and are, to our knowledge, the first to present evidence of an association between readmission and hospital-wide mortality adjusted for age, sex, and ethnicity.

Our results suggest maximum readmission penalties are a function of population health and public health capacity. The rates of ambulatory care sensitive condition (ACSC) discharges were substantially higher in HSAs of maximum penalty hospitals relative to nonpenalty hospitals (108 vs 63 per 1000 Medicare enrollees, P < 0.001). ACSC discharges have been used to measure primary care quality for 30 years, with the assumption being that admission for chronic conditions, such as HF, can be prevented with effective primary care.26,27 Moreover, patients discharged from maximum-penalty hospitals were more likely to have an emergency room visit within 30 days of discharge (20.8% vs 18.4%, P < 0.001). Higher rates of ACSCs and postdischarge emergency department visits suggest outpatient resources in maximum-penalty service areas struggle to manage the disease burden of high-risk populations. Geography may be a contributor; maximum-penalty hospitals were more likely to be rural than no-penalty hospitals (24% vs 5%, P = 0.022).

Our findings suggest hospitals providing care to vulnerable communities (defined by low income, low education, and high rates of ambulatory sensitive discharges) are disproportionately penalized. McHugh et al. revealed high nurse staffing levels to be protective against readmission penalties28, yet high penalties to low-margin hospitals may encourage reduced rather than increased staff. It may be better policy to direct resources rather than penalties to underserved communities; our findings echo others with concern about disproportionate penalties to hospitals serving low SES patients.2,5,6,29

Secondary Analysis: Geographic Matching

Geographic matching paired each maximum-penalty hospital to the nearest no-penalty hospital in an attempt to control for unmeasured regional factors that may confound an association between socioeconomic profile and health outcomes. For example, cost of living 30, 31 and obesity 32,33 vary regionally. Our study was unequipped to assess potential regional confounders; we attempted to control for them with geographical matching.

Median distance between maximum-penalty and no-penalty hospitals was 42.5 miles. Seven pairs were located within the same county, thus both case and control were assigned the same socioeconomic profile. Despite close proximity and identical SES profile in 7 of 39 pairs, maximum-penalty hospitals were in counties with lower income and lower rates of education, strengthening the association between SES and maximum readmission penalties.

Implications and Future Directions

In response to criticism surrounding the HRRP, the National Quality Forum endorsed the general concept of SES adjustment for hospital quality measures.34 Subsequently, in a briefing dated March 24, 2015, MedPAC, a government agency which provides Medicare policy analysis to Congress, proposed an SES adjustment methodology of “dividing hospitals into peer groups based on their overall share of low-income Medicare patients, and then setting a benchmark readmissions target for each peer group”;35 in other words, lower standards for hospitals that serve low-income populations. MedPAC’s proposal will reduce penalties to “safety net” institutions, which is progress but not a solution. Although the HRRP appears to be working, according to the US Department of Health and Human Services, readmissions fell by 150,000 between January 2012 and February 2013,36 we are concerned neither the HRRP nor the MedPac revision proposal considers geographic and environmental components of readmission. The HRRP promotes national improvement in exchange for regional regression.

Fair quality measures are key to value-based reimbursement models; yet, implicit in penalties for excess readmissions is the assumed ability to calculate hospital performance targets. Benchmarks for safety, timely care, and patient satisfaction can be uniform; rates of central line infections should not be influenced by patient mix. However, 9 of the 39 maximum-penalty hospitals under the HRRP are in rural Kentucky; one could hypothesize many reasons why rural Kentucky is a hotbed for excess readmission, including the regional production of tobacco and bourbon.

The fundamental question raised by our study is whether poor performance on quality measures is a function of underperforming hospitals or a manifestation of underserved communities. Moving forward, we encourage data systems and study designs that focus research on geospatial distribution of population health within the context of social and behavioral health determinants.37 Small-area studies of factors that drive health outcomes will inform rational alignment of healthcare policies and resources (including penalties and incentives) with underlying population needs.

 

 

Strengths and Weaknesses

Matching is a strength of the study. Primary analysis matched case and controls by hospital characteristics, generating cohorts similar across a spectrum of hospital metrics. Therefore, variation in readmission rates was less likely confounded by hospital characteristics. The secondary analysis was matched by geography in an effort to adjust for unmeasured, regional factors, including obesity and cost of living that may confound an association between SES and health outcomes. Geographic matching adds strength to our assertion that SES drives distinction between maximum-penalty hospitals and nonpenalty hospitals.

One weakness was the regional unit of analysis for socioeconomic and Dartmouth Atlas data, which is not a precise profile of the corresponding hospital. Each hospital was assigned a county-level socioeconomic profile. A more robust methodology would analyze patient-level SES data; this was impractical given a cohort of 78 hospitals. Regional health outcomes data limits analysis of readmission penalties as a function of hospital quality. Instead, regional data facilitated associations between readmission and population health, consistent with the aim of our study.

We analyzed 116 of 3668 hospitals eligible for the HRRP (3.2%), limiting the generalizability of our findings. Eighty-four percent of hospitals in the primary analysis have below the median number of beds, and none of them are teaching hospitals. Our analysis, restricted to maximum-penalty and no-penalty cohorts, does not address potential association between submaximal readmission penalties and socioeconomics.

Both matching techniques potentially controlled for similar SES factors and skewed our results towards null, especially in terms of race and ethnicity. Geographic matching generated 7 pairs (18%) within in the same county; both maximum-penalty and no-penalty hospitals were assigned the same socioeconomic profile, as well as 6 pairs (15%) within the same HSA, and both cases and controls had identical Dartmouth Atlas health outcomes profiles. We retained these pairs in our analysis to avoid artificially inflating SES and population health differences between cohorts.

Thirty-nine hospitals received a maximum penalty in the 3rd year of the HRRP. Relative to geographically matched no-penalty hospitals, maximum-penalty hospitals were more likely to be rural and located in counties with less educational attainment, more poverty and more poorly controlled chronic disease. In contrast to nationwide studies, a matched analysis plan revealed no difference between the cohorts in terms of race and ethnicity and provided evidence that maximum penalty hospitals had higher rates of age-, sex-, and race-adjusted hospital-wide mortality.

Our results highlight potential consequences of nationally derived benchmarks for phenomena underpinned by social, behavioral, and environmental factors and raise the question of whether maximum HRRP penalties are a consequence of underperforming hospitals or a manifestation of underserved communities. We are encouraged by MedPAC’s proposal to stratify HRRP by SES, yet recommend further small-area geographic analyses to better align quality measures, penalties, and incentives with resources and needs of distinct populations.

Acknowledgments

The authors thank William Hisey, who laid the foundation for the analysis and without whom the project would not have been possible.

DISCLOSURE

The authors certify that none of the material in this manuscript has been previously published and that none of this material is currently under consideration for publication elsewhere. This project received no funding. None of the authors on this manuscript have any commercial relationships to disclose in relation to this manuscript. All authors have reviewed and approved this manuscript and have contributed significantly to the design, conduct, and/or analysis of the research. No authors have any financial interests to disclose. No authors have any potential conflicts of interest to disclose. No authors have financial or personal relationships with any of the subject material presented in the manuscript.

References

1. Jencks SF, Williams MV, Coleman EA. Rehospitalizations among patients in the Medicare fee-for-service program. N Engl J Med. 2009;360(14):1418-1428. PubMed
2. Axon RN, Williams MV. Hospital readmission as an accountability measure. JAMA. 2011;305(5):504-505. PubMed
3. Amarasingham R, Moore BJ, Tabak YP, et al. An automated model to identify heart failure patients at risk for 30-day readmission or death using electronic medical record data. Med Care. 2010;48(11):981-988. PubMed
4. Calvillo-King L, Arnold D, Eubank KJ, et al. Impact of social factors on risk of readmission or mortality in pneumonia and heart failure: systematic review. J Gen Intern Med. 2013;28(2):269-282. PubMed
5. Feemster LC, Au DH. Penalizing hospitals for chronic obstructive pulmonary disease readmissions. Am J Respir Crit Care Med. 2014;189(6):634-639. PubMed
6. Sjoding MW, Cooke CR. Readmission penalties for chronic obstructive pulmonary disease will further stress hospitals caring for vulnerable patient populations. Am J Respir Crit Care Med. 2014;190(9):1072-1074. PubMed
7. Hu J, Gonsahn MD, Nerenz DR. Socioeconomic status and readmissions: evidence from an urban teaching hospital. Health Aff (Project Hope). 2014;33(5):778-785. PubMed
8. Mather JF, Fortunato GJ, Ash JL, et al. Prediction of pneumonia 30-day readmissions: a single-center attempt to increase model performance. Respir Care. 2014;59(2):199-208. PubMed
9. Philbin EF, Dec GW, Jenkins PL, et al. Socioeconomic status as an independent risk factor for hospital readmission for heart failure. Am J Cardiol. 2001;87(12):1367-1371. PubMed
10. Bikdeli B, Wayda B, Bao H, et al. Place of residence and outcomes of patients with heart failure: analysis from the telemonitoring to improve heart failure outcomes trial. Circ Cardiovasc Qual Outcomes. 2014;7(5):749-756. PubMed
11. Lindenauer PK, Lagu T, Rothberg MB, et al. Income inequality and 30 day outcomes after acute myocardial infarction, heart failure, and pneumonia: retrospective cohort study. BMJ. 2013;346:f521. PubMed
12. Joynt KE, Jha AK. Characteristics of hospitals receiving penalties under the Hospital Readmissions Reduction Program. JAMA. 2013;309(4):342-343. PubMed
13. Medicare Fines 2,610 Hospitals in Third Round of Readmission Penalties. Kaiser Health News. October 2, 2014, 2014. 
14. Centers for Medicare and Medicaid Services. Fiscal Year 2015 IPPS Hospital Readmission Reduction Program Supplemental Data File. https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/FY2015-IPPS-Final-Rule-Home-Page.html Last accessed July 10, 2017.
15. Atlas D. “Hospital and Post-Acute Care” and “Selected Hospital and Physician Capacity Measures”. In: Practice TDIfHPaC, ed. http://www.dartmouthatlas.org/tools/downloads.aspx. Last Accessed July 10, 2017.
16. Services CfMaM. Cost Reports by Year: 2014. https://www.cms.gov/Research-Statistics-Data-and-Systems/Downloadable-Public-Use-Files/Cost-Reports/Cost-Reports-by-Fiscal-Year.html. Last Accessed July 10, 2017.
17. Walsh SJ, Page PH, Gesler WM. Normative models and healthcare planning: network-based simulations within a geographic information system environment. Health Serv Res. 1997;32(2):243-260. PubMed
18. Emch M, Ali M, Root ED, et al. Spatial and environmental connectivity analysis in a cholera vaccine trial. Soc Sci Med. 2009;68(4):631-637. PubMed
19. Joynt KE, Orav EJ, Jha AK. Thirty-day readmission rates for Medicare beneficiaries by race and site of care. JAMA. 2011;305(7):675-681. PubMed
20. Vivo RP, Krim SR, Liang L, et al. Short- and long-term rehospitalization and mortality for heart failure in 4 racial/ethnic populations. J Am Heart Assoc. 2014;3(5):e001134. PubMed
21. Detailed comments on the Inpatient Prospective Payment System Proposed Rule for FY 2013 [press release]. http://www.aha.org/advocacy-issues/letter/2012/120619-cl-ipps.pdf. June 19, 2012. Last accessed July 10, 2017.
22. Dailey EA, Cizik A, Kasten J, et al.Risk factors for readmission of orthopaedic surgical patients. J Bone Joint Surg Am. 2013;95(11):1012-1019. PubMed
23. Tsai TC, Orav EJ, Joynt KE. Disparities in surgical 30-day readmission rates for Medicare beneficiaries by race and site of care. Ann Surg. 2014;259(6):1086-1090. PubMed
24. Krumholz HM, Lin Z, Keenan PS, et al. Relationship between hospital readmission and mortality rates for patients hospitalized with acute myocardial infarction, heart failure, or pneumonia. JAMA. 2013;309(6):587-593. PubMed
25. Committee MPA. Chapter 4: Refining the hospital readmissions reduction program. Report to the Congress: Medicare and the Health Care Delivery System. http://www.medpac.gov/docs/default-source/reports/jun13_ch04.pdf?sfvrsn=0 Last accessed July 10, 2017.
26. Rutstein DD, Berenberg W, Chalmers TC, Child CG, 3rd, Fishman AP, Perrin EB. Measuring the quality of medical care. A clinical method. N Engl J Med. 1976;294(11):582-588. PubMed
27. Purdy S, Griffin T, Salisbury C, Sharp D. Ambulatory care sensitive conditions: terminology and disease coding need to be more specific to aid policy makers and clinicians. Public Health. 2009;123(2):169-173. PubMed
28. McHugh MD, Berez J, Small DS. Hospitals with higher nurse staffing had lower odds of readmissions penalties than hospitals with lower staffing. Health Aff (Project Hope). 2013;32(10):1740-1747. PubMed
29. Joynt KE, Jha AK. Thirty-day readmissions--truth and consequences. N Engl J Med. 2012;366(15):1366-1369. PubMed
30. Bethell C, Simpson L, Stumbo S, Carle AC, Gombojav N. National, state and local disparities in childhood obesity. Health Aff. 2010; 29(3): 347-356. PubMed
31. Singh GK, Kogan MD, van Dyck PC. Changes in state-specific childhood obesity and overweight prevalence in the United States from 2003 to 2007. Arch Pediatr Adolesc Med. 2010;164(7):598-607. PubMed
32. Aten BH, Figueroa EB, Martin TB. Regional Price Parities for States and Metropolitan Areas, 2006–2010. Survey of Current Business 2012;92:229-242. 

33. Dubay L, Wheaton L, Zedlewski S. Geographic variation in the cost of living: implications for poverty guidelines and program eligibility. Urban Institute. 2013. https://aspe.hhs.gov/system/files/pdf/174186/UrbanGeographicVariation.pdf. Accessed on February 22, 2017. Last accessed July 10, 2017

34. National Quality Forum. Risk Adjustment for Socioeconomic Status or Other Sociodemographic Factors: a Technical Report. 2014. http://www.qualityforum. org/Publications/2014/08/Risk_Adjustment_for_Socioeconomic_Status_or_Other_Sociodemographic_Factors.aspx. Accessed July 10, 2017.

36. Services CfMaM. New HHS Data Shows Major Strides Made in Patient Safety, Leading to Improved Care and Savings. In: Services USDoHaH, ed. https://innovation.cms.gov/Files/reports/patient-safety-results.pdf. Accessed July 10, 2017.

 

 

37. Harrison KM, Dean HD. Use of data systems to address social determinants of health: a need to do more. Public Health Reports (Washington, DC:1974). 2011;126 Suppl 3:1-5. PubMed

References

1. Jencks SF, Williams MV, Coleman EA. Rehospitalizations among patients in the Medicare fee-for-service program. N Engl J Med. 2009;360(14):1418-1428. PubMed
2. Axon RN, Williams MV. Hospital readmission as an accountability measure. JAMA. 2011;305(5):504-505. PubMed
3. Amarasingham R, Moore BJ, Tabak YP, et al. An automated model to identify heart failure patients at risk for 30-day readmission or death using electronic medical record data. Med Care. 2010;48(11):981-988. PubMed
4. Calvillo-King L, Arnold D, Eubank KJ, et al. Impact of social factors on risk of readmission or mortality in pneumonia and heart failure: systematic review. J Gen Intern Med. 2013;28(2):269-282. PubMed
5. Feemster LC, Au DH. Penalizing hospitals for chronic obstructive pulmonary disease readmissions. Am J Respir Crit Care Med. 2014;189(6):634-639. PubMed
6. Sjoding MW, Cooke CR. Readmission penalties for chronic obstructive pulmonary disease will further stress hospitals caring for vulnerable patient populations. Am J Respir Crit Care Med. 2014;190(9):1072-1074. PubMed
7. Hu J, Gonsahn MD, Nerenz DR. Socioeconomic status and readmissions: evidence from an urban teaching hospital. Health Aff (Project Hope). 2014;33(5):778-785. PubMed
8. Mather JF, Fortunato GJ, Ash JL, et al. Prediction of pneumonia 30-day readmissions: a single-center attempt to increase model performance. Respir Care. 2014;59(2):199-208. PubMed
9. Philbin EF, Dec GW, Jenkins PL, et al. Socioeconomic status as an independent risk factor for hospital readmission for heart failure. Am J Cardiol. 2001;87(12):1367-1371. PubMed
10. Bikdeli B, Wayda B, Bao H, et al. Place of residence and outcomes of patients with heart failure: analysis from the telemonitoring to improve heart failure outcomes trial. Circ Cardiovasc Qual Outcomes. 2014;7(5):749-756. PubMed
11. Lindenauer PK, Lagu T, Rothberg MB, et al. Income inequality and 30 day outcomes after acute myocardial infarction, heart failure, and pneumonia: retrospective cohort study. BMJ. 2013;346:f521. PubMed
12. Joynt KE, Jha AK. Characteristics of hospitals receiving penalties under the Hospital Readmissions Reduction Program. JAMA. 2013;309(4):342-343. PubMed
13. Medicare Fines 2,610 Hospitals in Third Round of Readmission Penalties. Kaiser Health News. October 2, 2014, 2014. 
14. Centers for Medicare and Medicaid Services. Fiscal Year 2015 IPPS Hospital Readmission Reduction Program Supplemental Data File. https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/FY2015-IPPS-Final-Rule-Home-Page.html Last accessed July 10, 2017.
15. Atlas D. “Hospital and Post-Acute Care” and “Selected Hospital and Physician Capacity Measures”. In: Practice TDIfHPaC, ed. http://www.dartmouthatlas.org/tools/downloads.aspx. Last Accessed July 10, 2017.
16. Services CfMaM. Cost Reports by Year: 2014. https://www.cms.gov/Research-Statistics-Data-and-Systems/Downloadable-Public-Use-Files/Cost-Reports/Cost-Reports-by-Fiscal-Year.html. Last Accessed July 10, 2017.
17. Walsh SJ, Page PH, Gesler WM. Normative models and healthcare planning: network-based simulations within a geographic information system environment. Health Serv Res. 1997;32(2):243-260. PubMed
18. Emch M, Ali M, Root ED, et al. Spatial and environmental connectivity analysis in a cholera vaccine trial. Soc Sci Med. 2009;68(4):631-637. PubMed
19. Joynt KE, Orav EJ, Jha AK. Thirty-day readmission rates for Medicare beneficiaries by race and site of care. JAMA. 2011;305(7):675-681. PubMed
20. Vivo RP, Krim SR, Liang L, et al. Short- and long-term rehospitalization and mortality for heart failure in 4 racial/ethnic populations. J Am Heart Assoc. 2014;3(5):e001134. PubMed
21. Detailed comments on the Inpatient Prospective Payment System Proposed Rule for FY 2013 [press release]. http://www.aha.org/advocacy-issues/letter/2012/120619-cl-ipps.pdf. June 19, 2012. Last accessed July 10, 2017.
22. Dailey EA, Cizik A, Kasten J, et al.Risk factors for readmission of orthopaedic surgical patients. J Bone Joint Surg Am. 2013;95(11):1012-1019. PubMed
23. Tsai TC, Orav EJ, Joynt KE. Disparities in surgical 30-day readmission rates for Medicare beneficiaries by race and site of care. Ann Surg. 2014;259(6):1086-1090. PubMed
24. Krumholz HM, Lin Z, Keenan PS, et al. Relationship between hospital readmission and mortality rates for patients hospitalized with acute myocardial infarction, heart failure, or pneumonia. JAMA. 2013;309(6):587-593. PubMed
25. Committee MPA. Chapter 4: Refining the hospital readmissions reduction program. Report to the Congress: Medicare and the Health Care Delivery System. http://www.medpac.gov/docs/default-source/reports/jun13_ch04.pdf?sfvrsn=0 Last accessed July 10, 2017.
26. Rutstein DD, Berenberg W, Chalmers TC, Child CG, 3rd, Fishman AP, Perrin EB. Measuring the quality of medical care. A clinical method. N Engl J Med. 1976;294(11):582-588. PubMed
27. Purdy S, Griffin T, Salisbury C, Sharp D. Ambulatory care sensitive conditions: terminology and disease coding need to be more specific to aid policy makers and clinicians. Public Health. 2009;123(2):169-173. PubMed
28. McHugh MD, Berez J, Small DS. Hospitals with higher nurse staffing had lower odds of readmissions penalties than hospitals with lower staffing. Health Aff (Project Hope). 2013;32(10):1740-1747. PubMed
29. Joynt KE, Jha AK. Thirty-day readmissions--truth and consequences. N Engl J Med. 2012;366(15):1366-1369. PubMed
30. Bethell C, Simpson L, Stumbo S, Carle AC, Gombojav N. National, state and local disparities in childhood obesity. Health Aff. 2010; 29(3): 347-356. PubMed
31. Singh GK, Kogan MD, van Dyck PC. Changes in state-specific childhood obesity and overweight prevalence in the United States from 2003 to 2007. Arch Pediatr Adolesc Med. 2010;164(7):598-607. PubMed
32. Aten BH, Figueroa EB, Martin TB. Regional Price Parities for States and Metropolitan Areas, 2006–2010. Survey of Current Business 2012;92:229-242. 

33. Dubay L, Wheaton L, Zedlewski S. Geographic variation in the cost of living: implications for poverty guidelines and program eligibility. Urban Institute. 2013. https://aspe.hhs.gov/system/files/pdf/174186/UrbanGeographicVariation.pdf. Accessed on February 22, 2017. Last accessed July 10, 2017

34. National Quality Forum. Risk Adjustment for Socioeconomic Status or Other Sociodemographic Factors: a Technical Report. 2014. http://www.qualityforum. org/Publications/2014/08/Risk_Adjustment_for_Socioeconomic_Status_or_Other_Sociodemographic_Factors.aspx. Accessed July 10, 2017.

36. Services CfMaM. New HHS Data Shows Major Strides Made in Patient Safety, Leading to Improved Care and Savings. In: Services USDoHaH, ed. https://innovation.cms.gov/Files/reports/patient-safety-results.pdf. Accessed July 10, 2017.

 

 

37. Harrison KM, Dean HD. Use of data systems to address social determinants of health: a need to do more. Public Health Reports (Washington, DC:1974). 2011;126 Suppl 3:1-5. PubMed

Issue
Journal of Hospital Medicine 12 (8)
Issue
Journal of Hospital Medicine 12 (8)
Page Number
610-617
Page Number
610-617
Topics
Article Type
Sections
Disallow All Ads
Correspondence Location
Christopher Caracciolo, 2 Twinbrook Drive, Woodbridge, CT 06525; Telephone: 203-988-3801; Fax: 203 298 9322; E-mail: [email protected]
Content Gating
Gated (full article locked unless allowed per User)
Alternative CME
Disqus Comments
Default
Gating Strategy
First Peek Free
Article PDF Media
Media Files

Fixed-Dose Combination Pills Enhance Adherence and Persistence to Antihypertensive Medications

Article Type
Changed
Wed, 02/28/2018 - 14:38
Display Headline
Fixed-Dose Combination Pills Enhance Adherence and Persistence to Antihypertensive Medications

Study Overview

Objective. To evaluate long-term adherence to antihypertensive therapy among patients on fixed-dose combination medication as well as antihypertensive monotherapy; and to identify demographic and clinical risk factors associated with selection of and adherence and persistence to antihypertensive medication therapy.

Design. Retrospective cohort study using claims data from a large nationwide insurer.

Setting and participants. The study population included patients older than age 18 who initiated antihypertensive medication between 1 January 2009 and 31 December 2012 and who were continually enrolled at least 180 days before and 365 days after the index date, defined as the date of initiation of antihypertensive therapy. Patients were excluded from the study if they had previously filled any antihypertensive medication at any time prior to the index date. Patients were categorized based on the number and type of antihypertensive medications (fixed-dose combination, defined as a single pill containing multiple medications; multi-pill combination, defined as 2 or more distinct antihypertensive tablets or capsules; or single therapy, defined as only 1 medication) using National Drug Codes (NDC). Study authors also measured patient baseline characteristics, such as age, region, gender, diagnoses as defined by ICD-9 codes, patient utilization characteristics (both outpatient visits and hospitalizations) and characteristics of the initiated medication, including patient copayment and number of days of medication supplied.

Main outcome measures. The primary outcome of inte-rest was persistence, defined as having supply for any antihypertensive medication that overlapped with the 365th day after initiation (index date), whether the initiated medication or other antihypertensive. Additional outcomes included adherence to at least 1 antihypertensive in the 12 months after initiation and refilling at least 1 antihypertensive medication. To determine adherence, the study authors calculated the proportion of days the patient had any antihypertensive available to them (proportion of days covered; PDC). PDC > 80% to at least 1 antihypertensive in the 12 months after initiation was defined as “fully adherent.”

Statistical analysis utilized modified multivariable Poisson regression models and sensitivity analyses were performed. The main study comparisons focused on patients initiating fixed-dose combination therapy and monotherapy because these groups were more comparable in terms of baseline characteristics and medications initiated than the multi-pill combination group.

Main results. The study sample consisted of 484,493 patients who initiated an oral antihypertensive, including 78,958 patient initiating fixed-dose combinations, 380,269 filled a single therapy, and 22,266 who initiated multi-pill combinations. The most frequently initiated fixed-dose combination was lisinopril-hydrochlorothiazide. Lisinopril, hydrochlorothiazide, and amlodipine with the most frequently initiated monotherapy. The mean age of the study population was 47.2 years and 51.8% were women. Patients initiating multiple pill combinations were older (mean age 52.5) and tended to be sicker with more comorbidities than fixed-dose combinations or monotherapy. Patients initiating fixed-dose combination had higher prescription copayments than patients using single medication (prescription copay $14.4 versus $9.6). Patients initiating fixed-dose combinations were 9% more likely to be persistent (relative risk [RR] 1.09, 95% CI 1.08–1.10) and 13% more likely to be adherent (RR 1.13, 95% CI 1.11–1.14) than those who started on a monotherapy. Refill rates were also slightly higher among fixed-dose combination initiators (RR 1.06, 95% CI 1.05-1.07).

Conclusion. Compared with monotherapy, fixed-dose combination therapy appears to improve adherence and persistence to antihypertensive medications.

Commentary

Approximately half of US of individuals with diagnosed hypertension obtain control of their condition based on currently defined targets [1]. The most effective approach to blood pressure management has been controversial. The JNC8 [2] guidelines liberalized blood pressure targets, while recent results from the SPRINT (systolic blood pressure intervention trial) [3] indicates that lower blood pressure targets are able to prevent hypertension-related complications without significant additional risk. Given these conflicts, there is clearly ambiguity in the most effective approach to initiating antihypertensive treatment. Prior studies have shown that fewer than 50% of patients continue to take their medications just 12 months after initiation [4,5].

Fixed-dose combination therapy for blood pressure management has been cited as better for adherence and is now making its way into clinical guidelines [6–8]. However, it should be noted that fixed-dose combination therapy for blood pressure management limits dosing flexibility. Dose titration may be needed, potentially leading to additional prescriptions, thus potentially complicating the drug regimen and adding additional cost. Complicating matters further, quality metrics and reporting requirements for hypertension require primary care providers to achieve blood pressure control while also ensuring patient adherence and concomitantly avoiding side effects related to medication therapy.

This study was conducted using claims data for commercially insured patients or those with Medicare Advan-tage and is unlikely to be representative of the entire population. Additionally, the study authors did not have detailed clinical information about patients, limiting the ability to understand the true clinical implications. Further, patients may have initiated medications for indications other than hypertension. In addition, causality cannot be established given the retrospective observational cohort nature of this study.

Applications for Clinical Practice

Primary care physicians face substantial challenges in the treatment of hypertension, including with respect to selection of initial medication therapy. Results from this study add to the evidence base that fixed-dose combination therapy is more effective in obtaining blood pressure control than monotherapy or multiple-pill therapy. Medication adherence in primary care practice is challenging. Strategies such as fixed-dose combination therapy are reasonable to employ to improve medication adherence; however, costs must be considered.

 

—Ajay Dharod, MD, Wake Forest School of Medicine, Winston-Salem, NC

References

1. Gu Q, Burt VL, Dillon CF, Yoon S. Trends in antihypertensive medication use and blood pressure control among United States adults with hypertension. Circulation 2012;126:2105–14.

2. James PA, Oparil S, Carter BL, et al. 2014 Evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014;311:507–20.

3. Group TSR. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med 2015;373:2103–16.

4. Yeaw J, Benner JS, Walt JG, et al. Comparing adherence and persistence across 6 chronic medication classes. J Manag Care Pharm 2009;15:728–40.

5. Baroletti S, Dell’Orfano H. Medication adherence in cardiovascular disease. Circulation 2010;121:1455–8.

6. Bangalore S, Kamalakkannan G, Parkar S, Messerli FH. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med 2007;120:713–9.

7. Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents. Hypertension 2010;55:399–407.

8. Pan F, Chernew ME, Fendrick AM. Impact of fixed-dose combination drugs on adherence to prescription medications. J Gen Intern Med 2008;23:611–4.

Issue
Journal of Clinical Outcomes Management - August 2017, Vol. 24, No 8
Publications
Topics
Sections

Study Overview

Objective. To evaluate long-term adherence to antihypertensive therapy among patients on fixed-dose combination medication as well as antihypertensive monotherapy; and to identify demographic and clinical risk factors associated with selection of and adherence and persistence to antihypertensive medication therapy.

Design. Retrospective cohort study using claims data from a large nationwide insurer.

Setting and participants. The study population included patients older than age 18 who initiated antihypertensive medication between 1 January 2009 and 31 December 2012 and who were continually enrolled at least 180 days before and 365 days after the index date, defined as the date of initiation of antihypertensive therapy. Patients were excluded from the study if they had previously filled any antihypertensive medication at any time prior to the index date. Patients were categorized based on the number and type of antihypertensive medications (fixed-dose combination, defined as a single pill containing multiple medications; multi-pill combination, defined as 2 or more distinct antihypertensive tablets or capsules; or single therapy, defined as only 1 medication) using National Drug Codes (NDC). Study authors also measured patient baseline characteristics, such as age, region, gender, diagnoses as defined by ICD-9 codes, patient utilization characteristics (both outpatient visits and hospitalizations) and characteristics of the initiated medication, including patient copayment and number of days of medication supplied.

Main outcome measures. The primary outcome of inte-rest was persistence, defined as having supply for any antihypertensive medication that overlapped with the 365th day after initiation (index date), whether the initiated medication or other antihypertensive. Additional outcomes included adherence to at least 1 antihypertensive in the 12 months after initiation and refilling at least 1 antihypertensive medication. To determine adherence, the study authors calculated the proportion of days the patient had any antihypertensive available to them (proportion of days covered; PDC). PDC > 80% to at least 1 antihypertensive in the 12 months after initiation was defined as “fully adherent.”

Statistical analysis utilized modified multivariable Poisson regression models and sensitivity analyses were performed. The main study comparisons focused on patients initiating fixed-dose combination therapy and monotherapy because these groups were more comparable in terms of baseline characteristics and medications initiated than the multi-pill combination group.

Main results. The study sample consisted of 484,493 patients who initiated an oral antihypertensive, including 78,958 patient initiating fixed-dose combinations, 380,269 filled a single therapy, and 22,266 who initiated multi-pill combinations. The most frequently initiated fixed-dose combination was lisinopril-hydrochlorothiazide. Lisinopril, hydrochlorothiazide, and amlodipine with the most frequently initiated monotherapy. The mean age of the study population was 47.2 years and 51.8% were women. Patients initiating multiple pill combinations were older (mean age 52.5) and tended to be sicker with more comorbidities than fixed-dose combinations or monotherapy. Patients initiating fixed-dose combination had higher prescription copayments than patients using single medication (prescription copay $14.4 versus $9.6). Patients initiating fixed-dose combinations were 9% more likely to be persistent (relative risk [RR] 1.09, 95% CI 1.08–1.10) and 13% more likely to be adherent (RR 1.13, 95% CI 1.11–1.14) than those who started on a monotherapy. Refill rates were also slightly higher among fixed-dose combination initiators (RR 1.06, 95% CI 1.05-1.07).

Conclusion. Compared with monotherapy, fixed-dose combination therapy appears to improve adherence and persistence to antihypertensive medications.

Commentary

Approximately half of US of individuals with diagnosed hypertension obtain control of their condition based on currently defined targets [1]. The most effective approach to blood pressure management has been controversial. The JNC8 [2] guidelines liberalized blood pressure targets, while recent results from the SPRINT (systolic blood pressure intervention trial) [3] indicates that lower blood pressure targets are able to prevent hypertension-related complications without significant additional risk. Given these conflicts, there is clearly ambiguity in the most effective approach to initiating antihypertensive treatment. Prior studies have shown that fewer than 50% of patients continue to take their medications just 12 months after initiation [4,5].

Fixed-dose combination therapy for blood pressure management has been cited as better for adherence and is now making its way into clinical guidelines [6–8]. However, it should be noted that fixed-dose combination therapy for blood pressure management limits dosing flexibility. Dose titration may be needed, potentially leading to additional prescriptions, thus potentially complicating the drug regimen and adding additional cost. Complicating matters further, quality metrics and reporting requirements for hypertension require primary care providers to achieve blood pressure control while also ensuring patient adherence and concomitantly avoiding side effects related to medication therapy.

This study was conducted using claims data for commercially insured patients or those with Medicare Advan-tage and is unlikely to be representative of the entire population. Additionally, the study authors did not have detailed clinical information about patients, limiting the ability to understand the true clinical implications. Further, patients may have initiated medications for indications other than hypertension. In addition, causality cannot be established given the retrospective observational cohort nature of this study.

Applications for Clinical Practice

Primary care physicians face substantial challenges in the treatment of hypertension, including with respect to selection of initial medication therapy. Results from this study add to the evidence base that fixed-dose combination therapy is more effective in obtaining blood pressure control than monotherapy or multiple-pill therapy. Medication adherence in primary care practice is challenging. Strategies such as fixed-dose combination therapy are reasonable to employ to improve medication adherence; however, costs must be considered.

 

—Ajay Dharod, MD, Wake Forest School of Medicine, Winston-Salem, NC

Study Overview

Objective. To evaluate long-term adherence to antihypertensive therapy among patients on fixed-dose combination medication as well as antihypertensive monotherapy; and to identify demographic and clinical risk factors associated with selection of and adherence and persistence to antihypertensive medication therapy.

Design. Retrospective cohort study using claims data from a large nationwide insurer.

Setting and participants. The study population included patients older than age 18 who initiated antihypertensive medication between 1 January 2009 and 31 December 2012 and who were continually enrolled at least 180 days before and 365 days after the index date, defined as the date of initiation of antihypertensive therapy. Patients were excluded from the study if they had previously filled any antihypertensive medication at any time prior to the index date. Patients were categorized based on the number and type of antihypertensive medications (fixed-dose combination, defined as a single pill containing multiple medications; multi-pill combination, defined as 2 or more distinct antihypertensive tablets or capsules; or single therapy, defined as only 1 medication) using National Drug Codes (NDC). Study authors also measured patient baseline characteristics, such as age, region, gender, diagnoses as defined by ICD-9 codes, patient utilization characteristics (both outpatient visits and hospitalizations) and characteristics of the initiated medication, including patient copayment and number of days of medication supplied.

Main outcome measures. The primary outcome of inte-rest was persistence, defined as having supply for any antihypertensive medication that overlapped with the 365th day after initiation (index date), whether the initiated medication or other antihypertensive. Additional outcomes included adherence to at least 1 antihypertensive in the 12 months after initiation and refilling at least 1 antihypertensive medication. To determine adherence, the study authors calculated the proportion of days the patient had any antihypertensive available to them (proportion of days covered; PDC). PDC > 80% to at least 1 antihypertensive in the 12 months after initiation was defined as “fully adherent.”

Statistical analysis utilized modified multivariable Poisson regression models and sensitivity analyses were performed. The main study comparisons focused on patients initiating fixed-dose combination therapy and monotherapy because these groups were more comparable in terms of baseline characteristics and medications initiated than the multi-pill combination group.

Main results. The study sample consisted of 484,493 patients who initiated an oral antihypertensive, including 78,958 patient initiating fixed-dose combinations, 380,269 filled a single therapy, and 22,266 who initiated multi-pill combinations. The most frequently initiated fixed-dose combination was lisinopril-hydrochlorothiazide. Lisinopril, hydrochlorothiazide, and amlodipine with the most frequently initiated monotherapy. The mean age of the study population was 47.2 years and 51.8% were women. Patients initiating multiple pill combinations were older (mean age 52.5) and tended to be sicker with more comorbidities than fixed-dose combinations or monotherapy. Patients initiating fixed-dose combination had higher prescription copayments than patients using single medication (prescription copay $14.4 versus $9.6). Patients initiating fixed-dose combinations were 9% more likely to be persistent (relative risk [RR] 1.09, 95% CI 1.08–1.10) and 13% more likely to be adherent (RR 1.13, 95% CI 1.11–1.14) than those who started on a monotherapy. Refill rates were also slightly higher among fixed-dose combination initiators (RR 1.06, 95% CI 1.05-1.07).

Conclusion. Compared with monotherapy, fixed-dose combination therapy appears to improve adherence and persistence to antihypertensive medications.

Commentary

Approximately half of US of individuals with diagnosed hypertension obtain control of their condition based on currently defined targets [1]. The most effective approach to blood pressure management has been controversial. The JNC8 [2] guidelines liberalized blood pressure targets, while recent results from the SPRINT (systolic blood pressure intervention trial) [3] indicates that lower blood pressure targets are able to prevent hypertension-related complications without significant additional risk. Given these conflicts, there is clearly ambiguity in the most effective approach to initiating antihypertensive treatment. Prior studies have shown that fewer than 50% of patients continue to take their medications just 12 months after initiation [4,5].

Fixed-dose combination therapy for blood pressure management has been cited as better for adherence and is now making its way into clinical guidelines [6–8]. However, it should be noted that fixed-dose combination therapy for blood pressure management limits dosing flexibility. Dose titration may be needed, potentially leading to additional prescriptions, thus potentially complicating the drug regimen and adding additional cost. Complicating matters further, quality metrics and reporting requirements for hypertension require primary care providers to achieve blood pressure control while also ensuring patient adherence and concomitantly avoiding side effects related to medication therapy.

This study was conducted using claims data for commercially insured patients or those with Medicare Advan-tage and is unlikely to be representative of the entire population. Additionally, the study authors did not have detailed clinical information about patients, limiting the ability to understand the true clinical implications. Further, patients may have initiated medications for indications other than hypertension. In addition, causality cannot be established given the retrospective observational cohort nature of this study.

Applications for Clinical Practice

Primary care physicians face substantial challenges in the treatment of hypertension, including with respect to selection of initial medication therapy. Results from this study add to the evidence base that fixed-dose combination therapy is more effective in obtaining blood pressure control than monotherapy or multiple-pill therapy. Medication adherence in primary care practice is challenging. Strategies such as fixed-dose combination therapy are reasonable to employ to improve medication adherence; however, costs must be considered.

 

—Ajay Dharod, MD, Wake Forest School of Medicine, Winston-Salem, NC

References

1. Gu Q, Burt VL, Dillon CF, Yoon S. Trends in antihypertensive medication use and blood pressure control among United States adults with hypertension. Circulation 2012;126:2105–14.

2. James PA, Oparil S, Carter BL, et al. 2014 Evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014;311:507–20.

3. Group TSR. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med 2015;373:2103–16.

4. Yeaw J, Benner JS, Walt JG, et al. Comparing adherence and persistence across 6 chronic medication classes. J Manag Care Pharm 2009;15:728–40.

5. Baroletti S, Dell’Orfano H. Medication adherence in cardiovascular disease. Circulation 2010;121:1455–8.

6. Bangalore S, Kamalakkannan G, Parkar S, Messerli FH. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med 2007;120:713–9.

7. Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents. Hypertension 2010;55:399–407.

8. Pan F, Chernew ME, Fendrick AM. Impact of fixed-dose combination drugs on adherence to prescription medications. J Gen Intern Med 2008;23:611–4.

References

1. Gu Q, Burt VL, Dillon CF, Yoon S. Trends in antihypertensive medication use and blood pressure control among United States adults with hypertension. Circulation 2012;126:2105–14.

2. James PA, Oparil S, Carter BL, et al. 2014 Evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014;311:507–20.

3. Group TSR. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med 2015;373:2103–16.

4. Yeaw J, Benner JS, Walt JG, et al. Comparing adherence and persistence across 6 chronic medication classes. J Manag Care Pharm 2009;15:728–40.

5. Baroletti S, Dell’Orfano H. Medication adherence in cardiovascular disease. Circulation 2010;121:1455–8.

6. Bangalore S, Kamalakkannan G, Parkar S, Messerli FH. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med 2007;120:713–9.

7. Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents. Hypertension 2010;55:399–407.

8. Pan F, Chernew ME, Fendrick AM. Impact of fixed-dose combination drugs on adherence to prescription medications. J Gen Intern Med 2008;23:611–4.

Issue
Journal of Clinical Outcomes Management - August 2017, Vol. 24, No 8
Issue
Journal of Clinical Outcomes Management - August 2017, Vol. 24, No 8
Publications
Publications
Topics
Article Type
Display Headline
Fixed-Dose Combination Pills Enhance Adherence and Persistence to Antihypertensive Medications
Display Headline
Fixed-Dose Combination Pills Enhance Adherence and Persistence to Antihypertensive Medications
Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default

How to sell your ObGyn practice

Article Type
Changed
Thu, 03/28/2019 - 14:49
Display Headline
How to sell your ObGyn practice
Your retirement may be a long way off, but the planning pointers presented here can help smooth the transition of your practice when you decide to sell

For ObGyns, 2 intensely stressful career milestones are the day you start your practice and the day you decide to put it up for sale.

One of us, Dr. Baum, started a practice in 1976. At that time, many clinicians seemed to work right up until the day they died—in mid-examination or with scalpel in hand! Today, clinicians seriously contemplate leaving an active practice at age 55, 60, or, more traditionally, 65.

ObGyns in group practice, even those with only 1 or 2 partners, presumably have in place a well-thought-out and properly drafted contract with buyout and phase-down provisions. For members of a group practice, it is imperative to critically review and discuss contractual arrangements periodically and decide if they make sense as much now as they did at the start. ObGyns who continually revisit their contracts probably have an exit strategy that is fairly self-executing and effective and that will provide the seller with a seamless transition to retirement.

A solo ObGyn who is selling a practice has 3 basic options: find a successor physician, sell to a hospital or to a larger group, or close the practice.


Related article:
ObGyns’ choice of practice environment is a big deal

Preparing your practice for sale

Regardless of who will take over your practice, you need to prepare for its transition.

The most important aspect of selling your practice is knowing its finances and ensuring that they are in order. Any serious buyer will ask to examine your books, see how you are running the business, and assess its vitality and potential growth. Simply, a buyer will want to know where your revenue comes from and where it goes.

Your practice will be attractive to a buyer if it shows a stable or growing revenue base, an attractive payer mix, reasonable overhead, and personal income that is steady if not increasing. If your earning capacity is low or declining, you will need to explain why.

Timing is key

We strongly recommend beginning the process 3 to 5 years before your intended exit.

By starting early, up to 5 years in advance, you can maximize the likelihood that your practice will retain all or most of its value. Moreover, you can use the long lead time to thoroughly explore all available options and find a committed buyer.

Selling a practice can be a complicated affair, and many ObGyns do not have the requisite skills. So much of the success in selling depends on the specifics of the practice, the physician, and the market (the hospital and physician environment).

Identifying potential buyers

Other ObGyns. Recruiting an ObGyn to take over your practice seems to be the best option but can prove very difficult in today’s environment. Many younger clinicians are either joining large groups or becoming hospital employees.

Other physician groups. While working your way down your list of potential buyers, you should also be quietly, subtly, and tactfully assessing other practices, even your competitors, to see if any are candidates for merging with and/or acquiring yours and all your charts, records, and referring physicians.

Hospitals. In today’s health care environment, in which more than half of clinicians are becoming hospital employees, selling to your associated hospital may be a viable option.

Your practice is probably contributing millions of dollars in income to that hospital each year, and of course the hospital would like to maintain this revenue stream. You should consider talking to the hospital’s CEO or medical director.

Hospitals also know that, if you leave and the market cannot absorb the resulting increase in demand for care, patients may go elsewhere, to a competing hospital or outside the community. Rather than lose your market share, a hospital may consider the obvious solution: recruit a replacement ObGyn for your practice.

Your goal here is to negotiate an agreement in which your hospital will recruit a replacement ObGyn, provide financial support, and transition your practice to that ObGyn over a specified period.

The hospital could acquire your practice and either employ you during the transition or provide recruiting support and an income guarantee to help your practice pay the new physician’s salary. Whether to sell or remain independent is often driven by the needs and desires of the recruit. As the vast majority of clinicians coming out of training are seeking employment, in most cases the agreement will require a sale.

Selling to a hospital a few years before your retirement can be a plus. You might find employment a welcome respite from the daunting responsibility of managing your own practice. Life can become much less stressful as you introduce and transition your patients to the new ObGyn. You will be working less, taking fewer calls, and maintaining or even increasing your income, all without the burden of managing the practice.

Read about determining your practice’s value

 

 

Putting a monetary value on your practice

After deciding to sell your practice, you need to determine its value. Buying a practice may be the largest financial transaction a young ObGyn will ever make. For a retiring physician, valuation of a practice may reflect a career’s worth of “sweat equity.”

What is your practice worth?

All ObGyns believe their practice is worth far more than any young ObGyn or hospital is willing to pay for it. After all, you have spent a medical lifetime creating, building, and nurturing your practice. You have cared for several thousand patients, who have been loyal and may want to stay with the practice under its new ObGyn. So, how does a retiring physician put a value on his or her practice and then “cast the net” to the marketplace? How do you find a buyer who will pay the asking price and then help the practice make the transition from seller to buyer and continue to serve their patients?

The buyer’s perspective on value. In a pure sense, the value of any asset is what a potential buyer is willing to pay. From a value standpoint, the price that potential buyers are willing to pay varies by the specifics of the situation, regardless of what a valuation or practice appraisal might indicate.

For example, once your plan to retire becomes known, why would a young ObGyn agree to pay X dollars for all your medical records? After all, the potential buyer knows that your existing patients and your referral base will need to seek care from another ObGyn after you leave, and they will likely stay with the practice if they feel they will be treated well by the new clinician.

A hospital may take a similar tack but more often will be willing to pay fair market value for your practice. Hospitals, however, cannot legally pay more than fair market value as determined by an independent appraiser.


Related article:
Four pillars of a successful practice: 1. Keep your current patients happy

Valuation methods

The valuation of any business generally is approached in terms of market, assets, and income.

The market approach usually is taken only with regard to office real estate. Given the lack of reliable and comparable sales information, this approach is seldom used in the valuation of medical practices. If you own your office real estate, a real estate appraiser will establish its fair market value.

In the assets approach, the individual assets of a medical practice are valued on the basis of their current market values. These assets are either tangible or intangible.

Tangible assets can be seen and touched. Furniture, equipment, and office real estate are examples.

The fair market value of used furniture and equipment is most often determined by replacement cost. The value of these items is limited. Usually it starts at 50% of the cost of buying new furniture or equipment of the same utility. From there, the value is lowered on the basis of the age and condition of the items.

Often, the market value of major ObGyn office equipment, such as a DXA (dual-energy x-ray absorptiometry) scanner, is based on similar items for sale or recently sold in the used secondary equipment market.

Tangible assets may include accounts receivable (A/R). A/R represents uncollected payment for work performed. Most buyers want to avoid paying for A/R and assuming the risk of collections. Generally, you should expect to retain your A/R and pay a small or nominal fee to have the buyer handle the collections after you have retired.

Intangible assets are not physical. Examples include the physician’s name, phone number, reputation, referral base, trained staff, and medical records—in other words, what gets patients to keep coming back. Most physicians value these goodwill or “blue-sky” assets highly. Today, unfortunately, most sellers are unable to reap any financial benefit from their intangible assets.

The income approach is based on the premise that the value of any business is in the income it generates for its owner. In simple terms, value in the income approach is a multiple of the cash the business generates after expenses.

Read important keys to transitioning the practice

 

 

Transitioning the practice: Role of the seller and the buyer

First and very important is the contract agreement regarding the overlap period, when both the exiting ObGyn and the new ObGyn are at the practice. We suggest making the overlap a minimum of 6 months and a maximum of 1 year. During this period, the exiting physician can introduce the incoming physician to the patients. A face-to-face introduction can amount to an endorsement, which can ease a patient’s mind and help her decide to take on the new ObGyn and philosophy rather than search elsewhere for obstetric and gynecologic care. The new ObGyn also can use the overlap period to become familiar and comfortable with the staff and learn the process for physician and staff management of case flow, from scheduling and examination to insurance and patient follow-up.

We suggest that the exiting ObGyn send a farewell/welcome letter to patients and referring physicians. The letter should state the exiting ObGyn’s intention to leave (or retire from) the practice and should introduce the ObGyn who will be taking over.

The exiting ObGyn should also take the new ObGyn to meet the physicians who have been providing referrals over the years. We suggest visiting each referring physician’s office to make the introduction. Another good way to introduce a new ObGyn to referring physicians and other professionals—endocrinologists, cardiologists, nurses, pharmaceutical representatives—is to host an open house at your practice. Invite the staff members of the referring physicians as well, since they can be invaluable in making referrals.

We recommend that the exiting ObGyn spend the money to update all the practice’s stationery, brochures, and print materials and ensure they look professional. Note that it is not acceptable to place the new ObGyn’s name under the exiting ObGyn’s name. If the practice has a website, introduce the new physician there and make any necessary updates regarding office hours and accepted insurance plans.

If the exiting ObGyn’s practice lacks a robust Internet and social media presence, the new ObGyn should establish one. We recommend setting up an interactive website that patients can use to make appointments and pay bills. The website should have an email component that can be used to ask questions, raise concerns, and get answers. We also recommend opening Facebook, YouTube, and Twitter accounts for the practice and being active on these social media.

In our experience, smoothly transitioning practices can achieve patient retention rates as high as 90% to 95%. For practices without a plan, however, these rates may be as low as 50%, or worse. Therefore, work out a plan in advance, and include the steps described here, so that on arrival the new ObGyn can hit the ground running.

Acquiring a successful medical practice is doable and offers many advantages, such as autonomy and the ability to make business decisions affecting the practice. Despite all the changes happening in health care, we still think this is the best way to go.


Related article:
Four pillars of a successful practice: 4. Motivate your staff

Bottom line

Selling an ObGyn practice can be a daunting process. However, deciding to sell your practice, performing the valuation, and ensuring a smooth transition are part and parcel of making the transfer a success, equitable for both the buyer and the seller.

 

Share your thoughts! Send your Letter to the Editor to [email protected]. Please include your name and the city and state in which you practice.

Article PDF
Author and Disclosure Information

Mr. Bauman is a practice management consultant and CEO of Delta Health Care, Brentwood, Tennessee.

Dr. Baum is a Professor of Clinical Urology at Tulane Medical School, New Orleans, Louisiana, and is the author of The Complete Business Guide for a Successful Medical Practice (Springer, 2016). He is an OBG Management Contributing Editor.

The authors report no financial relationships relevant to this article.

Issue
OBG Management - 29(8)
Publications
Topics
Page Number
24-26, 28-29
Sections
Author and Disclosure Information

Mr. Bauman is a practice management consultant and CEO of Delta Health Care, Brentwood, Tennessee.

Dr. Baum is a Professor of Clinical Urology at Tulane Medical School, New Orleans, Louisiana, and is the author of The Complete Business Guide for a Successful Medical Practice (Springer, 2016). He is an OBG Management Contributing Editor.

The authors report no financial relationships relevant to this article.

Author and Disclosure Information

Mr. Bauman is a practice management consultant and CEO of Delta Health Care, Brentwood, Tennessee.

Dr. Baum is a Professor of Clinical Urology at Tulane Medical School, New Orleans, Louisiana, and is the author of The Complete Business Guide for a Successful Medical Practice (Springer, 2016). He is an OBG Management Contributing Editor.

The authors report no financial relationships relevant to this article.

Article PDF
Article PDF
Your retirement may be a long way off, but the planning pointers presented here can help smooth the transition of your practice when you decide to sell
Your retirement may be a long way off, but the planning pointers presented here can help smooth the transition of your practice when you decide to sell

For ObGyns, 2 intensely stressful career milestones are the day you start your practice and the day you decide to put it up for sale.

One of us, Dr. Baum, started a practice in 1976. At that time, many clinicians seemed to work right up until the day they died—in mid-examination or with scalpel in hand! Today, clinicians seriously contemplate leaving an active practice at age 55, 60, or, more traditionally, 65.

ObGyns in group practice, even those with only 1 or 2 partners, presumably have in place a well-thought-out and properly drafted contract with buyout and phase-down provisions. For members of a group practice, it is imperative to critically review and discuss contractual arrangements periodically and decide if they make sense as much now as they did at the start. ObGyns who continually revisit their contracts probably have an exit strategy that is fairly self-executing and effective and that will provide the seller with a seamless transition to retirement.

A solo ObGyn who is selling a practice has 3 basic options: find a successor physician, sell to a hospital or to a larger group, or close the practice.


Related article:
ObGyns’ choice of practice environment is a big deal

Preparing your practice for sale

Regardless of who will take over your practice, you need to prepare for its transition.

The most important aspect of selling your practice is knowing its finances and ensuring that they are in order. Any serious buyer will ask to examine your books, see how you are running the business, and assess its vitality and potential growth. Simply, a buyer will want to know where your revenue comes from and where it goes.

Your practice will be attractive to a buyer if it shows a stable or growing revenue base, an attractive payer mix, reasonable overhead, and personal income that is steady if not increasing. If your earning capacity is low or declining, you will need to explain why.

Timing is key

We strongly recommend beginning the process 3 to 5 years before your intended exit.

By starting early, up to 5 years in advance, you can maximize the likelihood that your practice will retain all or most of its value. Moreover, you can use the long lead time to thoroughly explore all available options and find a committed buyer.

Selling a practice can be a complicated affair, and many ObGyns do not have the requisite skills. So much of the success in selling depends on the specifics of the practice, the physician, and the market (the hospital and physician environment).

Identifying potential buyers

Other ObGyns. Recruiting an ObGyn to take over your practice seems to be the best option but can prove very difficult in today’s environment. Many younger clinicians are either joining large groups or becoming hospital employees.

Other physician groups. While working your way down your list of potential buyers, you should also be quietly, subtly, and tactfully assessing other practices, even your competitors, to see if any are candidates for merging with and/or acquiring yours and all your charts, records, and referring physicians.

Hospitals. In today’s health care environment, in which more than half of clinicians are becoming hospital employees, selling to your associated hospital may be a viable option.

Your practice is probably contributing millions of dollars in income to that hospital each year, and of course the hospital would like to maintain this revenue stream. You should consider talking to the hospital’s CEO or medical director.

Hospitals also know that, if you leave and the market cannot absorb the resulting increase in demand for care, patients may go elsewhere, to a competing hospital or outside the community. Rather than lose your market share, a hospital may consider the obvious solution: recruit a replacement ObGyn for your practice.

Your goal here is to negotiate an agreement in which your hospital will recruit a replacement ObGyn, provide financial support, and transition your practice to that ObGyn over a specified period.

The hospital could acquire your practice and either employ you during the transition or provide recruiting support and an income guarantee to help your practice pay the new physician’s salary. Whether to sell or remain independent is often driven by the needs and desires of the recruit. As the vast majority of clinicians coming out of training are seeking employment, in most cases the agreement will require a sale.

Selling to a hospital a few years before your retirement can be a plus. You might find employment a welcome respite from the daunting responsibility of managing your own practice. Life can become much less stressful as you introduce and transition your patients to the new ObGyn. You will be working less, taking fewer calls, and maintaining or even increasing your income, all without the burden of managing the practice.

Read about determining your practice’s value

 

 

Putting a monetary value on your practice

After deciding to sell your practice, you need to determine its value. Buying a practice may be the largest financial transaction a young ObGyn will ever make. For a retiring physician, valuation of a practice may reflect a career’s worth of “sweat equity.”

What is your practice worth?

All ObGyns believe their practice is worth far more than any young ObGyn or hospital is willing to pay for it. After all, you have spent a medical lifetime creating, building, and nurturing your practice. You have cared for several thousand patients, who have been loyal and may want to stay with the practice under its new ObGyn. So, how does a retiring physician put a value on his or her practice and then “cast the net” to the marketplace? How do you find a buyer who will pay the asking price and then help the practice make the transition from seller to buyer and continue to serve their patients?

The buyer’s perspective on value. In a pure sense, the value of any asset is what a potential buyer is willing to pay. From a value standpoint, the price that potential buyers are willing to pay varies by the specifics of the situation, regardless of what a valuation or practice appraisal might indicate.

For example, once your plan to retire becomes known, why would a young ObGyn agree to pay X dollars for all your medical records? After all, the potential buyer knows that your existing patients and your referral base will need to seek care from another ObGyn after you leave, and they will likely stay with the practice if they feel they will be treated well by the new clinician.

A hospital may take a similar tack but more often will be willing to pay fair market value for your practice. Hospitals, however, cannot legally pay more than fair market value as determined by an independent appraiser.


Related article:
Four pillars of a successful practice: 1. Keep your current patients happy

Valuation methods

The valuation of any business generally is approached in terms of market, assets, and income.

The market approach usually is taken only with regard to office real estate. Given the lack of reliable and comparable sales information, this approach is seldom used in the valuation of medical practices. If you own your office real estate, a real estate appraiser will establish its fair market value.

In the assets approach, the individual assets of a medical practice are valued on the basis of their current market values. These assets are either tangible or intangible.

Tangible assets can be seen and touched. Furniture, equipment, and office real estate are examples.

The fair market value of used furniture and equipment is most often determined by replacement cost. The value of these items is limited. Usually it starts at 50% of the cost of buying new furniture or equipment of the same utility. From there, the value is lowered on the basis of the age and condition of the items.

Often, the market value of major ObGyn office equipment, such as a DXA (dual-energy x-ray absorptiometry) scanner, is based on similar items for sale or recently sold in the used secondary equipment market.

Tangible assets may include accounts receivable (A/R). A/R represents uncollected payment for work performed. Most buyers want to avoid paying for A/R and assuming the risk of collections. Generally, you should expect to retain your A/R and pay a small or nominal fee to have the buyer handle the collections after you have retired.

Intangible assets are not physical. Examples include the physician’s name, phone number, reputation, referral base, trained staff, and medical records—in other words, what gets patients to keep coming back. Most physicians value these goodwill or “blue-sky” assets highly. Today, unfortunately, most sellers are unable to reap any financial benefit from their intangible assets.

The income approach is based on the premise that the value of any business is in the income it generates for its owner. In simple terms, value in the income approach is a multiple of the cash the business generates after expenses.

Read important keys to transitioning the practice

 

 

Transitioning the practice: Role of the seller and the buyer

First and very important is the contract agreement regarding the overlap period, when both the exiting ObGyn and the new ObGyn are at the practice. We suggest making the overlap a minimum of 6 months and a maximum of 1 year. During this period, the exiting physician can introduce the incoming physician to the patients. A face-to-face introduction can amount to an endorsement, which can ease a patient’s mind and help her decide to take on the new ObGyn and philosophy rather than search elsewhere for obstetric and gynecologic care. The new ObGyn also can use the overlap period to become familiar and comfortable with the staff and learn the process for physician and staff management of case flow, from scheduling and examination to insurance and patient follow-up.

We suggest that the exiting ObGyn send a farewell/welcome letter to patients and referring physicians. The letter should state the exiting ObGyn’s intention to leave (or retire from) the practice and should introduce the ObGyn who will be taking over.

The exiting ObGyn should also take the new ObGyn to meet the physicians who have been providing referrals over the years. We suggest visiting each referring physician’s office to make the introduction. Another good way to introduce a new ObGyn to referring physicians and other professionals—endocrinologists, cardiologists, nurses, pharmaceutical representatives—is to host an open house at your practice. Invite the staff members of the referring physicians as well, since they can be invaluable in making referrals.

We recommend that the exiting ObGyn spend the money to update all the practice’s stationery, brochures, and print materials and ensure they look professional. Note that it is not acceptable to place the new ObGyn’s name under the exiting ObGyn’s name. If the practice has a website, introduce the new physician there and make any necessary updates regarding office hours and accepted insurance plans.

If the exiting ObGyn’s practice lacks a robust Internet and social media presence, the new ObGyn should establish one. We recommend setting up an interactive website that patients can use to make appointments and pay bills. The website should have an email component that can be used to ask questions, raise concerns, and get answers. We also recommend opening Facebook, YouTube, and Twitter accounts for the practice and being active on these social media.

In our experience, smoothly transitioning practices can achieve patient retention rates as high as 90% to 95%. For practices without a plan, however, these rates may be as low as 50%, or worse. Therefore, work out a plan in advance, and include the steps described here, so that on arrival the new ObGyn can hit the ground running.

Acquiring a successful medical practice is doable and offers many advantages, such as autonomy and the ability to make business decisions affecting the practice. Despite all the changes happening in health care, we still think this is the best way to go.


Related article:
Four pillars of a successful practice: 4. Motivate your staff

Bottom line

Selling an ObGyn practice can be a daunting process. However, deciding to sell your practice, performing the valuation, and ensuring a smooth transition are part and parcel of making the transfer a success, equitable for both the buyer and the seller.

 

Share your thoughts! Send your Letter to the Editor to [email protected]. Please include your name and the city and state in which you practice.

For ObGyns, 2 intensely stressful career milestones are the day you start your practice and the day you decide to put it up for sale.

One of us, Dr. Baum, started a practice in 1976. At that time, many clinicians seemed to work right up until the day they died—in mid-examination or with scalpel in hand! Today, clinicians seriously contemplate leaving an active practice at age 55, 60, or, more traditionally, 65.

ObGyns in group practice, even those with only 1 or 2 partners, presumably have in place a well-thought-out and properly drafted contract with buyout and phase-down provisions. For members of a group practice, it is imperative to critically review and discuss contractual arrangements periodically and decide if they make sense as much now as they did at the start. ObGyns who continually revisit their contracts probably have an exit strategy that is fairly self-executing and effective and that will provide the seller with a seamless transition to retirement.

A solo ObGyn who is selling a practice has 3 basic options: find a successor physician, sell to a hospital or to a larger group, or close the practice.


Related article:
ObGyns’ choice of practice environment is a big deal

Preparing your practice for sale

Regardless of who will take over your practice, you need to prepare for its transition.

The most important aspect of selling your practice is knowing its finances and ensuring that they are in order. Any serious buyer will ask to examine your books, see how you are running the business, and assess its vitality and potential growth. Simply, a buyer will want to know where your revenue comes from and where it goes.

Your practice will be attractive to a buyer if it shows a stable or growing revenue base, an attractive payer mix, reasonable overhead, and personal income that is steady if not increasing. If your earning capacity is low or declining, you will need to explain why.

Timing is key

We strongly recommend beginning the process 3 to 5 years before your intended exit.

By starting early, up to 5 years in advance, you can maximize the likelihood that your practice will retain all or most of its value. Moreover, you can use the long lead time to thoroughly explore all available options and find a committed buyer.

Selling a practice can be a complicated affair, and many ObGyns do not have the requisite skills. So much of the success in selling depends on the specifics of the practice, the physician, and the market (the hospital and physician environment).

Identifying potential buyers

Other ObGyns. Recruiting an ObGyn to take over your practice seems to be the best option but can prove very difficult in today’s environment. Many younger clinicians are either joining large groups or becoming hospital employees.

Other physician groups. While working your way down your list of potential buyers, you should also be quietly, subtly, and tactfully assessing other practices, even your competitors, to see if any are candidates for merging with and/or acquiring yours and all your charts, records, and referring physicians.

Hospitals. In today’s health care environment, in which more than half of clinicians are becoming hospital employees, selling to your associated hospital may be a viable option.

Your practice is probably contributing millions of dollars in income to that hospital each year, and of course the hospital would like to maintain this revenue stream. You should consider talking to the hospital’s CEO or medical director.

Hospitals also know that, if you leave and the market cannot absorb the resulting increase in demand for care, patients may go elsewhere, to a competing hospital or outside the community. Rather than lose your market share, a hospital may consider the obvious solution: recruit a replacement ObGyn for your practice.

Your goal here is to negotiate an agreement in which your hospital will recruit a replacement ObGyn, provide financial support, and transition your practice to that ObGyn over a specified period.

The hospital could acquire your practice and either employ you during the transition or provide recruiting support and an income guarantee to help your practice pay the new physician’s salary. Whether to sell or remain independent is often driven by the needs and desires of the recruit. As the vast majority of clinicians coming out of training are seeking employment, in most cases the agreement will require a sale.

Selling to a hospital a few years before your retirement can be a plus. You might find employment a welcome respite from the daunting responsibility of managing your own practice. Life can become much less stressful as you introduce and transition your patients to the new ObGyn. You will be working less, taking fewer calls, and maintaining or even increasing your income, all without the burden of managing the practice.

Read about determining your practice’s value

 

 

Putting a monetary value on your practice

After deciding to sell your practice, you need to determine its value. Buying a practice may be the largest financial transaction a young ObGyn will ever make. For a retiring physician, valuation of a practice may reflect a career’s worth of “sweat equity.”

What is your practice worth?

All ObGyns believe their practice is worth far more than any young ObGyn or hospital is willing to pay for it. After all, you have spent a medical lifetime creating, building, and nurturing your practice. You have cared for several thousand patients, who have been loyal and may want to stay with the practice under its new ObGyn. So, how does a retiring physician put a value on his or her practice and then “cast the net” to the marketplace? How do you find a buyer who will pay the asking price and then help the practice make the transition from seller to buyer and continue to serve their patients?

The buyer’s perspective on value. In a pure sense, the value of any asset is what a potential buyer is willing to pay. From a value standpoint, the price that potential buyers are willing to pay varies by the specifics of the situation, regardless of what a valuation or practice appraisal might indicate.

For example, once your plan to retire becomes known, why would a young ObGyn agree to pay X dollars for all your medical records? After all, the potential buyer knows that your existing patients and your referral base will need to seek care from another ObGyn after you leave, and they will likely stay with the practice if they feel they will be treated well by the new clinician.

A hospital may take a similar tack but more often will be willing to pay fair market value for your practice. Hospitals, however, cannot legally pay more than fair market value as determined by an independent appraiser.


Related article:
Four pillars of a successful practice: 1. Keep your current patients happy

Valuation methods

The valuation of any business generally is approached in terms of market, assets, and income.

The market approach usually is taken only with regard to office real estate. Given the lack of reliable and comparable sales information, this approach is seldom used in the valuation of medical practices. If you own your office real estate, a real estate appraiser will establish its fair market value.

In the assets approach, the individual assets of a medical practice are valued on the basis of their current market values. These assets are either tangible or intangible.

Tangible assets can be seen and touched. Furniture, equipment, and office real estate are examples.

The fair market value of used furniture and equipment is most often determined by replacement cost. The value of these items is limited. Usually it starts at 50% of the cost of buying new furniture or equipment of the same utility. From there, the value is lowered on the basis of the age and condition of the items.

Often, the market value of major ObGyn office equipment, such as a DXA (dual-energy x-ray absorptiometry) scanner, is based on similar items for sale or recently sold in the used secondary equipment market.

Tangible assets may include accounts receivable (A/R). A/R represents uncollected payment for work performed. Most buyers want to avoid paying for A/R and assuming the risk of collections. Generally, you should expect to retain your A/R and pay a small or nominal fee to have the buyer handle the collections after you have retired.

Intangible assets are not physical. Examples include the physician’s name, phone number, reputation, referral base, trained staff, and medical records—in other words, what gets patients to keep coming back. Most physicians value these goodwill or “blue-sky” assets highly. Today, unfortunately, most sellers are unable to reap any financial benefit from their intangible assets.

The income approach is based on the premise that the value of any business is in the income it generates for its owner. In simple terms, value in the income approach is a multiple of the cash the business generates after expenses.

Read important keys to transitioning the practice

 

 

Transitioning the practice: Role of the seller and the buyer

First and very important is the contract agreement regarding the overlap period, when both the exiting ObGyn and the new ObGyn are at the practice. We suggest making the overlap a minimum of 6 months and a maximum of 1 year. During this period, the exiting physician can introduce the incoming physician to the patients. A face-to-face introduction can amount to an endorsement, which can ease a patient’s mind and help her decide to take on the new ObGyn and philosophy rather than search elsewhere for obstetric and gynecologic care. The new ObGyn also can use the overlap period to become familiar and comfortable with the staff and learn the process for physician and staff management of case flow, from scheduling and examination to insurance and patient follow-up.

We suggest that the exiting ObGyn send a farewell/welcome letter to patients and referring physicians. The letter should state the exiting ObGyn’s intention to leave (or retire from) the practice and should introduce the ObGyn who will be taking over.

The exiting ObGyn should also take the new ObGyn to meet the physicians who have been providing referrals over the years. We suggest visiting each referring physician’s office to make the introduction. Another good way to introduce a new ObGyn to referring physicians and other professionals—endocrinologists, cardiologists, nurses, pharmaceutical representatives—is to host an open house at your practice. Invite the staff members of the referring physicians as well, since they can be invaluable in making referrals.

We recommend that the exiting ObGyn spend the money to update all the practice’s stationery, brochures, and print materials and ensure they look professional. Note that it is not acceptable to place the new ObGyn’s name under the exiting ObGyn’s name. If the practice has a website, introduce the new physician there and make any necessary updates regarding office hours and accepted insurance plans.

If the exiting ObGyn’s practice lacks a robust Internet and social media presence, the new ObGyn should establish one. We recommend setting up an interactive website that patients can use to make appointments and pay bills. The website should have an email component that can be used to ask questions, raise concerns, and get answers. We also recommend opening Facebook, YouTube, and Twitter accounts for the practice and being active on these social media.

In our experience, smoothly transitioning practices can achieve patient retention rates as high as 90% to 95%. For practices without a plan, however, these rates may be as low as 50%, or worse. Therefore, work out a plan in advance, and include the steps described here, so that on arrival the new ObGyn can hit the ground running.

Acquiring a successful medical practice is doable and offers many advantages, such as autonomy and the ability to make business decisions affecting the practice. Despite all the changes happening in health care, we still think this is the best way to go.


Related article:
Four pillars of a successful practice: 4. Motivate your staff

Bottom line

Selling an ObGyn practice can be a daunting process. However, deciding to sell your practice, performing the valuation, and ensuring a smooth transition are part and parcel of making the transfer a success, equitable for both the buyer and the seller.

 

Share your thoughts! Send your Letter to the Editor to [email protected]. Please include your name and the city and state in which you practice.

Issue
OBG Management - 29(8)
Issue
OBG Management - 29(8)
Page Number
24-26, 28-29
Page Number
24-26, 28-29
Publications
Publications
Topics
Article Type
Display Headline
How to sell your ObGyn practice
Display Headline
How to sell your ObGyn practice
Sections
Inside the Article
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Article PDF Media

How Often Are EEGs Overread?

Article Type
Changed
Mon, 01/07/2019 - 10:32
Lack of training and inexperience may contribute to misinterpretation of EEGs.

BOSTONBetween 30% and 40% of patients diagnosed with intractable epilepsy do not have epilepsy, according to an overview presented at the 69th Annual Meeting of the American Academy of Neurology. A combination of overreading and overemphasizing EEGs can contribute to misdiagnosis, said Selim R. Benbadis, MD, Professor of Neurology and Director of the Comprehensive Epilepsy Program at the University of South Florida in Tampa.

Selim R. Benbadis, MD

Neurologists overread EEGs “because of the perception that there is less risk in overdiagnosing epilepsy, as opposed to underdiagnosing [the disease], and that is not correct,” said Dr. Benbadis.

The consequences of an epilepsy misdiagnosis can be serious. Patients can lose driving privileges, which may limit their employment opportunities. Epilepsy also is associated with a stigma that can be difficult to dispel, said Dr. Benbadis. In addition, patients misdiagnosed with epilepsy can have side effects from seizure medications.

Why Are EEGs Overread?

Two of the major reasons for misinterpration of EEGs are lack of training and inexperience, said Dr. Benbadis. Currently, it is not mandatory to learn how to read an EEG during neurology residency. Many neurology programs do require EEG training, but many do not. “If you are not experienced in looking at [an EEG], you will overread and think that everything is abnormal,” said Dr. Benbadis. Many normal variants and artifacts can look like epileptiform discharges to neurologists who are inexperienced in reading EEG.

Commonly overread EEG patterns include normal variants such as wicket rhythms, nonspecific temporal fluctuations, and rhythmic midtemporal theta of drowsiness. In addition, one study found that most patients were misdiagnosed with epilepsy because of overread EEGs; nonspecific fluctuations in the temporal region were misread as sharp waves.

The idea that “phase reversals” represent EEG abnormalities is a misconception, said Dr. Benbadis. A phase reversal, which identifies the location of maximum voltage, does not indicate abnormalities. Every normal waveform can have phase reversals, he said. A “history bias” can also lead to a misdiagnosis of epilepsy. For example, if a patient has a history of seizures or suspected seizures, a neurologist might be biased toward a diagnosis of epilepsy, and “look too hard” when reading the EEG, said Dr. Benbadis.

Steps to Improve EEG Interpretation

When deciding whether a discharge is epileptiform, neurologists should look for waves with an asymmetric contour that clearly stand out from the ongoing background of an EEG. About 98% of the time, with clear epileptiform discharges, neurologists can be sure that they indicate epilepsy without knowing the patient’s history, said Dr. Benbadis. Experts should develop consensus guidelines for EEG interpretation, and all neurology residents should be required to train in the EEG laboratory, said Dr. Benbadis. In addition, when there is doubt about whether an EEG was abnormal, “we must obtain the very EEG previously read as abnormal and redo the tracing or consult a colleague,” he added. Patients who have been diagnosed with epilepsy due to an abnormal EEG are encouraged to get a second opinion from an epilepsy or EEG specialist.

Erica Tricarico

Suggested Reading

Benbadis SR. “Just like EKGs!” Should EEGs undergo a confirmatory interpretation by a clinical neurophysiologist? Neurology. 2013; 80(1 Suppl 1):S47-S51.

Issue
Neurology Reviews - 25(8)
Publications
Topics
Page Number
13
Sections
Related Articles
Lack of training and inexperience may contribute to misinterpretation of EEGs.
Lack of training and inexperience may contribute to misinterpretation of EEGs.

BOSTONBetween 30% and 40% of patients diagnosed with intractable epilepsy do not have epilepsy, according to an overview presented at the 69th Annual Meeting of the American Academy of Neurology. A combination of overreading and overemphasizing EEGs can contribute to misdiagnosis, said Selim R. Benbadis, MD, Professor of Neurology and Director of the Comprehensive Epilepsy Program at the University of South Florida in Tampa.

Selim R. Benbadis, MD

Neurologists overread EEGs “because of the perception that there is less risk in overdiagnosing epilepsy, as opposed to underdiagnosing [the disease], and that is not correct,” said Dr. Benbadis.

The consequences of an epilepsy misdiagnosis can be serious. Patients can lose driving privileges, which may limit their employment opportunities. Epilepsy also is associated with a stigma that can be difficult to dispel, said Dr. Benbadis. In addition, patients misdiagnosed with epilepsy can have side effects from seizure medications.

Why Are EEGs Overread?

Two of the major reasons for misinterpration of EEGs are lack of training and inexperience, said Dr. Benbadis. Currently, it is not mandatory to learn how to read an EEG during neurology residency. Many neurology programs do require EEG training, but many do not. “If you are not experienced in looking at [an EEG], you will overread and think that everything is abnormal,” said Dr. Benbadis. Many normal variants and artifacts can look like epileptiform discharges to neurologists who are inexperienced in reading EEG.

Commonly overread EEG patterns include normal variants such as wicket rhythms, nonspecific temporal fluctuations, and rhythmic midtemporal theta of drowsiness. In addition, one study found that most patients were misdiagnosed with epilepsy because of overread EEGs; nonspecific fluctuations in the temporal region were misread as sharp waves.

The idea that “phase reversals” represent EEG abnormalities is a misconception, said Dr. Benbadis. A phase reversal, which identifies the location of maximum voltage, does not indicate abnormalities. Every normal waveform can have phase reversals, he said. A “history bias” can also lead to a misdiagnosis of epilepsy. For example, if a patient has a history of seizures or suspected seizures, a neurologist might be biased toward a diagnosis of epilepsy, and “look too hard” when reading the EEG, said Dr. Benbadis.

Steps to Improve EEG Interpretation

When deciding whether a discharge is epileptiform, neurologists should look for waves with an asymmetric contour that clearly stand out from the ongoing background of an EEG. About 98% of the time, with clear epileptiform discharges, neurologists can be sure that they indicate epilepsy without knowing the patient’s history, said Dr. Benbadis. Experts should develop consensus guidelines for EEG interpretation, and all neurology residents should be required to train in the EEG laboratory, said Dr. Benbadis. In addition, when there is doubt about whether an EEG was abnormal, “we must obtain the very EEG previously read as abnormal and redo the tracing or consult a colleague,” he added. Patients who have been diagnosed with epilepsy due to an abnormal EEG are encouraged to get a second opinion from an epilepsy or EEG specialist.

Erica Tricarico

Suggested Reading

Benbadis SR. “Just like EKGs!” Should EEGs undergo a confirmatory interpretation by a clinical neurophysiologist? Neurology. 2013; 80(1 Suppl 1):S47-S51.

BOSTONBetween 30% and 40% of patients diagnosed with intractable epilepsy do not have epilepsy, according to an overview presented at the 69th Annual Meeting of the American Academy of Neurology. A combination of overreading and overemphasizing EEGs can contribute to misdiagnosis, said Selim R. Benbadis, MD, Professor of Neurology and Director of the Comprehensive Epilepsy Program at the University of South Florida in Tampa.

Selim R. Benbadis, MD

Neurologists overread EEGs “because of the perception that there is less risk in overdiagnosing epilepsy, as opposed to underdiagnosing [the disease], and that is not correct,” said Dr. Benbadis.

The consequences of an epilepsy misdiagnosis can be serious. Patients can lose driving privileges, which may limit their employment opportunities. Epilepsy also is associated with a stigma that can be difficult to dispel, said Dr. Benbadis. In addition, patients misdiagnosed with epilepsy can have side effects from seizure medications.

Why Are EEGs Overread?

Two of the major reasons for misinterpration of EEGs are lack of training and inexperience, said Dr. Benbadis. Currently, it is not mandatory to learn how to read an EEG during neurology residency. Many neurology programs do require EEG training, but many do not. “If you are not experienced in looking at [an EEG], you will overread and think that everything is abnormal,” said Dr. Benbadis. Many normal variants and artifacts can look like epileptiform discharges to neurologists who are inexperienced in reading EEG.

Commonly overread EEG patterns include normal variants such as wicket rhythms, nonspecific temporal fluctuations, and rhythmic midtemporal theta of drowsiness. In addition, one study found that most patients were misdiagnosed with epilepsy because of overread EEGs; nonspecific fluctuations in the temporal region were misread as sharp waves.

The idea that “phase reversals” represent EEG abnormalities is a misconception, said Dr. Benbadis. A phase reversal, which identifies the location of maximum voltage, does not indicate abnormalities. Every normal waveform can have phase reversals, he said. A “history bias” can also lead to a misdiagnosis of epilepsy. For example, if a patient has a history of seizures or suspected seizures, a neurologist might be biased toward a diagnosis of epilepsy, and “look too hard” when reading the EEG, said Dr. Benbadis.

Steps to Improve EEG Interpretation

When deciding whether a discharge is epileptiform, neurologists should look for waves with an asymmetric contour that clearly stand out from the ongoing background of an EEG. About 98% of the time, with clear epileptiform discharges, neurologists can be sure that they indicate epilepsy without knowing the patient’s history, said Dr. Benbadis. Experts should develop consensus guidelines for EEG interpretation, and all neurology residents should be required to train in the EEG laboratory, said Dr. Benbadis. In addition, when there is doubt about whether an EEG was abnormal, “we must obtain the very EEG previously read as abnormal and redo the tracing or consult a colleague,” he added. Patients who have been diagnosed with epilepsy due to an abnormal EEG are encouraged to get a second opinion from an epilepsy or EEG specialist.

Erica Tricarico

Suggested Reading

Benbadis SR. “Just like EKGs!” Should EEGs undergo a confirmatory interpretation by a clinical neurophysiologist? Neurology. 2013; 80(1 Suppl 1):S47-S51.

Issue
Neurology Reviews - 25(8)
Issue
Neurology Reviews - 25(8)
Page Number
13
Page Number
13
Publications
Publications
Topics
Article Type
Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default

For the management of labor, patience is a virtue

Article Type
Changed
Tue, 08/28/2018 - 11:09
Display Headline
For the management of labor, patience is a virtue
Start using the ACOG/SMFM labor management guidelines in your practice

During the past 45 years, the cesarean delivery (CD) rate in the United States has increased from 5.5% in 1970 to 33% from 2009 to 2013, followed by a small decrease to 32% in 2014 and 2015.1 Many clinical problems cause clinicians and patients to decide that CD is an optimal birth route, including: abnormal labor progress, abnormal or indeterminate fetal heart rate pattern, breech presentation, multiple gestation, macrosomia, placental and cord abnormalities, preeclampsia, prior uterine surgery, and prior CD.2 Recent secular trends that contribute to the current rate of CD include an adversarial liability environment,3,4 increasing rates of maternal obesity,5 and widespread use of continuous fetal-heart monitoring during labor.6

Wide variation in CD rate has been reported among countries, states, and hospitals. The variation is due, in part, to different perspectives about balancing the harms and benefits of vaginal delivery versus CD. In Europe, in 2010 the CD rates in Sweden and Italy were 17.1% and 38%, respectively.7 In 2010, among the states, Alaska had the lowest rate of CD at 22% and Kentucky had the highest rate at 40%.8 In 2015, the highest rate was 38%, in Mississippi (FIGURE).9 In 2014, among Massachusetts hospitals with more than 2,500 births, the CD rate ranged from a low of 22% to a high of 37%.10

Clinicians, patients, policy experts, and the media are perplexed and troubled by the “high” US CD rate and the major variation in rate among countries, states, and hospitals. Labor management practices likely influence the rate of CD and diverse approaches to labor management likely account for the wide variation in CD rates.

A nationwide effort to standardize and continuously improve labor management might result in a decrease in the CD rate. Building on this opportunity, the American College of Obstetricians and Gynecologists (ACOG) and the Society of Maternal-Fetal Medicine (SMFM) have jointly recommended new labor management guidelines that may reduce the primary CD rate.8

The ACOG/SMFM guidelines encourage obstetricians to extend the time for labor progress in both the 1st and 2nd stages prior to recommending a CD.8 These new guidelines emphasize that for a modern obstetrician, patience is a virtue. There are 2 important caveats to this statement: to safely extend the length of time of labor requires both (1) a reassuring fetal heart rate tracing and (2) stable maternal health. If the fetus demonstrates a persistent worrisome Category II or a Category IIIheart-rate tracing, decisive intervention is necessary and permitting an extended labor would not be optimal. Similarly, if the mother has rapidly worsening preeclampsia it may not be wise to extend an induction of labor (IOL) over many days.

There are risks with extending the length of labor. An extended duration of the 1st stage of labor is associated with an increased rate of maternal chorioamnionitis and shoulder dystocia at birth.11 An extended duration of the 2nd stage of labor is associated with an increase in the rate of maternal chorioamnionitis, anal sphincter injury, uterine atony, and neonatal admission to an intensive care unit.12 Clinicians who adopt practices that permit an extended length of labor must weigh the benefits of avoiding a CD against these maternal and fetal complications.

Active phase redefined

Central to the ACOG/SMFM guidelines is a new definition of the active phase of labor. The research of Dr. Emmanuel Friedman indicated that at approximately 4 cm of cervical dilation many women in labor transition from the latent phase, a time of slow change in cervical dilation, to the active phase, a time of more rapid change in cervical dilation.13,14 However, more recent research indicates that the transition between the latent and active phase is difficult to precisely define, but more often occurs at about 6 cm of cervical dilation and not 4 cm of dilation.15 Adopting these new norms means that laboring women will spend much more time in the latent phase, a phase of labor in which patience is a virtue.

The ACOG/SMFM guidelines

Main takeaways from the ACOG/SMFM guidelines are summarized below. Interventions that address common obstetric issues and labor abnormalities are outlined below.

Do not perform CD for a prolonged latent phase of labor, defined as regular contractions of >20 hours duration in nulliparous women and >14 hours duration in multiparous women. Patience with a prolonged latent phase will be rewarded by the majority of women entering the active phase of labor. Alternatively, if appropriate, cervical ripening followed by oxytocin IOL and amniotomy will help the patient with a prolonged latent phase to enter the active phase of labor.16

For women with an unfavorable cervix as assessed by the Bishop score, cervical ripening should be performed prior to IOL. Use of cervical ripening prior to IOL increases the chance of achieving vaginal delivery within 24 hours and may result in a modest decrease in the rate of CD.17,18


Related article:
Should oxytocin and a Foley catheter be used concurrently for cervical ripening in induction of labor?
 

Failed IOL in the latent phase should only be diagnosed following 12 to 18 hours of both ruptured membranes and adequate contractions stimulated with oxytocin. The key ingredients for the successful management of the latent phase of labor are patience, oxytocin, and amniotomy.16

CD for the indication of active phase arrest requires cervical dilation ≥6 cm with ruptured membranes and no change in cervical dilation for ≥4 hours of adequate uterine activity. In the past, most obstetricians defined active phase arrest, a potential indication for CD, as the absence of cervical change for 2 or more hours in the presence of adequate uterine contractions and cervical dilation of at least 4 cm. Given the new definition of active phase arrest, slow but progressive progress in the 1st stage of labor is not an indication for CD.11,19

“A specific absolute maximum length of time spent in the 2nd stage beyond which all women should be offered an operative delivery has not been identified.”8 Diagnosis of arrest of labor in the 2nd stage may be considered after at least 2 hours of pushing in multiparous women and 3 hours of pushing in nulliparous women, especially if no fetal descent is occurring. The guidelines also state “longer durations may be appropriate on an individualized basis (eg, with use of epidural analgesia or with fetal malposition)” as long as fetal descent is observed.

Patience is a virtue, especially in the management of the 2nd stage of labor. Extending the 2nd stage up to 4 hours appears to be reasonably safe if the fetal status is reassuring and the mother is physiologically stable. In a study from San Francisco of 42,268 births with normal newborn outcomes, the 95th percentile for the length of the 2nd stage of labor for nulliparous women was 3.3 hours without an epidural and 5.6 hours with an epidural.20

In a study of 53,285 births, longer duration of pushing was associated with a small increase in the rate of neonatal adverse outcomes. In nulliparous women the rate of adverse neonatal outcomes increased from 1.3% with less than 60 minutes of pushing to 2.4% with greater than 240 minutes of pushing. Remarkably, even after 4 hours of pushing, 78% of nulliparous women who continued to push had a vaginal delivery.21 In this study, among nulliparous women the rate of anal sphincter injury increased from 5% with less than 60 minutes of pushing to 16% with greater than 240 minutes of pushing, and the rate of postpartum hemorrhage increased from 1% with less than 60 minutes of pushing to 3.3% with greater than 240 minutes of pushing.

I am not enthusiastic about patiently watching a labor extend into the 5th hour of the 2nd stage, especially if the fetus is at +2 station or lower. In a nulliparous woman, after 4 hours of managing the 2nd stage of labor, my patience is exhausted and I am inclined to identify a clear plan for delivery, either by enhanced labor coaching, operative vaginal delivery, or CD.

Operative vaginal delivery in the 2nd stage of labor is an acceptable alternative to CD. The rate of operative vaginal delivery in the United States has declined over the past 2 decades (TABLE). In Sweden in 2010 the operative vaginal delivery rate was 7.6% with a CD rate of 17.1%.7 In the United States in 2010 the operative delivery rate was 3.6%, and the CD rate was 33%.1 A renewed focus on operative vaginal delivery with ongoing training and team simulation for the procedure would increase our use of operative delivery and decrease the overall rate of CD.


Related article:
STOP using instruments to assist with delivery of the head at cesarean
 

Encourage the detection of persistent fetal occiput posterior position by physical examination and/or ultrasound and consider manual rotation of the fetal occiput from the posterior to anterior position in the 2nd stage. Persistent occiput posterior is the most common fetal malposition.22 This malposition is associated with an increased rate of CD.23 There are few randomized trials of manual rotation of the fetal occiput from posterior to anterior position in the 2nd stage of labor, and the evidence is insufficient to determine the efficacy of manual rotation.24 Small nonrandomized studies report that manual rotation of the occiput from posterior to anterior position may reduce the CD rate.25–27

For persistent 2nd stage fetal occiput posterior position in a woman with an adequate pelvis, where manual rotation was not successful and the fetus is at +2 station or below, operative vaginal delivery is an option. “Vacuum or forceps?” and “If forceps, to rotate or not to rotate?” those are the clinical questions. Forceps delivery is more likely to be successfulthan vacuum delivery.28 Direct forceps delivery of the occiput posterior fetus is associated with more anal sphincter injuries than forceps delivery after successful rotation, but few clinicians regularly perform rotational forceps.29 In a study of 2,351 women in the 2nd stage of labor with the fetus at +2 station or below, compared with either forceps or vacuum delivery, CD was associated with more maternal infections and fewer perineal lacerations. Neonatal composite morbidity was not significantly different among the 3 routes of operative delivery.30

Amnioinfusion for repetitive variable decelerations of the fetal heart rate may reduce the risk of CD for an indeterminate fetal heart-rate pattern.31

IOL in a well-dated pregnancy at 41 weeks will reduce the risk of CD. In a large clinical trial, 3,407 women at 41 weeks of gestation were randomly assigned to IOL or expectant management. The rate of CD was significantly lower in the women assigned to IOL compared with expectant management (21% vs 25%, respectively; P = .03).32 The rate of neonatal morbidity was similar in the 2 groups.

Women with twin gestations and the first twin in a cephalic presentation may elect vaginal delivery. In a large clinical trial, 1,398 women with a twin gestation and the first twin in a cephalic presentation were randomly assigned to planned vaginal delivery (with cesarean only if necessary) or planned CD.33 The rate of CD was 44% and 91% for the women in the planned-vaginal and planned-cesarean groups, respectively. There was no significant difference in composite fetal or neonatal death or serious morbidity. The authors concluded that, for twin pregnancy with the presenting twin in the cephalic presentation, there were no demonstrated benefits of planned CD.

Develop maternity care systems that encourage the use of trial of labor after cesarean (TOLAC). The ACOG/SMFM guidelines focus on interventions to reduce the rate of primary CD and do not address the role of TOLAC in reducing CD rates. There are little data from clinical trials to assess the benefits and harms from TOLAC versus scheduled repeat CD.34 However, our experience with TOLAC in the 1990s strongly suggests that encouraging TOLAC will decrease the rate of CD. In 1996 the US rate of vaginal birth after cesarean (VBAC) peaked at 28%, and the rate of CD achieved a recent historic nadir of 21%. Growing concerns that TOLAC occasionally results in fetal harm was followed by a decrease in the VBAC rate to 12% in 2015.1 A recent study of obstetric practices in countries with high and low VBAC rates concluded that patient and clinician commitment and comfort with prioritizing TOLAC over scheduled repeat CD greatly influenced the VBAC rate.35


Related article:
Should lower uterine segment thickness measurement be included in the TOLAC decision-making process?

Labor management is an art

During labor obstetricians must balance the unique needs of mother and fetus, which requires great clinical skill and patience. Evolving concepts of normal labor progress necessitate that we change our expectations concerning the acceptable rate of progress in the 1st and 2nd stage of labor. Consistent application of these new labor guidelines may help to reduce the rate of CD.

 

Share your thoughts! Send your Letter to the Editor to [email protected]. Please include your name and the city and state in which you practice.

References
  1. Martin JA, Hamilton BE, Osterman MJ, Driscoll AK, Matthews TJ. Births: final data for 2015. Natl Vital Stat Rep. 2017;66(1):1–70. https://www.cdc.gov/nchs/data/nvsr/nvsr66/nvsr66_01.pdf. Accessed July 5, 2017.
  2. Barber EL, Lundsberg LS, Belanger K, Pettker CM, Funai EF, Illuzzi JL. Indications contributing to the increasing cesarean delivery rate. Obstet Gynecol. 2011;118(1):29–38.
  3. Localio AR, Lawthers AG, Bengtson JM, et al. Relationship between malpractice claims and cesarean delivery. JAMA. 1993;269(3):366–373.
  4. Cheng YW, Snowden JM, Handler SJ, Tager IB, Hubbard AE, Caughey AB. Litigation in obstetrics: does defensive medicine contribute to increases in cesarean delivery? J Matern Fetal Neonatal Med. 2014;27(16):1668–1675.
  5. Graham LE, Brunner Huber LR, Thompson ME, Ersek JL. Does amount of weight gain during pregnancy modify the association between obesity and cesarean section delivery? Birth. 2014;41(1):93–99.
  6. Alfirevic Z, Devane D, Gyte GM. Continuous cardiotocography (CTG) as a form of electronic fetal monitoring (EFM) for fetal assessment during labour. Cochrane Database Syst Rev. 2013;(5):CD006066.
  7. European Perinatal Health Report. Euro-Peristat website. http://www.europeristat.com/. Published 2012. Accessed July 5, 2017.
  8. American College of Obstetricians and Gynecologists; Society for Maternal-Fetal Medicine. Obstetric care consensus no. 1: safe prevention of the primary cesarean delivery. Obstet Gynecol. 2014;123(3):693–711.
  9. Cesarean delivery rate by state, 2015. Centers for Disease Control and Prevention website. https://www.cdc.gov/nchs/pressroom/sosmap/cesarean_births/cesareans.htm. Updated  January 9, 2017. Accessed July 18, 2017.
  10. Baker CD, Land T; Massachusetts Department of Public Health. Massachusetts Births 2014. Massachusetts Executive Office of Health and Human Services website. http://www.mass.gov/eohhs/gov/departments/dph/programs/admin/dmoa/repi/birth-data.html. Published September 2015. Accessed July 5, 2017.
  11. Henry DE, Cheng YW, Shaffer BL, Kaimal AJ, Bianco K, Caughey AB. Perinatal outcomes in the setting of active phase arrest of labor. Obstet Gynecol. 2008;112(5):1109–1115.
  12. Rouse DJ, Weiner SJ, Bloom SL, et al; Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Second-stage labor duration in nulliparous women: relationship to maternal and perinatal outcomes. Am J Obstet Gynecol. 2009;201(4):357.e1–e7.
  13. Friedman EZ. Labour: Clinical evaluation and management. Appleton-Century-Crofts: New York, NY; 1967.
  14. Friedman E. The graphic analysis of labor. Am J Obstet Gynecol. 1954;68(6):1568–1575.
  15. Zhang J, Landy HJ, Branch DW, et al; Consortium on Safe Labor. Contemporary patterns  of spontaneous labor with normal neonatal outcomes. Obstet Gynecol. 2010;116(6):1281–1287.
  16. Wei S, Wo BL, Qi HP, et al. Early amniotomy and early oxytocin for prevention of, or therapy for, delay in first stage spontaneous labour compared with routine care. Cochrane Database Syst Rev. 2013;(8):CD006794.
  17. Thomas J, Fairclough A, Kavanagh J, Kelly AJ. Vaginal prostaglandin (PGE2  and  PGF2a) for induction of labour at term. Cochrane Database Syst Rev. 2014;(6):CD003101.
  18. Alfirevic Z, Kelly AJ, Dowswell T. Intravenous oxytocin alone for cervical ripening and induction of labour. Cochrane Database Syst Rev. 2009;(4):CD003246.
  19. Rouse DJ, Owen J, Savage KG, Hauth JC. Active phase labor arrest: revisiting the 2-hour minimum. Obstet Gynecol. 2001;98(4):550–554.
  20. Cheng YW, Shaffer BL, Nicholson JM, Caughey AB. Second stage of labor and epidural use: a larger effect than previously suggested. Obstet Gynecol. 2014;123(3):527–535.
  21. Grobman WA, Bailit J, Lai Y, et al; Eunice Kennedy Shriver National Institute of Child  and Human Development (NICHD) Maternal-Fetal Medicine Units (MFMU) Network. Association of the duration of active pushing with obstetric outcomes. Obstet Gynecol. 2016;127(4):667–673.
  22. Barth WH Jr. Persistent occiput posterior. Obstet Gynecol. 2015;125(3):695–709.
  23. Carseldine WJ, Phipps H, Zawada SF, et al. Does occiput posterior position in the second stage of labour increase the operative delivery rate? Aust N Z J Obstet Gynaecol. 2013;53(3):265–270.
  24. Phipps H, de Vries B, Hyett J, Osborn DA. Prophylactic manual rotation for fetal  malposition to reduce operative delivery. Cochrane Database Syst Rev. 2014;(12):CD009298.
  25. Shaffer BL, Cheng YW, Vargas JE, Caughey AB. Manual rotation to reduce caesarean delivery in persistent occiput posterior or transverse position. J Matern Fetal Neonatal Med. 2011;24(1):65–72.
  26. Le Ray C, Serres P, Schmitz T, Cabrol D, Goffinet F. Manual rotation in occiput posterior or transverse positions: risk factors and consequences on the cesarean delivery rate. Obstet Gynecol. 2007;110(4):873–879.
  27. Reichman O, Gdansky E, Latinsky B, Labi S, Samueloff A. Digital rotation from occipito-posterior to occipito-anterior decreases the need for cesarean section. Eur J Obstet Gynecol Repro Biol. 2008;136:25–28.
  28. O’Mahony F, Hofmeyr GJ, Menon V. Choice of instruments for assisted vaginal delivery. Cochrane Database Syst Rev. 2010;(11):CD005455.
  29. Hirsch E, Elue R, Wagner A Jr, et al. Severe perineal laceration during operative vaginal  delivery: the impact of occiput posterior position. J Perinatol. 2014;34(12):898–900.
  30. Bailit JL, Grobman WA, Rice MM, et al; Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Evaluation of delivery options for second-stage events. Am J Obstet Gynecol. 2016;214(5):638.e1–e10.
  31. Hofmeyr GJ, Lawrie TA. Amnioinfusion for potential or suspected umbilical cord compression in labour. Cochrane Database Syst Rev. 2012;1:CD000013.
  32. Hannah ME, Hannah WJ, Hellmann J, Hewson S, Milner R, Willan A. Induction of labor as compared with serial antenatal monitoring in post-term pregnancy. A randomized controlled trial. The Canadian Multicenter Post-term Pregnancy Trial Group. N Engl J Med. 1992;326(24): 1587–1592.
  33. Barrett JF, Hannah ME, Hutton EK, et al; Twin Birth Study Collaborative Group. A randomized trial of planned cesarean or vaginal delivery for twin pregnancy. N Engl J Med. 2013;369(14):1295–1305.
  34. Dodd JM, Crowther CA, Huertas E, Guise JM, Horey D. Planned elective repeat cesarean section versus planned vaginal birth for women with a previous caesarean birth. Cochrane Database Syst Rev. 2013;(12):CD004224.
  35. Lundgren I, van Limbeek E, Vehvilainen-Julkunen K, Nilsson C. Clinicians’ views of factors of importance for improving the rate of VBAC (vaginal birth after caesarean section): a qualitative study from countries with high VBAC rates. BMC Pregnancy Childbirth. 2015;15:196.
Article PDF
Author and Disclosure Information

Dr. Barbieri is Editor in Chief, OBG Management; Chair, Obstetrics and Gynecology, Brigham and Women’s Hospital; and Kate Macy Ladd Professor of Obstetrics, Gynecology, and Reproductive Biology, Harvard Medical School, Boston, Massachusetts.

Dr. Barbieri reports no financial relationships relevant to this article.

Issue
OBG Management - 29(8)
Publications
Topics
Page Number
6-11
Sections
Author and Disclosure Information

Dr. Barbieri is Editor in Chief, OBG Management; Chair, Obstetrics and Gynecology, Brigham and Women’s Hospital; and Kate Macy Ladd Professor of Obstetrics, Gynecology, and Reproductive Biology, Harvard Medical School, Boston, Massachusetts.

Dr. Barbieri reports no financial relationships relevant to this article.

Author and Disclosure Information

Dr. Barbieri is Editor in Chief, OBG Management; Chair, Obstetrics and Gynecology, Brigham and Women’s Hospital; and Kate Macy Ladd Professor of Obstetrics, Gynecology, and Reproductive Biology, Harvard Medical School, Boston, Massachusetts.

Dr. Barbieri reports no financial relationships relevant to this article.

Article PDF
Article PDF
Start using the ACOG/SMFM labor management guidelines in your practice
Start using the ACOG/SMFM labor management guidelines in your practice

During the past 45 years, the cesarean delivery (CD) rate in the United States has increased from 5.5% in 1970 to 33% from 2009 to 2013, followed by a small decrease to 32% in 2014 and 2015.1 Many clinical problems cause clinicians and patients to decide that CD is an optimal birth route, including: abnormal labor progress, abnormal or indeterminate fetal heart rate pattern, breech presentation, multiple gestation, macrosomia, placental and cord abnormalities, preeclampsia, prior uterine surgery, and prior CD.2 Recent secular trends that contribute to the current rate of CD include an adversarial liability environment,3,4 increasing rates of maternal obesity,5 and widespread use of continuous fetal-heart monitoring during labor.6

Wide variation in CD rate has been reported among countries, states, and hospitals. The variation is due, in part, to different perspectives about balancing the harms and benefits of vaginal delivery versus CD. In Europe, in 2010 the CD rates in Sweden and Italy were 17.1% and 38%, respectively.7 In 2010, among the states, Alaska had the lowest rate of CD at 22% and Kentucky had the highest rate at 40%.8 In 2015, the highest rate was 38%, in Mississippi (FIGURE).9 In 2014, among Massachusetts hospitals with more than 2,500 births, the CD rate ranged from a low of 22% to a high of 37%.10

Clinicians, patients, policy experts, and the media are perplexed and troubled by the “high” US CD rate and the major variation in rate among countries, states, and hospitals. Labor management practices likely influence the rate of CD and diverse approaches to labor management likely account for the wide variation in CD rates.

A nationwide effort to standardize and continuously improve labor management might result in a decrease in the CD rate. Building on this opportunity, the American College of Obstetricians and Gynecologists (ACOG) and the Society of Maternal-Fetal Medicine (SMFM) have jointly recommended new labor management guidelines that may reduce the primary CD rate.8

The ACOG/SMFM guidelines encourage obstetricians to extend the time for labor progress in both the 1st and 2nd stages prior to recommending a CD.8 These new guidelines emphasize that for a modern obstetrician, patience is a virtue. There are 2 important caveats to this statement: to safely extend the length of time of labor requires both (1) a reassuring fetal heart rate tracing and (2) stable maternal health. If the fetus demonstrates a persistent worrisome Category II or a Category IIIheart-rate tracing, decisive intervention is necessary and permitting an extended labor would not be optimal. Similarly, if the mother has rapidly worsening preeclampsia it may not be wise to extend an induction of labor (IOL) over many days.

There are risks with extending the length of labor. An extended duration of the 1st stage of labor is associated with an increased rate of maternal chorioamnionitis and shoulder dystocia at birth.11 An extended duration of the 2nd stage of labor is associated with an increase in the rate of maternal chorioamnionitis, anal sphincter injury, uterine atony, and neonatal admission to an intensive care unit.12 Clinicians who adopt practices that permit an extended length of labor must weigh the benefits of avoiding a CD against these maternal and fetal complications.

Active phase redefined

Central to the ACOG/SMFM guidelines is a new definition of the active phase of labor. The research of Dr. Emmanuel Friedman indicated that at approximately 4 cm of cervical dilation many women in labor transition from the latent phase, a time of slow change in cervical dilation, to the active phase, a time of more rapid change in cervical dilation.13,14 However, more recent research indicates that the transition between the latent and active phase is difficult to precisely define, but more often occurs at about 6 cm of cervical dilation and not 4 cm of dilation.15 Adopting these new norms means that laboring women will spend much more time in the latent phase, a phase of labor in which patience is a virtue.

The ACOG/SMFM guidelines

Main takeaways from the ACOG/SMFM guidelines are summarized below. Interventions that address common obstetric issues and labor abnormalities are outlined below.

Do not perform CD for a prolonged latent phase of labor, defined as regular contractions of >20 hours duration in nulliparous women and >14 hours duration in multiparous women. Patience with a prolonged latent phase will be rewarded by the majority of women entering the active phase of labor. Alternatively, if appropriate, cervical ripening followed by oxytocin IOL and amniotomy will help the patient with a prolonged latent phase to enter the active phase of labor.16

For women with an unfavorable cervix as assessed by the Bishop score, cervical ripening should be performed prior to IOL. Use of cervical ripening prior to IOL increases the chance of achieving vaginal delivery within 24 hours and may result in a modest decrease in the rate of CD.17,18


Related article:
Should oxytocin and a Foley catheter be used concurrently for cervical ripening in induction of labor?
 

Failed IOL in the latent phase should only be diagnosed following 12 to 18 hours of both ruptured membranes and adequate contractions stimulated with oxytocin. The key ingredients for the successful management of the latent phase of labor are patience, oxytocin, and amniotomy.16

CD for the indication of active phase arrest requires cervical dilation ≥6 cm with ruptured membranes and no change in cervical dilation for ≥4 hours of adequate uterine activity. In the past, most obstetricians defined active phase arrest, a potential indication for CD, as the absence of cervical change for 2 or more hours in the presence of adequate uterine contractions and cervical dilation of at least 4 cm. Given the new definition of active phase arrest, slow but progressive progress in the 1st stage of labor is not an indication for CD.11,19

“A specific absolute maximum length of time spent in the 2nd stage beyond which all women should be offered an operative delivery has not been identified.”8 Diagnosis of arrest of labor in the 2nd stage may be considered after at least 2 hours of pushing in multiparous women and 3 hours of pushing in nulliparous women, especially if no fetal descent is occurring. The guidelines also state “longer durations may be appropriate on an individualized basis (eg, with use of epidural analgesia or with fetal malposition)” as long as fetal descent is observed.

Patience is a virtue, especially in the management of the 2nd stage of labor. Extending the 2nd stage up to 4 hours appears to be reasonably safe if the fetal status is reassuring and the mother is physiologically stable. In a study from San Francisco of 42,268 births with normal newborn outcomes, the 95th percentile for the length of the 2nd stage of labor for nulliparous women was 3.3 hours without an epidural and 5.6 hours with an epidural.20

In a study of 53,285 births, longer duration of pushing was associated with a small increase in the rate of neonatal adverse outcomes. In nulliparous women the rate of adverse neonatal outcomes increased from 1.3% with less than 60 minutes of pushing to 2.4% with greater than 240 minutes of pushing. Remarkably, even after 4 hours of pushing, 78% of nulliparous women who continued to push had a vaginal delivery.21 In this study, among nulliparous women the rate of anal sphincter injury increased from 5% with less than 60 minutes of pushing to 16% with greater than 240 minutes of pushing, and the rate of postpartum hemorrhage increased from 1% with less than 60 minutes of pushing to 3.3% with greater than 240 minutes of pushing.

I am not enthusiastic about patiently watching a labor extend into the 5th hour of the 2nd stage, especially if the fetus is at +2 station or lower. In a nulliparous woman, after 4 hours of managing the 2nd stage of labor, my patience is exhausted and I am inclined to identify a clear plan for delivery, either by enhanced labor coaching, operative vaginal delivery, or CD.

Operative vaginal delivery in the 2nd stage of labor is an acceptable alternative to CD. The rate of operative vaginal delivery in the United States has declined over the past 2 decades (TABLE). In Sweden in 2010 the operative vaginal delivery rate was 7.6% with a CD rate of 17.1%.7 In the United States in 2010 the operative delivery rate was 3.6%, and the CD rate was 33%.1 A renewed focus on operative vaginal delivery with ongoing training and team simulation for the procedure would increase our use of operative delivery and decrease the overall rate of CD.


Related article:
STOP using instruments to assist with delivery of the head at cesarean
 

Encourage the detection of persistent fetal occiput posterior position by physical examination and/or ultrasound and consider manual rotation of the fetal occiput from the posterior to anterior position in the 2nd stage. Persistent occiput posterior is the most common fetal malposition.22 This malposition is associated with an increased rate of CD.23 There are few randomized trials of manual rotation of the fetal occiput from posterior to anterior position in the 2nd stage of labor, and the evidence is insufficient to determine the efficacy of manual rotation.24 Small nonrandomized studies report that manual rotation of the occiput from posterior to anterior position may reduce the CD rate.25–27

For persistent 2nd stage fetal occiput posterior position in a woman with an adequate pelvis, where manual rotation was not successful and the fetus is at +2 station or below, operative vaginal delivery is an option. “Vacuum or forceps?” and “If forceps, to rotate or not to rotate?” those are the clinical questions. Forceps delivery is more likely to be successfulthan vacuum delivery.28 Direct forceps delivery of the occiput posterior fetus is associated with more anal sphincter injuries than forceps delivery after successful rotation, but few clinicians regularly perform rotational forceps.29 In a study of 2,351 women in the 2nd stage of labor with the fetus at +2 station or below, compared with either forceps or vacuum delivery, CD was associated with more maternal infections and fewer perineal lacerations. Neonatal composite morbidity was not significantly different among the 3 routes of operative delivery.30

Amnioinfusion for repetitive variable decelerations of the fetal heart rate may reduce the risk of CD for an indeterminate fetal heart-rate pattern.31

IOL in a well-dated pregnancy at 41 weeks will reduce the risk of CD. In a large clinical trial, 3,407 women at 41 weeks of gestation were randomly assigned to IOL or expectant management. The rate of CD was significantly lower in the women assigned to IOL compared with expectant management (21% vs 25%, respectively; P = .03).32 The rate of neonatal morbidity was similar in the 2 groups.

Women with twin gestations and the first twin in a cephalic presentation may elect vaginal delivery. In a large clinical trial, 1,398 women with a twin gestation and the first twin in a cephalic presentation were randomly assigned to planned vaginal delivery (with cesarean only if necessary) or planned CD.33 The rate of CD was 44% and 91% for the women in the planned-vaginal and planned-cesarean groups, respectively. There was no significant difference in composite fetal or neonatal death or serious morbidity. The authors concluded that, for twin pregnancy with the presenting twin in the cephalic presentation, there were no demonstrated benefits of planned CD.

Develop maternity care systems that encourage the use of trial of labor after cesarean (TOLAC). The ACOG/SMFM guidelines focus on interventions to reduce the rate of primary CD and do not address the role of TOLAC in reducing CD rates. There are little data from clinical trials to assess the benefits and harms from TOLAC versus scheduled repeat CD.34 However, our experience with TOLAC in the 1990s strongly suggests that encouraging TOLAC will decrease the rate of CD. In 1996 the US rate of vaginal birth after cesarean (VBAC) peaked at 28%, and the rate of CD achieved a recent historic nadir of 21%. Growing concerns that TOLAC occasionally results in fetal harm was followed by a decrease in the VBAC rate to 12% in 2015.1 A recent study of obstetric practices in countries with high and low VBAC rates concluded that patient and clinician commitment and comfort with prioritizing TOLAC over scheduled repeat CD greatly influenced the VBAC rate.35


Related article:
Should lower uterine segment thickness measurement be included in the TOLAC decision-making process?

Labor management is an art

During labor obstetricians must balance the unique needs of mother and fetus, which requires great clinical skill and patience. Evolving concepts of normal labor progress necessitate that we change our expectations concerning the acceptable rate of progress in the 1st and 2nd stage of labor. Consistent application of these new labor guidelines may help to reduce the rate of CD.

 

Share your thoughts! Send your Letter to the Editor to [email protected]. Please include your name and the city and state in which you practice.

During the past 45 years, the cesarean delivery (CD) rate in the United States has increased from 5.5% in 1970 to 33% from 2009 to 2013, followed by a small decrease to 32% in 2014 and 2015.1 Many clinical problems cause clinicians and patients to decide that CD is an optimal birth route, including: abnormal labor progress, abnormal or indeterminate fetal heart rate pattern, breech presentation, multiple gestation, macrosomia, placental and cord abnormalities, preeclampsia, prior uterine surgery, and prior CD.2 Recent secular trends that contribute to the current rate of CD include an adversarial liability environment,3,4 increasing rates of maternal obesity,5 and widespread use of continuous fetal-heart monitoring during labor.6

Wide variation in CD rate has been reported among countries, states, and hospitals. The variation is due, in part, to different perspectives about balancing the harms and benefits of vaginal delivery versus CD. In Europe, in 2010 the CD rates in Sweden and Italy were 17.1% and 38%, respectively.7 In 2010, among the states, Alaska had the lowest rate of CD at 22% and Kentucky had the highest rate at 40%.8 In 2015, the highest rate was 38%, in Mississippi (FIGURE).9 In 2014, among Massachusetts hospitals with more than 2,500 births, the CD rate ranged from a low of 22% to a high of 37%.10

Clinicians, patients, policy experts, and the media are perplexed and troubled by the “high” US CD rate and the major variation in rate among countries, states, and hospitals. Labor management practices likely influence the rate of CD and diverse approaches to labor management likely account for the wide variation in CD rates.

A nationwide effort to standardize and continuously improve labor management might result in a decrease in the CD rate. Building on this opportunity, the American College of Obstetricians and Gynecologists (ACOG) and the Society of Maternal-Fetal Medicine (SMFM) have jointly recommended new labor management guidelines that may reduce the primary CD rate.8

The ACOG/SMFM guidelines encourage obstetricians to extend the time for labor progress in both the 1st and 2nd stages prior to recommending a CD.8 These new guidelines emphasize that for a modern obstetrician, patience is a virtue. There are 2 important caveats to this statement: to safely extend the length of time of labor requires both (1) a reassuring fetal heart rate tracing and (2) stable maternal health. If the fetus demonstrates a persistent worrisome Category II or a Category IIIheart-rate tracing, decisive intervention is necessary and permitting an extended labor would not be optimal. Similarly, if the mother has rapidly worsening preeclampsia it may not be wise to extend an induction of labor (IOL) over many days.

There are risks with extending the length of labor. An extended duration of the 1st stage of labor is associated with an increased rate of maternal chorioamnionitis and shoulder dystocia at birth.11 An extended duration of the 2nd stage of labor is associated with an increase in the rate of maternal chorioamnionitis, anal sphincter injury, uterine atony, and neonatal admission to an intensive care unit.12 Clinicians who adopt practices that permit an extended length of labor must weigh the benefits of avoiding a CD against these maternal and fetal complications.

Active phase redefined

Central to the ACOG/SMFM guidelines is a new definition of the active phase of labor. The research of Dr. Emmanuel Friedman indicated that at approximately 4 cm of cervical dilation many women in labor transition from the latent phase, a time of slow change in cervical dilation, to the active phase, a time of more rapid change in cervical dilation.13,14 However, more recent research indicates that the transition between the latent and active phase is difficult to precisely define, but more often occurs at about 6 cm of cervical dilation and not 4 cm of dilation.15 Adopting these new norms means that laboring women will spend much more time in the latent phase, a phase of labor in which patience is a virtue.

The ACOG/SMFM guidelines

Main takeaways from the ACOG/SMFM guidelines are summarized below. Interventions that address common obstetric issues and labor abnormalities are outlined below.

Do not perform CD for a prolonged latent phase of labor, defined as regular contractions of >20 hours duration in nulliparous women and >14 hours duration in multiparous women. Patience with a prolonged latent phase will be rewarded by the majority of women entering the active phase of labor. Alternatively, if appropriate, cervical ripening followed by oxytocin IOL and amniotomy will help the patient with a prolonged latent phase to enter the active phase of labor.16

For women with an unfavorable cervix as assessed by the Bishop score, cervical ripening should be performed prior to IOL. Use of cervical ripening prior to IOL increases the chance of achieving vaginal delivery within 24 hours and may result in a modest decrease in the rate of CD.17,18


Related article:
Should oxytocin and a Foley catheter be used concurrently for cervical ripening in induction of labor?
 

Failed IOL in the latent phase should only be diagnosed following 12 to 18 hours of both ruptured membranes and adequate contractions stimulated with oxytocin. The key ingredients for the successful management of the latent phase of labor are patience, oxytocin, and amniotomy.16

CD for the indication of active phase arrest requires cervical dilation ≥6 cm with ruptured membranes and no change in cervical dilation for ≥4 hours of adequate uterine activity. In the past, most obstetricians defined active phase arrest, a potential indication for CD, as the absence of cervical change for 2 or more hours in the presence of adequate uterine contractions and cervical dilation of at least 4 cm. Given the new definition of active phase arrest, slow but progressive progress in the 1st stage of labor is not an indication for CD.11,19

“A specific absolute maximum length of time spent in the 2nd stage beyond which all women should be offered an operative delivery has not been identified.”8 Diagnosis of arrest of labor in the 2nd stage may be considered after at least 2 hours of pushing in multiparous women and 3 hours of pushing in nulliparous women, especially if no fetal descent is occurring. The guidelines also state “longer durations may be appropriate on an individualized basis (eg, with use of epidural analgesia or with fetal malposition)” as long as fetal descent is observed.

Patience is a virtue, especially in the management of the 2nd stage of labor. Extending the 2nd stage up to 4 hours appears to be reasonably safe if the fetal status is reassuring and the mother is physiologically stable. In a study from San Francisco of 42,268 births with normal newborn outcomes, the 95th percentile for the length of the 2nd stage of labor for nulliparous women was 3.3 hours without an epidural and 5.6 hours with an epidural.20

In a study of 53,285 births, longer duration of pushing was associated with a small increase in the rate of neonatal adverse outcomes. In nulliparous women the rate of adverse neonatal outcomes increased from 1.3% with less than 60 minutes of pushing to 2.4% with greater than 240 minutes of pushing. Remarkably, even after 4 hours of pushing, 78% of nulliparous women who continued to push had a vaginal delivery.21 In this study, among nulliparous women the rate of anal sphincter injury increased from 5% with less than 60 minutes of pushing to 16% with greater than 240 minutes of pushing, and the rate of postpartum hemorrhage increased from 1% with less than 60 minutes of pushing to 3.3% with greater than 240 minutes of pushing.

I am not enthusiastic about patiently watching a labor extend into the 5th hour of the 2nd stage, especially if the fetus is at +2 station or lower. In a nulliparous woman, after 4 hours of managing the 2nd stage of labor, my patience is exhausted and I am inclined to identify a clear plan for delivery, either by enhanced labor coaching, operative vaginal delivery, or CD.

Operative vaginal delivery in the 2nd stage of labor is an acceptable alternative to CD. The rate of operative vaginal delivery in the United States has declined over the past 2 decades (TABLE). In Sweden in 2010 the operative vaginal delivery rate was 7.6% with a CD rate of 17.1%.7 In the United States in 2010 the operative delivery rate was 3.6%, and the CD rate was 33%.1 A renewed focus on operative vaginal delivery with ongoing training and team simulation for the procedure would increase our use of operative delivery and decrease the overall rate of CD.


Related article:
STOP using instruments to assist with delivery of the head at cesarean
 

Encourage the detection of persistent fetal occiput posterior position by physical examination and/or ultrasound and consider manual rotation of the fetal occiput from the posterior to anterior position in the 2nd stage. Persistent occiput posterior is the most common fetal malposition.22 This malposition is associated with an increased rate of CD.23 There are few randomized trials of manual rotation of the fetal occiput from posterior to anterior position in the 2nd stage of labor, and the evidence is insufficient to determine the efficacy of manual rotation.24 Small nonrandomized studies report that manual rotation of the occiput from posterior to anterior position may reduce the CD rate.25–27

For persistent 2nd stage fetal occiput posterior position in a woman with an adequate pelvis, where manual rotation was not successful and the fetus is at +2 station or below, operative vaginal delivery is an option. “Vacuum or forceps?” and “If forceps, to rotate or not to rotate?” those are the clinical questions. Forceps delivery is more likely to be successfulthan vacuum delivery.28 Direct forceps delivery of the occiput posterior fetus is associated with more anal sphincter injuries than forceps delivery after successful rotation, but few clinicians regularly perform rotational forceps.29 In a study of 2,351 women in the 2nd stage of labor with the fetus at +2 station or below, compared with either forceps or vacuum delivery, CD was associated with more maternal infections and fewer perineal lacerations. Neonatal composite morbidity was not significantly different among the 3 routes of operative delivery.30

Amnioinfusion for repetitive variable decelerations of the fetal heart rate may reduce the risk of CD for an indeterminate fetal heart-rate pattern.31

IOL in a well-dated pregnancy at 41 weeks will reduce the risk of CD. In a large clinical trial, 3,407 women at 41 weeks of gestation were randomly assigned to IOL or expectant management. The rate of CD was significantly lower in the women assigned to IOL compared with expectant management (21% vs 25%, respectively; P = .03).32 The rate of neonatal morbidity was similar in the 2 groups.

Women with twin gestations and the first twin in a cephalic presentation may elect vaginal delivery. In a large clinical trial, 1,398 women with a twin gestation and the first twin in a cephalic presentation were randomly assigned to planned vaginal delivery (with cesarean only if necessary) or planned CD.33 The rate of CD was 44% and 91% for the women in the planned-vaginal and planned-cesarean groups, respectively. There was no significant difference in composite fetal or neonatal death or serious morbidity. The authors concluded that, for twin pregnancy with the presenting twin in the cephalic presentation, there were no demonstrated benefits of planned CD.

Develop maternity care systems that encourage the use of trial of labor after cesarean (TOLAC). The ACOG/SMFM guidelines focus on interventions to reduce the rate of primary CD and do not address the role of TOLAC in reducing CD rates. There are little data from clinical trials to assess the benefits and harms from TOLAC versus scheduled repeat CD.34 However, our experience with TOLAC in the 1990s strongly suggests that encouraging TOLAC will decrease the rate of CD. In 1996 the US rate of vaginal birth after cesarean (VBAC) peaked at 28%, and the rate of CD achieved a recent historic nadir of 21%. Growing concerns that TOLAC occasionally results in fetal harm was followed by a decrease in the VBAC rate to 12% in 2015.1 A recent study of obstetric practices in countries with high and low VBAC rates concluded that patient and clinician commitment and comfort with prioritizing TOLAC over scheduled repeat CD greatly influenced the VBAC rate.35


Related article:
Should lower uterine segment thickness measurement be included in the TOLAC decision-making process?

Labor management is an art

During labor obstetricians must balance the unique needs of mother and fetus, which requires great clinical skill and patience. Evolving concepts of normal labor progress necessitate that we change our expectations concerning the acceptable rate of progress in the 1st and 2nd stage of labor. Consistent application of these new labor guidelines may help to reduce the rate of CD.

 

Share your thoughts! Send your Letter to the Editor to [email protected]. Please include your name and the city and state in which you practice.

References
  1. Martin JA, Hamilton BE, Osterman MJ, Driscoll AK, Matthews TJ. Births: final data for 2015. Natl Vital Stat Rep. 2017;66(1):1–70. https://www.cdc.gov/nchs/data/nvsr/nvsr66/nvsr66_01.pdf. Accessed July 5, 2017.
  2. Barber EL, Lundsberg LS, Belanger K, Pettker CM, Funai EF, Illuzzi JL. Indications contributing to the increasing cesarean delivery rate. Obstet Gynecol. 2011;118(1):29–38.
  3. Localio AR, Lawthers AG, Bengtson JM, et al. Relationship between malpractice claims and cesarean delivery. JAMA. 1993;269(3):366–373.
  4. Cheng YW, Snowden JM, Handler SJ, Tager IB, Hubbard AE, Caughey AB. Litigation in obstetrics: does defensive medicine contribute to increases in cesarean delivery? J Matern Fetal Neonatal Med. 2014;27(16):1668–1675.
  5. Graham LE, Brunner Huber LR, Thompson ME, Ersek JL. Does amount of weight gain during pregnancy modify the association between obesity and cesarean section delivery? Birth. 2014;41(1):93–99.
  6. Alfirevic Z, Devane D, Gyte GM. Continuous cardiotocography (CTG) as a form of electronic fetal monitoring (EFM) for fetal assessment during labour. Cochrane Database Syst Rev. 2013;(5):CD006066.
  7. European Perinatal Health Report. Euro-Peristat website. http://www.europeristat.com/. Published 2012. Accessed July 5, 2017.
  8. American College of Obstetricians and Gynecologists; Society for Maternal-Fetal Medicine. Obstetric care consensus no. 1: safe prevention of the primary cesarean delivery. Obstet Gynecol. 2014;123(3):693–711.
  9. Cesarean delivery rate by state, 2015. Centers for Disease Control and Prevention website. https://www.cdc.gov/nchs/pressroom/sosmap/cesarean_births/cesareans.htm. Updated  January 9, 2017. Accessed July 18, 2017.
  10. Baker CD, Land T; Massachusetts Department of Public Health. Massachusetts Births 2014. Massachusetts Executive Office of Health and Human Services website. http://www.mass.gov/eohhs/gov/departments/dph/programs/admin/dmoa/repi/birth-data.html. Published September 2015. Accessed July 5, 2017.
  11. Henry DE, Cheng YW, Shaffer BL, Kaimal AJ, Bianco K, Caughey AB. Perinatal outcomes in the setting of active phase arrest of labor. Obstet Gynecol. 2008;112(5):1109–1115.
  12. Rouse DJ, Weiner SJ, Bloom SL, et al; Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Second-stage labor duration in nulliparous women: relationship to maternal and perinatal outcomes. Am J Obstet Gynecol. 2009;201(4):357.e1–e7.
  13. Friedman EZ. Labour: Clinical evaluation and management. Appleton-Century-Crofts: New York, NY; 1967.
  14. Friedman E. The graphic analysis of labor. Am J Obstet Gynecol. 1954;68(6):1568–1575.
  15. Zhang J, Landy HJ, Branch DW, et al; Consortium on Safe Labor. Contemporary patterns  of spontaneous labor with normal neonatal outcomes. Obstet Gynecol. 2010;116(6):1281–1287.
  16. Wei S, Wo BL, Qi HP, et al. Early amniotomy and early oxytocin for prevention of, or therapy for, delay in first stage spontaneous labour compared with routine care. Cochrane Database Syst Rev. 2013;(8):CD006794.
  17. Thomas J, Fairclough A, Kavanagh J, Kelly AJ. Vaginal prostaglandin (PGE2  and  PGF2a) for induction of labour at term. Cochrane Database Syst Rev. 2014;(6):CD003101.
  18. Alfirevic Z, Kelly AJ, Dowswell T. Intravenous oxytocin alone for cervical ripening and induction of labour. Cochrane Database Syst Rev. 2009;(4):CD003246.
  19. Rouse DJ, Owen J, Savage KG, Hauth JC. Active phase labor arrest: revisiting the 2-hour minimum. Obstet Gynecol. 2001;98(4):550–554.
  20. Cheng YW, Shaffer BL, Nicholson JM, Caughey AB. Second stage of labor and epidural use: a larger effect than previously suggested. Obstet Gynecol. 2014;123(3):527–535.
  21. Grobman WA, Bailit J, Lai Y, et al; Eunice Kennedy Shriver National Institute of Child  and Human Development (NICHD) Maternal-Fetal Medicine Units (MFMU) Network. Association of the duration of active pushing with obstetric outcomes. Obstet Gynecol. 2016;127(4):667–673.
  22. Barth WH Jr. Persistent occiput posterior. Obstet Gynecol. 2015;125(3):695–709.
  23. Carseldine WJ, Phipps H, Zawada SF, et al. Does occiput posterior position in the second stage of labour increase the operative delivery rate? Aust N Z J Obstet Gynaecol. 2013;53(3):265–270.
  24. Phipps H, de Vries B, Hyett J, Osborn DA. Prophylactic manual rotation for fetal  malposition to reduce operative delivery. Cochrane Database Syst Rev. 2014;(12):CD009298.
  25. Shaffer BL, Cheng YW, Vargas JE, Caughey AB. Manual rotation to reduce caesarean delivery in persistent occiput posterior or transverse position. J Matern Fetal Neonatal Med. 2011;24(1):65–72.
  26. Le Ray C, Serres P, Schmitz T, Cabrol D, Goffinet F. Manual rotation in occiput posterior or transverse positions: risk factors and consequences on the cesarean delivery rate. Obstet Gynecol. 2007;110(4):873–879.
  27. Reichman O, Gdansky E, Latinsky B, Labi S, Samueloff A. Digital rotation from occipito-posterior to occipito-anterior decreases the need for cesarean section. Eur J Obstet Gynecol Repro Biol. 2008;136:25–28.
  28. O’Mahony F, Hofmeyr GJ, Menon V. Choice of instruments for assisted vaginal delivery. Cochrane Database Syst Rev. 2010;(11):CD005455.
  29. Hirsch E, Elue R, Wagner A Jr, et al. Severe perineal laceration during operative vaginal  delivery: the impact of occiput posterior position. J Perinatol. 2014;34(12):898–900.
  30. Bailit JL, Grobman WA, Rice MM, et al; Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Evaluation of delivery options for second-stage events. Am J Obstet Gynecol. 2016;214(5):638.e1–e10.
  31. Hofmeyr GJ, Lawrie TA. Amnioinfusion for potential or suspected umbilical cord compression in labour. Cochrane Database Syst Rev. 2012;1:CD000013.
  32. Hannah ME, Hannah WJ, Hellmann J, Hewson S, Milner R, Willan A. Induction of labor as compared with serial antenatal monitoring in post-term pregnancy. A randomized controlled trial. The Canadian Multicenter Post-term Pregnancy Trial Group. N Engl J Med. 1992;326(24): 1587–1592.
  33. Barrett JF, Hannah ME, Hutton EK, et al; Twin Birth Study Collaborative Group. A randomized trial of planned cesarean or vaginal delivery for twin pregnancy. N Engl J Med. 2013;369(14):1295–1305.
  34. Dodd JM, Crowther CA, Huertas E, Guise JM, Horey D. Planned elective repeat cesarean section versus planned vaginal birth for women with a previous caesarean birth. Cochrane Database Syst Rev. 2013;(12):CD004224.
  35. Lundgren I, van Limbeek E, Vehvilainen-Julkunen K, Nilsson C. Clinicians’ views of factors of importance for improving the rate of VBAC (vaginal birth after caesarean section): a qualitative study from countries with high VBAC rates. BMC Pregnancy Childbirth. 2015;15:196.
References
  1. Martin JA, Hamilton BE, Osterman MJ, Driscoll AK, Matthews TJ. Births: final data for 2015. Natl Vital Stat Rep. 2017;66(1):1–70. https://www.cdc.gov/nchs/data/nvsr/nvsr66/nvsr66_01.pdf. Accessed July 5, 2017.
  2. Barber EL, Lundsberg LS, Belanger K, Pettker CM, Funai EF, Illuzzi JL. Indications contributing to the increasing cesarean delivery rate. Obstet Gynecol. 2011;118(1):29–38.
  3. Localio AR, Lawthers AG, Bengtson JM, et al. Relationship between malpractice claims and cesarean delivery. JAMA. 1993;269(3):366–373.
  4. Cheng YW, Snowden JM, Handler SJ, Tager IB, Hubbard AE, Caughey AB. Litigation in obstetrics: does defensive medicine contribute to increases in cesarean delivery? J Matern Fetal Neonatal Med. 2014;27(16):1668–1675.
  5. Graham LE, Brunner Huber LR, Thompson ME, Ersek JL. Does amount of weight gain during pregnancy modify the association between obesity and cesarean section delivery? Birth. 2014;41(1):93–99.
  6. Alfirevic Z, Devane D, Gyte GM. Continuous cardiotocography (CTG) as a form of electronic fetal monitoring (EFM) for fetal assessment during labour. Cochrane Database Syst Rev. 2013;(5):CD006066.
  7. European Perinatal Health Report. Euro-Peristat website. http://www.europeristat.com/. Published 2012. Accessed July 5, 2017.
  8. American College of Obstetricians and Gynecologists; Society for Maternal-Fetal Medicine. Obstetric care consensus no. 1: safe prevention of the primary cesarean delivery. Obstet Gynecol. 2014;123(3):693–711.
  9. Cesarean delivery rate by state, 2015. Centers for Disease Control and Prevention website. https://www.cdc.gov/nchs/pressroom/sosmap/cesarean_births/cesareans.htm. Updated  January 9, 2017. Accessed July 18, 2017.
  10. Baker CD, Land T; Massachusetts Department of Public Health. Massachusetts Births 2014. Massachusetts Executive Office of Health and Human Services website. http://www.mass.gov/eohhs/gov/departments/dph/programs/admin/dmoa/repi/birth-data.html. Published September 2015. Accessed July 5, 2017.
  11. Henry DE, Cheng YW, Shaffer BL, Kaimal AJ, Bianco K, Caughey AB. Perinatal outcomes in the setting of active phase arrest of labor. Obstet Gynecol. 2008;112(5):1109–1115.
  12. Rouse DJ, Weiner SJ, Bloom SL, et al; Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Second-stage labor duration in nulliparous women: relationship to maternal and perinatal outcomes. Am J Obstet Gynecol. 2009;201(4):357.e1–e7.
  13. Friedman EZ. Labour: Clinical evaluation and management. Appleton-Century-Crofts: New York, NY; 1967.
  14. Friedman E. The graphic analysis of labor. Am J Obstet Gynecol. 1954;68(6):1568–1575.
  15. Zhang J, Landy HJ, Branch DW, et al; Consortium on Safe Labor. Contemporary patterns  of spontaneous labor with normal neonatal outcomes. Obstet Gynecol. 2010;116(6):1281–1287.
  16. Wei S, Wo BL, Qi HP, et al. Early amniotomy and early oxytocin for prevention of, or therapy for, delay in first stage spontaneous labour compared with routine care. Cochrane Database Syst Rev. 2013;(8):CD006794.
  17. Thomas J, Fairclough A, Kavanagh J, Kelly AJ. Vaginal prostaglandin (PGE2  and  PGF2a) for induction of labour at term. Cochrane Database Syst Rev. 2014;(6):CD003101.
  18. Alfirevic Z, Kelly AJ, Dowswell T. Intravenous oxytocin alone for cervical ripening and induction of labour. Cochrane Database Syst Rev. 2009;(4):CD003246.
  19. Rouse DJ, Owen J, Savage KG, Hauth JC. Active phase labor arrest: revisiting the 2-hour minimum. Obstet Gynecol. 2001;98(4):550–554.
  20. Cheng YW, Shaffer BL, Nicholson JM, Caughey AB. Second stage of labor and epidural use: a larger effect than previously suggested. Obstet Gynecol. 2014;123(3):527–535.
  21. Grobman WA, Bailit J, Lai Y, et al; Eunice Kennedy Shriver National Institute of Child  and Human Development (NICHD) Maternal-Fetal Medicine Units (MFMU) Network. Association of the duration of active pushing with obstetric outcomes. Obstet Gynecol. 2016;127(4):667–673.
  22. Barth WH Jr. Persistent occiput posterior. Obstet Gynecol. 2015;125(3):695–709.
  23. Carseldine WJ, Phipps H, Zawada SF, et al. Does occiput posterior position in the second stage of labour increase the operative delivery rate? Aust N Z J Obstet Gynaecol. 2013;53(3):265–270.
  24. Phipps H, de Vries B, Hyett J, Osborn DA. Prophylactic manual rotation for fetal  malposition to reduce operative delivery. Cochrane Database Syst Rev. 2014;(12):CD009298.
  25. Shaffer BL, Cheng YW, Vargas JE, Caughey AB. Manual rotation to reduce caesarean delivery in persistent occiput posterior or transverse position. J Matern Fetal Neonatal Med. 2011;24(1):65–72.
  26. Le Ray C, Serres P, Schmitz T, Cabrol D, Goffinet F. Manual rotation in occiput posterior or transverse positions: risk factors and consequences on the cesarean delivery rate. Obstet Gynecol. 2007;110(4):873–879.
  27. Reichman O, Gdansky E, Latinsky B, Labi S, Samueloff A. Digital rotation from occipito-posterior to occipito-anterior decreases the need for cesarean section. Eur J Obstet Gynecol Repro Biol. 2008;136:25–28.
  28. O’Mahony F, Hofmeyr GJ, Menon V. Choice of instruments for assisted vaginal delivery. Cochrane Database Syst Rev. 2010;(11):CD005455.
  29. Hirsch E, Elue R, Wagner A Jr, et al. Severe perineal laceration during operative vaginal  delivery: the impact of occiput posterior position. J Perinatol. 2014;34(12):898–900.
  30. Bailit JL, Grobman WA, Rice MM, et al; Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Evaluation of delivery options for second-stage events. Am J Obstet Gynecol. 2016;214(5):638.e1–e10.
  31. Hofmeyr GJ, Lawrie TA. Amnioinfusion for potential or suspected umbilical cord compression in labour. Cochrane Database Syst Rev. 2012;1:CD000013.
  32. Hannah ME, Hannah WJ, Hellmann J, Hewson S, Milner R, Willan A. Induction of labor as compared with serial antenatal monitoring in post-term pregnancy. A randomized controlled trial. The Canadian Multicenter Post-term Pregnancy Trial Group. N Engl J Med. 1992;326(24): 1587–1592.
  33. Barrett JF, Hannah ME, Hutton EK, et al; Twin Birth Study Collaborative Group. A randomized trial of planned cesarean or vaginal delivery for twin pregnancy. N Engl J Med. 2013;369(14):1295–1305.
  34. Dodd JM, Crowther CA, Huertas E, Guise JM, Horey D. Planned elective repeat cesarean section versus planned vaginal birth for women with a previous caesarean birth. Cochrane Database Syst Rev. 2013;(12):CD004224.
  35. Lundgren I, van Limbeek E, Vehvilainen-Julkunen K, Nilsson C. Clinicians’ views of factors of importance for improving the rate of VBAC (vaginal birth after caesarean section): a qualitative study from countries with high VBAC rates. BMC Pregnancy Childbirth. 2015;15:196.
Issue
OBG Management - 29(8)
Issue
OBG Management - 29(8)
Page Number
6-11
Page Number
6-11
Publications
Publications
Topics
Article Type
Display Headline
For the management of labor, patience is a virtue
Display Headline
For the management of labor, patience is a virtue
Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Article PDF Media

Free water in brain marks Parkinson’s progression

Article Type
Changed
Mon, 01/07/2019 - 12:58

 

Free water in the posterior substantia nigra brain region increased as clinical Parkinson’s disease progressed in a 4-year longitudinal study of participants in the Parkinson’s Progression Markers Initiative.

Image courtesy of David Vaillancourt, PhD, University of Florida
NIH-funded scientists have discovered that Parkinson's disease increases the amount of "free" water in the posterior substantia nigra (in squares).
The research, published online July 28 in Brain, was led by Roxana G. Burciu, PhD, of the University of Florida, Gainesville (Brain. 2017:140;2183-92). Dr. Burciu and her colleagues used imaging data from the Parkinson’s Progression Markers Initiative (PPMI), a longitudinal, multisite, international observational study, to measure free water in 103 newly diagnosed, early-stage Parkinson’s patients imaged at baseline and 1 year (n = 69 males), and in 49 healthy controls (n = 29 males). Patients and controls were matched for age and sex, and the mean age in the cohort was 60.

Dr. Burciu and her colleagues found that free water increased over the first year post diagnosis in Parkinson’s patients but not in controls (P = .043), confirming similar results from an earlier study (Neurobiol Aging. 2015a;36:1097-104; Brain. 2015b;138:2322-31).

The researchers also looked at data from 46 Parkinson’s patients in the cohort who underwent imaging at 2 and 4 years to learn whether the observed increases in free water corresponded to progression measured on the Hoehn and Yahr scale, a widely used measure of Parkinson’s symptom severity.

Free water continued to increase in the Parkinson’s patients through 4 years, and increases in the first and second years after diagnosis were significantly associated with worsening of symptoms through 4 years (P less than .05 for both). Moreover, the investigators noted, men saw greater 4-year increases in free water levels, compared with women.

“The short-term increase in free water is related to the long-term progression of motor symptoms. Moreover, sex and baseline free water levels significantly predicted the rate of change in free water in [the posterior substantia nigra] over 4 years,” the investigators wrote.

The results were consistent across study sites, they found.

Dr. Burciu and her colleagues disclosed funding from the PPMI, which is supported by the Michael J. Fox Foundation and a consortium of pharmaceutical, biotech, and financial firms. The researchers also received funding from the National Institutes of Health. None disclosed financial conflicts of interest.

Publications
Topics
Sections

 

Free water in the posterior substantia nigra brain region increased as clinical Parkinson’s disease progressed in a 4-year longitudinal study of participants in the Parkinson’s Progression Markers Initiative.

Image courtesy of David Vaillancourt, PhD, University of Florida
NIH-funded scientists have discovered that Parkinson's disease increases the amount of "free" water in the posterior substantia nigra (in squares).
The research, published online July 28 in Brain, was led by Roxana G. Burciu, PhD, of the University of Florida, Gainesville (Brain. 2017:140;2183-92). Dr. Burciu and her colleagues used imaging data from the Parkinson’s Progression Markers Initiative (PPMI), a longitudinal, multisite, international observational study, to measure free water in 103 newly diagnosed, early-stage Parkinson’s patients imaged at baseline and 1 year (n = 69 males), and in 49 healthy controls (n = 29 males). Patients and controls were matched for age and sex, and the mean age in the cohort was 60.

Dr. Burciu and her colleagues found that free water increased over the first year post diagnosis in Parkinson’s patients but not in controls (P = .043), confirming similar results from an earlier study (Neurobiol Aging. 2015a;36:1097-104; Brain. 2015b;138:2322-31).

The researchers also looked at data from 46 Parkinson’s patients in the cohort who underwent imaging at 2 and 4 years to learn whether the observed increases in free water corresponded to progression measured on the Hoehn and Yahr scale, a widely used measure of Parkinson’s symptom severity.

Free water continued to increase in the Parkinson’s patients through 4 years, and increases in the first and second years after diagnosis were significantly associated with worsening of symptoms through 4 years (P less than .05 for both). Moreover, the investigators noted, men saw greater 4-year increases in free water levels, compared with women.

“The short-term increase in free water is related to the long-term progression of motor symptoms. Moreover, sex and baseline free water levels significantly predicted the rate of change in free water in [the posterior substantia nigra] over 4 years,” the investigators wrote.

The results were consistent across study sites, they found.

Dr. Burciu and her colleagues disclosed funding from the PPMI, which is supported by the Michael J. Fox Foundation and a consortium of pharmaceutical, biotech, and financial firms. The researchers also received funding from the National Institutes of Health. None disclosed financial conflicts of interest.

 

Free water in the posterior substantia nigra brain region increased as clinical Parkinson’s disease progressed in a 4-year longitudinal study of participants in the Parkinson’s Progression Markers Initiative.

Image courtesy of David Vaillancourt, PhD, University of Florida
NIH-funded scientists have discovered that Parkinson's disease increases the amount of "free" water in the posterior substantia nigra (in squares).
The research, published online July 28 in Brain, was led by Roxana G. Burciu, PhD, of the University of Florida, Gainesville (Brain. 2017:140;2183-92). Dr. Burciu and her colleagues used imaging data from the Parkinson’s Progression Markers Initiative (PPMI), a longitudinal, multisite, international observational study, to measure free water in 103 newly diagnosed, early-stage Parkinson’s patients imaged at baseline and 1 year (n = 69 males), and in 49 healthy controls (n = 29 males). Patients and controls were matched for age and sex, and the mean age in the cohort was 60.

Dr. Burciu and her colleagues found that free water increased over the first year post diagnosis in Parkinson’s patients but not in controls (P = .043), confirming similar results from an earlier study (Neurobiol Aging. 2015a;36:1097-104; Brain. 2015b;138:2322-31).

The researchers also looked at data from 46 Parkinson’s patients in the cohort who underwent imaging at 2 and 4 years to learn whether the observed increases in free water corresponded to progression measured on the Hoehn and Yahr scale, a widely used measure of Parkinson’s symptom severity.

Free water continued to increase in the Parkinson’s patients through 4 years, and increases in the first and second years after diagnosis were significantly associated with worsening of symptoms through 4 years (P less than .05 for both). Moreover, the investigators noted, men saw greater 4-year increases in free water levels, compared with women.

“The short-term increase in free water is related to the long-term progression of motor symptoms. Moreover, sex and baseline free water levels significantly predicted the rate of change in free water in [the posterior substantia nigra] over 4 years,” the investigators wrote.

The results were consistent across study sites, they found.

Dr. Burciu and her colleagues disclosed funding from the PPMI, which is supported by the Michael J. Fox Foundation and a consortium of pharmaceutical, biotech, and financial firms. The researchers also received funding from the National Institutes of Health. None disclosed financial conflicts of interest.

Publications
Publications
Topics
Article Type
Click for Credit Status
Ready
Sections
Article Source

FROM BRAIN

Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Vitals

 

Key clinical point: Water in one brain region increases alongside Parkinson’s symptoms over a 4-year period, making it a biomarker for disease progression.

Major finding: Increases measured in years 1 or 2 after diagnosis were associated with worsening of symptoms through year 4 (P less than .05)

Data source: Analysis of 103 patients and 49 controls from a large, multisite, international, observational, longitudinal study seeking Parkinson’s biomarkers.

Disclosures: The National Institutes of Health and the Parkinson’s Progression Markers Initiative (PPMI) funded this analysis. The PPMI receives broad funding from industry and foundations. None of the researchers disclosed financial conflicts of interest.

Disqus Comments
Default

VIDEO: Less follow-up proposed for low-risk thyroid cancer

Article Type
Changed
Tue, 07/21/2020 - 14:18

 

Many selected patients with low- or intermediate-risk differentiated thyroid cancer who have had excellent or good responses to their treatment may be able to safely transition to follow-up monitoring at longer intervals, Bryan R. Haugen, MD, suggested in a keynote lecture during the World Congress on Thyroid Cancer.

Traditionally, thyroid cancer specialists have monitored these patients for persistent or recurrent disease as often as every 6 or 12 months. “But what we’ve realized with recent assessments of response to treatment is that some patients do well without a recurrence over many years; so, the concept of doing less monitoring and less imaging, especially in patients with an excellent response [to their initial treatment], is being studied,” Dr. Haugen said in a video interview following his talk.

He estimated that perhaps two-thirds or as many as three-quarters of patients with differentiated thyroid cancer fall into the category of having low- or intermediate-risk disease with an excellent or good response to treatment, and hence they are potential candidates for eventually transitioning to less frequent follow-up.

During his talk, Dr. Haugen suggested that after several years with no sign of disease recurrence, lower-risk patients with an excellent treatment response may be able to stop undergoing regular monitoring, and those with a good treatment response may be able to safely have their monitoring intervals extended.

According to the most recent (2015) guidelines for differentiated thyroid cancer management from the American Thyroid Association, lower-risk patients with an excellent treatment response should have their serum thyroglobulin measured every 12-24 months and undergo an ultrasound examination every 3-5 years, while patients with a good response are targeted for serum thyroglobulin measurement annually with an ultrasound every 1-3 years (Thyroid. 2016 Jan;26[1]:1-133). Dr. Haugen chaired the expert panel that wrote these guidelines.

In another provocative suggestion, Dr. Haugen proposed that once well-responsive, lower-risk patients have remained disease free for several years, their less frequent follow-up monitoring could be continued by a primary care physician or another less specialized clinician.

At some time in the future, “a patient’s primary care physician could follow a simple tumor marker, thyroglobulin, maybe once every 5 years,” said Dr. Haugen, professor of medicine and head of the division of endocrinology, metabolism, and diabetes at the University of Colorado in Aurora. “At the University of Colorado, we use advanced-practice providers to do long-term follow-up” for lower-risk, treatment-responsive patients, he said.

The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel
[email protected]

On Twitter @mitchelzoler
Meeting/Event
Publications
Topics
Sections
Meeting/Event
Meeting/Event

 

Many selected patients with low- or intermediate-risk differentiated thyroid cancer who have had excellent or good responses to their treatment may be able to safely transition to follow-up monitoring at longer intervals, Bryan R. Haugen, MD, suggested in a keynote lecture during the World Congress on Thyroid Cancer.

Traditionally, thyroid cancer specialists have monitored these patients for persistent or recurrent disease as often as every 6 or 12 months. “But what we’ve realized with recent assessments of response to treatment is that some patients do well without a recurrence over many years; so, the concept of doing less monitoring and less imaging, especially in patients with an excellent response [to their initial treatment], is being studied,” Dr. Haugen said in a video interview following his talk.

He estimated that perhaps two-thirds or as many as three-quarters of patients with differentiated thyroid cancer fall into the category of having low- or intermediate-risk disease with an excellent or good response to treatment, and hence they are potential candidates for eventually transitioning to less frequent follow-up.

During his talk, Dr. Haugen suggested that after several years with no sign of disease recurrence, lower-risk patients with an excellent treatment response may be able to stop undergoing regular monitoring, and those with a good treatment response may be able to safely have their monitoring intervals extended.

According to the most recent (2015) guidelines for differentiated thyroid cancer management from the American Thyroid Association, lower-risk patients with an excellent treatment response should have their serum thyroglobulin measured every 12-24 months and undergo an ultrasound examination every 3-5 years, while patients with a good response are targeted for serum thyroglobulin measurement annually with an ultrasound every 1-3 years (Thyroid. 2016 Jan;26[1]:1-133). Dr. Haugen chaired the expert panel that wrote these guidelines.

In another provocative suggestion, Dr. Haugen proposed that once well-responsive, lower-risk patients have remained disease free for several years, their less frequent follow-up monitoring could be continued by a primary care physician or another less specialized clinician.

At some time in the future, “a patient’s primary care physician could follow a simple tumor marker, thyroglobulin, maybe once every 5 years,” said Dr. Haugen, professor of medicine and head of the division of endocrinology, metabolism, and diabetes at the University of Colorado in Aurora. “At the University of Colorado, we use advanced-practice providers to do long-term follow-up” for lower-risk, treatment-responsive patients, he said.

The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel
[email protected]

On Twitter @mitchelzoler

 

Many selected patients with low- or intermediate-risk differentiated thyroid cancer who have had excellent or good responses to their treatment may be able to safely transition to follow-up monitoring at longer intervals, Bryan R. Haugen, MD, suggested in a keynote lecture during the World Congress on Thyroid Cancer.

Traditionally, thyroid cancer specialists have monitored these patients for persistent or recurrent disease as often as every 6 or 12 months. “But what we’ve realized with recent assessments of response to treatment is that some patients do well without a recurrence over many years; so, the concept of doing less monitoring and less imaging, especially in patients with an excellent response [to their initial treatment], is being studied,” Dr. Haugen said in a video interview following his talk.

He estimated that perhaps two-thirds or as many as three-quarters of patients with differentiated thyroid cancer fall into the category of having low- or intermediate-risk disease with an excellent or good response to treatment, and hence they are potential candidates for eventually transitioning to less frequent follow-up.

During his talk, Dr. Haugen suggested that after several years with no sign of disease recurrence, lower-risk patients with an excellent treatment response may be able to stop undergoing regular monitoring, and those with a good treatment response may be able to safely have their monitoring intervals extended.

According to the most recent (2015) guidelines for differentiated thyroid cancer management from the American Thyroid Association, lower-risk patients with an excellent treatment response should have their serum thyroglobulin measured every 12-24 months and undergo an ultrasound examination every 3-5 years, while patients with a good response are targeted for serum thyroglobulin measurement annually with an ultrasound every 1-3 years (Thyroid. 2016 Jan;26[1]:1-133). Dr. Haugen chaired the expert panel that wrote these guidelines.

In another provocative suggestion, Dr. Haugen proposed that once well-responsive, lower-risk patients have remained disease free for several years, their less frequent follow-up monitoring could be continued by a primary care physician or another less specialized clinician.

At some time in the future, “a patient’s primary care physician could follow a simple tumor marker, thyroglobulin, maybe once every 5 years,” said Dr. Haugen, professor of medicine and head of the division of endocrinology, metabolism, and diabetes at the University of Colorado in Aurora. “At the University of Colorado, we use advanced-practice providers to do long-term follow-up” for lower-risk, treatment-responsive patients, he said.

The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel
[email protected]

On Twitter @mitchelzoler
Publications
Publications
Topics
Article Type
Sections
Article Source

AT WCTC 2017

Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default

FDA advisory panel backs safety of new hepatitis B vaccine for adults

Article Type
Changed
Fri, 01/18/2019 - 16:56


The Food and Drug Administration’s Vaccines and Related Biological Products Advisory Committee approved licensure for Heplisav-B, a new two-dose recombinant hepatitis B vaccination, after voting that presented data proved the vaccine to be safe for adults 18 and over.

 

At an advisory meeting, after hearing testimony from government researchers and representatives of Dynavax Technologies Corporation, the manufacturer of Heplisav-B, 11 members voted to approve the drug, 1 member voted no, and 3 abstained.

There are more than 20,000 new infections each year, with a reported increase of 21% between 2014 and 2015, according to research presented by William Schaffner, MD, professor of preventative medicine and infectious diseases at Vanderbilt University, Nashville, Tenn.

There are two approved immunizations for hepatitis B: Engerix-B, manufactured by GlaxoSmithKline, and Recombivax HB, by Merck. Both are three-dose, recombinant vaccines produced from yeast cells.

Like the current vaccines, Heplisav-B is a recombinant hepatitis B surface antigen that is derived from yeast; however, this vaccine would be administered in two doses over 1 month, as opposed to three doses over 6 months as is the schedule for currently approved vaccines. Both manufacturing representatives and approving members of the committee stressed this as an important factor due to vaccination dropout rates.

“We have a problem with hepatitis B infections in this country as well as problems with the current vaccines,“ said John Ward, MD, director of the division of viral hepatitis at the Centers for Disease Control and Prevention, “and they happen in these populations where, in terms of data, both of those audiences have problems about going for the second and third dose.”

Patients that drop out before the third dose are at high risk of infection, as only 20%-50% of adults have the appropriate seroprotection after two doses. However, only 54% of patients in a vaccine safety Datalink study reported completing the vaccination series, with 81% reporting having received two doses, according to Dr. Schaffner.

While the committee did approve the safety research as sufficient to approve use of Heplisav-B in adults 18 years and older, members of the committee had an issue with the drug’s correlation with myocardial infarction.

In one of the studies presented, Heplisav-B’s acute myocardial infarction (AMI) events (14 patients) greatly outnumbered those of Engerix-B (1 patient), presenting an AMI relative risk of 6.97.

Dynavax representatives, in response to this concern, presented intention to conduct a postmarketing analysis of the risk of MI in patients who have been administered Heplisav-B, which committee members considered to be a crucial contingency for approval.

“I would like to say I am for the approval of this vaccine, I just think as a statistician that the safety was inconclusive,” said Mei-Ling Ting Lee, PhD, director of the Biostatistics and Risk Assessment Center at the University of Maryland. “But I think for the pharmacological vigilance plan, I think that it will be good to have specific analysis for the myocardial infarction and other risks.”

Courtesy Wikimedia Commons/FitzColinGerald/Creative Commons License
With approval from the Vaccines and Related Biological Products Advisory Committee, Heplisav-B will be subject to review by the FDA, after which it will seek a recommendation from the CDC’s Advisory Committee on Immunization Practices during its October 2017 meeting.

Dynavax intends to introduce the vaccine commercially in the United States by the middle of 2018, according to a press release.

Publications
Topics
Sections


The Food and Drug Administration’s Vaccines and Related Biological Products Advisory Committee approved licensure for Heplisav-B, a new two-dose recombinant hepatitis B vaccination, after voting that presented data proved the vaccine to be safe for adults 18 and over.

 

At an advisory meeting, after hearing testimony from government researchers and representatives of Dynavax Technologies Corporation, the manufacturer of Heplisav-B, 11 members voted to approve the drug, 1 member voted no, and 3 abstained.

There are more than 20,000 new infections each year, with a reported increase of 21% between 2014 and 2015, according to research presented by William Schaffner, MD, professor of preventative medicine and infectious diseases at Vanderbilt University, Nashville, Tenn.

There are two approved immunizations for hepatitis B: Engerix-B, manufactured by GlaxoSmithKline, and Recombivax HB, by Merck. Both are three-dose, recombinant vaccines produced from yeast cells.

Like the current vaccines, Heplisav-B is a recombinant hepatitis B surface antigen that is derived from yeast; however, this vaccine would be administered in two doses over 1 month, as opposed to three doses over 6 months as is the schedule for currently approved vaccines. Both manufacturing representatives and approving members of the committee stressed this as an important factor due to vaccination dropout rates.

“We have a problem with hepatitis B infections in this country as well as problems with the current vaccines,“ said John Ward, MD, director of the division of viral hepatitis at the Centers for Disease Control and Prevention, “and they happen in these populations where, in terms of data, both of those audiences have problems about going for the second and third dose.”

Patients that drop out before the third dose are at high risk of infection, as only 20%-50% of adults have the appropriate seroprotection after two doses. However, only 54% of patients in a vaccine safety Datalink study reported completing the vaccination series, with 81% reporting having received two doses, according to Dr. Schaffner.

While the committee did approve the safety research as sufficient to approve use of Heplisav-B in adults 18 years and older, members of the committee had an issue with the drug’s correlation with myocardial infarction.

In one of the studies presented, Heplisav-B’s acute myocardial infarction (AMI) events (14 patients) greatly outnumbered those of Engerix-B (1 patient), presenting an AMI relative risk of 6.97.

Dynavax representatives, in response to this concern, presented intention to conduct a postmarketing analysis of the risk of MI in patients who have been administered Heplisav-B, which committee members considered to be a crucial contingency for approval.

“I would like to say I am for the approval of this vaccine, I just think as a statistician that the safety was inconclusive,” said Mei-Ling Ting Lee, PhD, director of the Biostatistics and Risk Assessment Center at the University of Maryland. “But I think for the pharmacological vigilance plan, I think that it will be good to have specific analysis for the myocardial infarction and other risks.”

Courtesy Wikimedia Commons/FitzColinGerald/Creative Commons License
With approval from the Vaccines and Related Biological Products Advisory Committee, Heplisav-B will be subject to review by the FDA, after which it will seek a recommendation from the CDC’s Advisory Committee on Immunization Practices during its October 2017 meeting.

Dynavax intends to introduce the vaccine commercially in the United States by the middle of 2018, according to a press release.


The Food and Drug Administration’s Vaccines and Related Biological Products Advisory Committee approved licensure for Heplisav-B, a new two-dose recombinant hepatitis B vaccination, after voting that presented data proved the vaccine to be safe for adults 18 and over.

 

At an advisory meeting, after hearing testimony from government researchers and representatives of Dynavax Technologies Corporation, the manufacturer of Heplisav-B, 11 members voted to approve the drug, 1 member voted no, and 3 abstained.

There are more than 20,000 new infections each year, with a reported increase of 21% between 2014 and 2015, according to research presented by William Schaffner, MD, professor of preventative medicine and infectious diseases at Vanderbilt University, Nashville, Tenn.

There are two approved immunizations for hepatitis B: Engerix-B, manufactured by GlaxoSmithKline, and Recombivax HB, by Merck. Both are three-dose, recombinant vaccines produced from yeast cells.

Like the current vaccines, Heplisav-B is a recombinant hepatitis B surface antigen that is derived from yeast; however, this vaccine would be administered in two doses over 1 month, as opposed to three doses over 6 months as is the schedule for currently approved vaccines. Both manufacturing representatives and approving members of the committee stressed this as an important factor due to vaccination dropout rates.

“We have a problem with hepatitis B infections in this country as well as problems with the current vaccines,“ said John Ward, MD, director of the division of viral hepatitis at the Centers for Disease Control and Prevention, “and they happen in these populations where, in terms of data, both of those audiences have problems about going for the second and third dose.”

Patients that drop out before the third dose are at high risk of infection, as only 20%-50% of adults have the appropriate seroprotection after two doses. However, only 54% of patients in a vaccine safety Datalink study reported completing the vaccination series, with 81% reporting having received two doses, according to Dr. Schaffner.

While the committee did approve the safety research as sufficient to approve use of Heplisav-B in adults 18 years and older, members of the committee had an issue with the drug’s correlation with myocardial infarction.

In one of the studies presented, Heplisav-B’s acute myocardial infarction (AMI) events (14 patients) greatly outnumbered those of Engerix-B (1 patient), presenting an AMI relative risk of 6.97.

Dynavax representatives, in response to this concern, presented intention to conduct a postmarketing analysis of the risk of MI in patients who have been administered Heplisav-B, which committee members considered to be a crucial contingency for approval.

“I would like to say I am for the approval of this vaccine, I just think as a statistician that the safety was inconclusive,” said Mei-Ling Ting Lee, PhD, director of the Biostatistics and Risk Assessment Center at the University of Maryland. “But I think for the pharmacological vigilance plan, I think that it will be good to have specific analysis for the myocardial infarction and other risks.”

Courtesy Wikimedia Commons/FitzColinGerald/Creative Commons License
With approval from the Vaccines and Related Biological Products Advisory Committee, Heplisav-B will be subject to review by the FDA, after which it will seek a recommendation from the CDC’s Advisory Committee on Immunization Practices during its October 2017 meeting.

Dynavax intends to introduce the vaccine commercially in the United States by the middle of 2018, according to a press release.

Publications
Publications
Topics
Article Type
Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default

New guidelines highlight rapid, interdisciplinary treatment of PANS/PANDAS

Article Type
Changed
Fri, 01/18/2019 - 16:56

 

Prompt, symptomatic, multidisciplinary treatment is the best way to curtail the symptoms of pediatric acute-onset neuropsychiatric syndrome (PANS) and pediatric autoimmune neuropsychiatric syndrome associated with streptococcal infection (PANDAS), according to new guidelines.

Dr. Margo Thienemann
PANS presents as a “lightning-like” onset of obsessive-compulsive disorder (OCD) or eating restrictions plus at least two of these symptoms: anxiety (especially separation anxiety), emotional lability or depression, irritability, aggression or severely oppositional behaviors, cognitive and attentional deficits that undermine school performance, sensory or motor abnormalities, and somatic symptoms such as sleep disturbances or enuresis. Acute-onset PAN triggered by Group A streptococcal infection meets criteria for PANDAS. To help guide treatment of both conditions, the PANS Research Consortium of immunologists, rheumatologists, neurologists, infectious disease experts, general pediatricians, psychiatrists, nurse practitioners, and other scientists published the three-part recommendations online July 19 in a special issue of the Journal of Child and Adolescent Psychopharmacology, the first part of which discusses psychiatric and behavioral interventions for the syndromes’ symptoms (2017 Jul 19. doi: 10.1089/cap.2016.0145).

Clinical management of PANS/PANDAS includes psychoeducational, psychotherapeutic, behavioral, family- and school-based, and pharmacologic interventions, Dr. Thienemann and her associates wrote. Starting CBT (exposure-response prevention) has the best chance of halting OCD behaviors. Acutely ill children might not be ready for CBT, but parents still can learn to “hold the line” to avoid accommodating and worsening irrational fears.

Options for psychoactive medications include benzodiazepines for anxiety; aripiprazole, risperidone, olanzapine, haloperidol, or quetiapine for psychosis; and SSRIs, such as fluoxetine, sertraline, and fluvoxamine for depression and OCD. Severe depression merits both psychotherapy and an SSRI. Antipsychotics are not indicated for OCD unless children are incapacitated and only if their QTc interval does not exceed 450 milliseconds. Because PANS/PANDAS patients can react severely to psychotropics, clinicians should “start low” at about a quarter of a typical dose and “go slow,” gradually titrating up.

It’s best to rule out other medical disorders first when patients refuse or restrict food or fluids. Next, clinicians should assess medical stability and support nutrition and hydration while treating underlying brain inflammation. “Feeding tubes may be necessary, at least during the acute phases of the illness,” the authors wrote. Chronic symptoms can warrant treatments for eating disorders.

Bouts of aggression or irritability are classic and can be especially challenging for families. Parents can refocus the child with toys or by dancing, singing, or acting silly but should also make a safety plan, such as calling 911, if aggressive behaviors are endangering the patient or family members. Pharmacologic options for aggression include diphenhydramine, benzodiazepines, and antipsychotics.

For tics, options include comprehensive behavioral intervention for tics, habit reversal training, and cautiously monitored pharmacotherapy with alpha-2 adrenergic agonists, clonidine, guanfacine, or short-course antipsychotics. Symptoms of attention-deficit/hyperactivity disorder merit classroom accommodations; methylphenidate compounds can be added if needed. For children with sleep disturbances, the best strategy is to focus on sleep hygiene before considering low-dose diphenhydramine, melatonin, cyproheptadine, clonidine, trazodone, or zolpidem. Pain, however, needs early treatment to stop it from becoming refractory. Pain and stiffness after awakening can signal arthritis, enthesitis, or inflammatory back pain and warrant physical therapy and evaluation by a pediatric rheumatologist or pain specialist.

Part II of the guidelines covers immunomodulators. As in other severe brain disorders, early treatment improves outcomes and helps prevent relapses, wrote Jennifer Frankovich, MD, also of Stanford University, and her associates. Clinicians should start second-line therapies if first-line treatment fails. Acute impairment can remit with NSAIDs or a short course of oral corticosteroids, but chronic symptoms often need more aggressive and prolonged immunotherapy. Children with moderate to severe impairment should receive intravenous immunoglobulins, and those with severe, chronic impairment may need bursts of high-dose corticosteroids or longer-term corticosteroids with taper. Patients with extreme or life-threatening impairment should receive first-line therapeutic plasma exchange alone or with intravenous immunoglobulins, high-dose intravenous corticosteroids, and rituximab.

Part III of the guidelines covers infections. Most cases involve group A streptococci (GAS), but other culprits include Mycoplasma pneumoniae and viruses, such as influenza, wrote Michael S. Cooperstock, MD, MPH, of the University of Missouri-Columbia and his associates. They recommend antistreptococcal treatment for “essentially all” newly diagnosed cases. They also suggest secondary antistreptococcal prophylaxis for severe neuropsychiatric symptoms or intermittent exacerbations associated with GAS. “For all other [cases], vigilance for GAS infection in both the patient and close contacts is recommended,” they wrote. “Since any intercurrent infection may induce a symptom flare, close observation with appropriate therapy for any treatable intercurrent infection is warranted.” They also recommend standard childhood immunizations and monitoring vitamin D levels.

The National Institutes of Health supported the research summarized in the guidelines. Dr. Thienemann disclosed grants from Auspex, Shire, Pfizer, F. Hoffmann-La Roche, AstraZeneca, Sunovion, Neurocrine Biosciences, Psyadon, and the PANDAS Network, as well as personal fees from the International OCD Foundation and the Tourette Syndrome Association. Dr. Frankovich and Dr. Cooperstock had no relevant disclosures.

Publications
Topics
Sections

 

Prompt, symptomatic, multidisciplinary treatment is the best way to curtail the symptoms of pediatric acute-onset neuropsychiatric syndrome (PANS) and pediatric autoimmune neuropsychiatric syndrome associated with streptococcal infection (PANDAS), according to new guidelines.

Dr. Margo Thienemann
PANS presents as a “lightning-like” onset of obsessive-compulsive disorder (OCD) or eating restrictions plus at least two of these symptoms: anxiety (especially separation anxiety), emotional lability or depression, irritability, aggression or severely oppositional behaviors, cognitive and attentional deficits that undermine school performance, sensory or motor abnormalities, and somatic symptoms such as sleep disturbances or enuresis. Acute-onset PAN triggered by Group A streptococcal infection meets criteria for PANDAS. To help guide treatment of both conditions, the PANS Research Consortium of immunologists, rheumatologists, neurologists, infectious disease experts, general pediatricians, psychiatrists, nurse practitioners, and other scientists published the three-part recommendations online July 19 in a special issue of the Journal of Child and Adolescent Psychopharmacology, the first part of which discusses psychiatric and behavioral interventions for the syndromes’ symptoms (2017 Jul 19. doi: 10.1089/cap.2016.0145).

Clinical management of PANS/PANDAS includes psychoeducational, psychotherapeutic, behavioral, family- and school-based, and pharmacologic interventions, Dr. Thienemann and her associates wrote. Starting CBT (exposure-response prevention) has the best chance of halting OCD behaviors. Acutely ill children might not be ready for CBT, but parents still can learn to “hold the line” to avoid accommodating and worsening irrational fears.

Options for psychoactive medications include benzodiazepines for anxiety; aripiprazole, risperidone, olanzapine, haloperidol, or quetiapine for psychosis; and SSRIs, such as fluoxetine, sertraline, and fluvoxamine for depression and OCD. Severe depression merits both psychotherapy and an SSRI. Antipsychotics are not indicated for OCD unless children are incapacitated and only if their QTc interval does not exceed 450 milliseconds. Because PANS/PANDAS patients can react severely to psychotropics, clinicians should “start low” at about a quarter of a typical dose and “go slow,” gradually titrating up.

It’s best to rule out other medical disorders first when patients refuse or restrict food or fluids. Next, clinicians should assess medical stability and support nutrition and hydration while treating underlying brain inflammation. “Feeding tubes may be necessary, at least during the acute phases of the illness,” the authors wrote. Chronic symptoms can warrant treatments for eating disorders.

Bouts of aggression or irritability are classic and can be especially challenging for families. Parents can refocus the child with toys or by dancing, singing, or acting silly but should also make a safety plan, such as calling 911, if aggressive behaviors are endangering the patient or family members. Pharmacologic options for aggression include diphenhydramine, benzodiazepines, and antipsychotics.

For tics, options include comprehensive behavioral intervention for tics, habit reversal training, and cautiously monitored pharmacotherapy with alpha-2 adrenergic agonists, clonidine, guanfacine, or short-course antipsychotics. Symptoms of attention-deficit/hyperactivity disorder merit classroom accommodations; methylphenidate compounds can be added if needed. For children with sleep disturbances, the best strategy is to focus on sleep hygiene before considering low-dose diphenhydramine, melatonin, cyproheptadine, clonidine, trazodone, or zolpidem. Pain, however, needs early treatment to stop it from becoming refractory. Pain and stiffness after awakening can signal arthritis, enthesitis, or inflammatory back pain and warrant physical therapy and evaluation by a pediatric rheumatologist or pain specialist.

Part II of the guidelines covers immunomodulators. As in other severe brain disorders, early treatment improves outcomes and helps prevent relapses, wrote Jennifer Frankovich, MD, also of Stanford University, and her associates. Clinicians should start second-line therapies if first-line treatment fails. Acute impairment can remit with NSAIDs or a short course of oral corticosteroids, but chronic symptoms often need more aggressive and prolonged immunotherapy. Children with moderate to severe impairment should receive intravenous immunoglobulins, and those with severe, chronic impairment may need bursts of high-dose corticosteroids or longer-term corticosteroids with taper. Patients with extreme or life-threatening impairment should receive first-line therapeutic plasma exchange alone or with intravenous immunoglobulins, high-dose intravenous corticosteroids, and rituximab.

Part III of the guidelines covers infections. Most cases involve group A streptococci (GAS), but other culprits include Mycoplasma pneumoniae and viruses, such as influenza, wrote Michael S. Cooperstock, MD, MPH, of the University of Missouri-Columbia and his associates. They recommend antistreptococcal treatment for “essentially all” newly diagnosed cases. They also suggest secondary antistreptococcal prophylaxis for severe neuropsychiatric symptoms or intermittent exacerbations associated with GAS. “For all other [cases], vigilance for GAS infection in both the patient and close contacts is recommended,” they wrote. “Since any intercurrent infection may induce a symptom flare, close observation with appropriate therapy for any treatable intercurrent infection is warranted.” They also recommend standard childhood immunizations and monitoring vitamin D levels.

The National Institutes of Health supported the research summarized in the guidelines. Dr. Thienemann disclosed grants from Auspex, Shire, Pfizer, F. Hoffmann-La Roche, AstraZeneca, Sunovion, Neurocrine Biosciences, Psyadon, and the PANDAS Network, as well as personal fees from the International OCD Foundation and the Tourette Syndrome Association. Dr. Frankovich and Dr. Cooperstock had no relevant disclosures.

 

Prompt, symptomatic, multidisciplinary treatment is the best way to curtail the symptoms of pediatric acute-onset neuropsychiatric syndrome (PANS) and pediatric autoimmune neuropsychiatric syndrome associated with streptococcal infection (PANDAS), according to new guidelines.

Dr. Margo Thienemann
PANS presents as a “lightning-like” onset of obsessive-compulsive disorder (OCD) or eating restrictions plus at least two of these symptoms: anxiety (especially separation anxiety), emotional lability or depression, irritability, aggression or severely oppositional behaviors, cognitive and attentional deficits that undermine school performance, sensory or motor abnormalities, and somatic symptoms such as sleep disturbances or enuresis. Acute-onset PAN triggered by Group A streptococcal infection meets criteria for PANDAS. To help guide treatment of both conditions, the PANS Research Consortium of immunologists, rheumatologists, neurologists, infectious disease experts, general pediatricians, psychiatrists, nurse practitioners, and other scientists published the three-part recommendations online July 19 in a special issue of the Journal of Child and Adolescent Psychopharmacology, the first part of which discusses psychiatric and behavioral interventions for the syndromes’ symptoms (2017 Jul 19. doi: 10.1089/cap.2016.0145).

Clinical management of PANS/PANDAS includes psychoeducational, psychotherapeutic, behavioral, family- and school-based, and pharmacologic interventions, Dr. Thienemann and her associates wrote. Starting CBT (exposure-response prevention) has the best chance of halting OCD behaviors. Acutely ill children might not be ready for CBT, but parents still can learn to “hold the line” to avoid accommodating and worsening irrational fears.

Options for psychoactive medications include benzodiazepines for anxiety; aripiprazole, risperidone, olanzapine, haloperidol, or quetiapine for psychosis; and SSRIs, such as fluoxetine, sertraline, and fluvoxamine for depression and OCD. Severe depression merits both psychotherapy and an SSRI. Antipsychotics are not indicated for OCD unless children are incapacitated and only if their QTc interval does not exceed 450 milliseconds. Because PANS/PANDAS patients can react severely to psychotropics, clinicians should “start low” at about a quarter of a typical dose and “go slow,” gradually titrating up.

It’s best to rule out other medical disorders first when patients refuse or restrict food or fluids. Next, clinicians should assess medical stability and support nutrition and hydration while treating underlying brain inflammation. “Feeding tubes may be necessary, at least during the acute phases of the illness,” the authors wrote. Chronic symptoms can warrant treatments for eating disorders.

Bouts of aggression or irritability are classic and can be especially challenging for families. Parents can refocus the child with toys or by dancing, singing, or acting silly but should also make a safety plan, such as calling 911, if aggressive behaviors are endangering the patient or family members. Pharmacologic options for aggression include diphenhydramine, benzodiazepines, and antipsychotics.

For tics, options include comprehensive behavioral intervention for tics, habit reversal training, and cautiously monitored pharmacotherapy with alpha-2 adrenergic agonists, clonidine, guanfacine, or short-course antipsychotics. Symptoms of attention-deficit/hyperactivity disorder merit classroom accommodations; methylphenidate compounds can be added if needed. For children with sleep disturbances, the best strategy is to focus on sleep hygiene before considering low-dose diphenhydramine, melatonin, cyproheptadine, clonidine, trazodone, or zolpidem. Pain, however, needs early treatment to stop it from becoming refractory. Pain and stiffness after awakening can signal arthritis, enthesitis, or inflammatory back pain and warrant physical therapy and evaluation by a pediatric rheumatologist or pain specialist.

Part II of the guidelines covers immunomodulators. As in other severe brain disorders, early treatment improves outcomes and helps prevent relapses, wrote Jennifer Frankovich, MD, also of Stanford University, and her associates. Clinicians should start second-line therapies if first-line treatment fails. Acute impairment can remit with NSAIDs or a short course of oral corticosteroids, but chronic symptoms often need more aggressive and prolonged immunotherapy. Children with moderate to severe impairment should receive intravenous immunoglobulins, and those with severe, chronic impairment may need bursts of high-dose corticosteroids or longer-term corticosteroids with taper. Patients with extreme or life-threatening impairment should receive first-line therapeutic plasma exchange alone or with intravenous immunoglobulins, high-dose intravenous corticosteroids, and rituximab.

Part III of the guidelines covers infections. Most cases involve group A streptococci (GAS), but other culprits include Mycoplasma pneumoniae and viruses, such as influenza, wrote Michael S. Cooperstock, MD, MPH, of the University of Missouri-Columbia and his associates. They recommend antistreptococcal treatment for “essentially all” newly diagnosed cases. They also suggest secondary antistreptococcal prophylaxis for severe neuropsychiatric symptoms or intermittent exacerbations associated with GAS. “For all other [cases], vigilance for GAS infection in both the patient and close contacts is recommended,” they wrote. “Since any intercurrent infection may induce a symptom flare, close observation with appropriate therapy for any treatable intercurrent infection is warranted.” They also recommend standard childhood immunizations and monitoring vitamin D levels.

The National Institutes of Health supported the research summarized in the guidelines. Dr. Thienemann disclosed grants from Auspex, Shire, Pfizer, F. Hoffmann-La Roche, AstraZeneca, Sunovion, Neurocrine Biosciences, Psyadon, and the PANDAS Network, as well as personal fees from the International OCD Foundation and the Tourette Syndrome Association. Dr. Frankovich and Dr. Cooperstock had no relevant disclosures.

Publications
Publications
Topics
Article Type
Click for Credit Status
Ready
Sections
Article Source

FROM JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY

Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default

We Want to Know: Eliciting Hospitalized Patients’ Perspectives on Breakdowns in Care

Article Type
Changed
Fri, 12/14/2018 - 08:07
Display Headline
We Want to Know: Eliciting Hospitalized Patients’ Perspectives on Breakdowns in Care

There is growing recognition that patients and family members have critical insights into healthcare experiences. As consumers of healthcare, patient experience is the definitive gauge of whether healthcare is patient centered. In addition, patients may know things about their healthcare that the care team does not. Several studies have demonstrated that patients have knowledge of adverse events and medical errors that are not detected by other methods.1-5 For these reasons, systems designed to elicit patient perspectives of care and detect patient-perceived breakdowns in care could be used to improve healthcare safety and quality, including the patient experience.

Historically, hospitals have relied on patient-initiated reporting via complaints or legal action as the main source of information regarding patient-perceived breakdowns in care. However, many patients are hesitant to speak up about problems or uncertain about how to report concerns.6-8 As a result, healthcare systems often only learn of the most severe breakdowns in care from a subset of activated patients, thus underestimating how widespread patient-perceived breakdowns are.

To overcome these limitations of patient-initiated reporting, hospitals could conduct outreach to patients to actively identify and learn about patient-perceived breakdowns in care. Potential benefits of outreach to patients include more reliable detection of patient-perceived breakdowns in care, identification of a broader range of types of breakdowns commonly experienced by patients, and recognition of problems in real-time when there is more opportunity for redress. Indeed, some hospitals have adopted active outreach programs such as structured nurse manager rounding or postdischarge phone calls.9

It is possible that outreach will not overcome patients’ reluctance to speak up, or patients may not share serious or actionable breakdowns. The manner in which outreach is conducted is likely to influence the information patients are willing to share. Prior studies examining patient perspectives of healthcare have primarily taken a structured approach with close-ended questions or a focus on specific aspects of care.1,10,11 Limited data collected using an open-ended approach suggest patient-perceived breakdowns in care may be very common.2,12,13 However, the impact of such breakdowns on patients has not been well characterized.

In order to design systems that can optimally detect patient-perceived breakdowns in care, additional information is needed to understand whether patients will report breakdowns in response to outreach programs, what types of problems they will report, and how these problems impact them. Understanding such issues will allow healthcare systems to respond to calls by federal health agencies to develop mechanisms for patients to report concerns about breakdowns in care, thereby providing truly patient-centered care.14 Therefore, we undertook this study with the overall goal of describing what may be learned from an open-ended outreach approach that directly asks patients about problems they have encountered during hospitalization. Specifically, we aim to (1) describe the types of problems reported by patients in response to this outreach approach and (2) characterize patients’ perceptions of the impact of these events.

METHODS 

Setting

We conducted this study in 2 hospitals between June 2014 and February 2015. One participating hospital is a large, urban, tertiary care medical center serving a predominantly white (78%) patient population in Baltimore, Maryland. The second hospital is a large, inner city, tertiary care medical center serving a predominantly African-American (71%) patient population in Washington, DC.

Three medical-surgical units (MSUs) at each hospital participated. We selected MSUs because MSU patients interact with a variety of clinicians, often have long stays, and are at risk for adverse events. Hospitalists were part of the clinical care team in each of the participating units, serving either as the attending of record or by comanaging patients.

Patient Eligibility

Patients were potentially eligible if they were at least 18 years old, able to speak English or Spanish, and admitted to the hospital for more than 24 hours. Ineligibility criteria included the following: imminent discharge, observation (noninpatient) status, on hospice, on infection precautions (for inpatient interviews only), psychiatric or violence concerns, prisoner status, significant confusion, or inability to provide informed consent.

Eligible patients in each unit were randomized. Interviewers consecutively approached patients according to their random assignment. If a patient was not available, the interviewer proceeded to the next room. Interviewers returned to rooms of missed patients when possible. Recruitment in the unit ended when the recruitment target for that unit was achieved.

 

 

Interviewers

Five interviewers conducted interviews. One author (KS) provided interviewer training that included didactic instruction, observation, feedback, and modeling. Interviewers participated in weekly debriefing sessions. One interviewer speaks Spanish fluently and was able to conduct interviews in Spanish. Translator services were available for the other interviewers.

Interview Process

Interviews were conducted in person while the patients were hospitalized or via telephone 7 - 30 days postdischarge. A patient who had completed an interview while hospitalized was not eligible for a postdischarge telephone interview. Family members or friends present at the time of the interviews could also participate in addition to or in lieu of the patients with the patients’ assent. Interviewers obtained verbal, informed consent at the start of each interview.

The interview domains and sample questions were developed specifically for the current study and are listed in Table 1. The goal of the interview was to elicit the patient’s (or family member’s) perception of their care experiences and their perceptions of the consequences of any problems with their care. The interviewer sought to obtain sufficient detail to understand the patient’s concerns and to determine what, if any, action might be needed to remediate problems reported by patients. Interviewers captured patient responses by taking detailed notes on a case report form or by directly entering patient responses using a computer or iPad at the time of interview at the discretion of the interviewer.

We defined a patient-perceived breakdown as something that went wrong during the hospitalization according to the patient. If a patient-perceived breakdown in care was identified, the interviewer attempted to resolve the concern. Some breakdowns had occurred in the past, making further resolution impossible (eg, a long wait in the emergency department). Other breakdowns were active and addressable, such as the patient having clinical questions that had not been answered. In such cases, the interviewer attempted to address the patient’s concerns, typically by working with unit nursing staff. For patients interviewed postdischarge, the interviewer worked to resolve ongoing patient concerns with the assistance of the patient safety, quality, and compliance teams as needed. The interviewer provided a brief narrative summary of all interviews to unit nursing leadership within 24 hours. Positive comments were sent to leadership but not captured systematically for research purposes. Further details of the process of responding to patients’ concerns will be reported elsewhere. All data were entered into REDCap to facilitate data management and reporting.15

The MedStar Health Research Institute Institutional Review Board reviewed and approved this study.

Categorizing Patients’ Responses: The Patient Experience Coding Tool

Using directed content analysis,16 we deductively created the Patient Experience Coding Tool (PECT) in order to summarize the narrative information captured during the interviews and categorize patient-perceived breakdowns in care. First, we referred to our prior interviews of patients’ views on breakdowns in cancer care6 and surrogate decision-makers’ views on breakdowns in intensive care units13 to create the initial categories. We then applied the resultant framework to the interviews in the present study and refined the categories. This involved applying the categorization to an initial set of interviews to check the sufficiency of the coding categories. We clarified the scope of each category (ie, what types of events fit under each category) and created additional categories (eg, medication-related problems) to capture patient experiences that were not included in the initial framework.

We then coded each interview using the PECT. A minimum of 2 readers reviewed the narrative notes for each interview. The first reader provided an initial categorization; the second reader reviewed the narrative and confirmed or questioned the initial categorization to improve coding accuracy. If a reader was uncertain about the correct categorization, it was discussed by three readers until an agreement was achieved. Because facilities-related problems (eg, food or parking) fall outside the realm of provider-based hospital care, such comments were not the focus of the outreach efforts and were not consistently recorded. Therefore, they were not included in the PECT and are not reported here.

Analyses

We computed simple, descriptive statistics including the number and percentage of patients identifying at least one breakdown, as well as the number and percent reporting each type of breakdown. We also computed the number and percentage of patients reporting any harm and each type of harm. We computed the percentage of patients reporting at least 1 breakdown by hospital, type of interview (postdischarge vs inpatient), selected patient demographic characteristics (eg, gender, age, education, race), and interviewee (patient vs someone other than the patient interviewed or present during the interview) using the chi-square statistic to test the statistical significance of the resulting differences. All statistical analyses were performed using SPSS version 22.

 

 

RESULTS

A total of 979 outreach interviews were conducted. Of these, 349 were conducted via telephone postdischarge, and 630 were conducted in person during hospitalization. The average interview duration was 8.5 minutes for telephone interviews and 12.2 minutes for in-person interviews. Of the patients approached to participate, 67% completed an interview (61% in person, 83% via telephone). Patient characteristics are summarized in Table 2.

Overall, 386 of 979 interviewees (39.4%) believed they had experienced at least one breakdown in care. The types of patient-perceived breakdowns reported were categorized using the PECT and are summarized in Table 3 and the Figure. The most common concern involved information exchange. Approximately 1 in 10 patients (n = 105, 10.7%) felt that they had not received the information they needed when they needed it. Medication-related concerns were reported by 12.3% (n = 120) of interviewees and predominantly included concerns about what medications were being administered (5.7%) and inadequately treated pain (5.6%). Many of the patients expressing concerns about what medications were administered questioned why they were not receiving their outpatient medications or did not understand why a different medication was being administered, suggesting that many of these instances were related to breakdowns in communication as well. Other relatively common concerns were delays in the admissions process (reported by 9.2% of interviewees), poor team communication (reported by 6.6% of interviewees), healthcare providers with a rude or uncaring manner (reported by 6.3% of interviewees), and problems related to discharge (reported by 5.7% of interviewees).


Of the 386 interviewees who perceived a breakdown in care, 140 (36.3%) perceived harm associated with the event (Table 3). The most common harms were physical (eg, pain; n = 66) and emotional (eg, distress, worry; n = 60). In addition, patients reported instances of damage to relationships with providers (n = 28) resulting in a loss of trust, with participants citing breakdowns as a reason for not coming back to a particular hospital or provider. In other cases, patients believed that breakdowns in care resulted in the need for additional care or a prolonged hospital stay.

We found no difference between the 2 hospitals where the study was conducted in the percentage of interviewees reporting at least 1 breakdown (39.1% vs 39.9%, P = 0.80). We also found no difference between interview method, (ie, in person vs telephone; 40.6% vs 37.2%, respectively, P = 0.30), patient gender (40.6% and 38.8% for men and women, respectively, P = 0.57), race (41.0% and 36.8% for white and black or African-American, respectively, P = 0.20) or between interviewers (P = 0.37). We did identify differences in rates of reporting at least 1 breakdown in care related to age (45.4% of patients aged 60 years or younger vs 34.5% of patients older than 60 years, P < 0.001) and education (32.7% of patients with a high school education or less vs 46.8% of those with at least some college education, P < 0.001). Patients interviewed alone reported fewer breakdowns than if another person was present during the interview or was interviewed in lieu of the patient (37.8% vs 53.4%, P = 0.002). The rate of reporting breakdowns for patients interviewed alone in the hospital is very similar to the rates of those interviewed via telephone (37.8% vs 37.2%). For most types of breakdowns, there were no differences in reporting for in-person vs postdischarge interviews. Discharge-related problems were more frequently reported among patients interviewed postdischarge (8.9% postdischarge vs 4.0% in person, P = 0.002). Patients interviewed in person were more likely to report problems with information exchange compared to patients interviewed postdischarge (17.6% vs 13.5%, respectively; P = 0.09), although this did not reach statistical significance.

DISCUSSION

Through interviews with nearly 1000 patients, we have found that approximately 4 in 10 hospitalized patients believed they experienced a breakdown in care. Not only are patient-perceived breakdowns in care distressingly common, more than one-third of these events resulted in harm according to the patient. Patients reported a diverse range of breakdowns, including problems related to patient experience, as well as breakdowns in technical aspects of medical care. Collectively, these findings illustrate a striking need to identify and address these frequent and potentially harmful breakdowns.

Our findings are consistent with prior studies in which 20% to 50% of patients identified a problem during hospitalization. For example, Weingart et al. interviewed patients in a single general medical unit and found that 20% experienced an adverse event, near miss, or medical error, while nearly 40% experienced what was defined as a service quality incident.2,12 Of note, both our study and the study by Weingart et al. systematically elicited patients’ perspectives of breakdowns in care with explicit questions about problems or breakdowns in care.2,12 Because patients are often reluctant to speak up about problems in care,without such efforts to actively identify problems, providers and leaders are likely to be unaware of the majority of these concerns.6-8 These findings suggest that hospital-based providers should at least consider routinely asking patients about breakdowns in care to identify and respond to patients’ concerns.

Not only are patient-perceived breakdowns common, more than one-third of patients who experienced a breakdown considered it to be harmful. This suggests that our outreach approach identified predominantly nontrivial concerns. We adopted a broad definition of harm that includes emotional distress, damage to the relationship with providers, and life disruption. This differs from other studies examining patient reports of breakdowns in care, in which harm was restricted to physical injury.1,2 We consider this inclusive definition of harm to be a strength of the present study as it provides the most complete picture of the impact of such events on patients. This approach is supported by other studies demonstrating that patients place great emphasis on the psychological consequences of adverse events.17-19 Thus, it is clear from our work and other studies that nonphysical harm is important and warrants concerted efforts to address.

Patients in our study reported a variety of breakdowns, including breakdowns related to patient experience (eg, communication, relationship with providers) and technical aspects of healthcare delivery (eg, diagnosis, treatment). This is consistent with other studies examining patient perspectives of breakdowns in care. Weingart et al.found that hospitalized patients reported a broad range of problems, including adverse events, medical errors, communication breakdowns, and problems with food.2,12 This variety of events suggests a need for integration between the various hospital groups that handle patient-perceived breakdowns, including bedside providers, risk management, patient relations, patient advocates, and quality and safety groups, in order to provide a coordinated and effective response to the full spectrum of patient-perceived breakdowns in care.

Patients in our study were more likely to report breakdowns related to communication and relationships with providers than those related to technical aspects of care. Similarly, Kuzel et al.found that the most common problems cited by patients in the primary care setting were breakdowns in the clinician-patient relationship and access-related problems.17This is not surprising, as patients are likely to have more direct knowledge about communication and interpersonal relationships than about technical aspects of care.

We identified several factors associated with the likelihood of reporting a breakdown in care. Most strikingly, involving a friend or family member in the interview was strongly associated with reporting a breakdown. Other work has also suggested that patients’ friends and family members are an important source of information about safety concerns.20,21 In addition, several patient characteristics were associated with an increased likelihood of reporting a breakdown, including being younger and better educated. These findings highlight the importance of engaging patients’ friends and families in efforts to elicit patient concerns about healthcare, and they confirm recommendations for patients to bring a friend or family member to healthcare encounters.22 In addition, they illustrate the need to better understand how patient characteristics affect perceptions of breakdowns in care and their willingness to speak up, as this could inform efforts to target outreach to especially vulnerable patients.

A strength of this study is the number of interviews completed (almost 1000), which provides a diverse range of patient views and experiences, as evidenced by the demographic characteristics of participants. Interviews were conducted at two hospitals that differ substantially with regard to populations served, further enhancing the generalizability of our findings. Despite the large number of interviews and diverse patient characteristics, patients were drawn from only 3 units at 2 hospitals, which may limit generalizability.

We did not conduct medical record reviews to validate patients’ reports of problems, which may be viewed as a limitation. While such a comparison would be informative, the intent of the current study was to elicit patients’ perceptions of care, including aspects of care that are not typically captured in the medical record, such as communication. Other studies have demonstrated that patients’ reports of medical errors and adverse events tend to differ from providers’ reports of the same subjects.19,23 Therefore, we considered the patients’ perceptions of care to be a useful endpoint in and of itself. We did not determine the extent to which providers were already aware of patients’ concerns or whether they considered patients’ concerns valid. A related limitation is our inability to determine whether the differences we identified in the rates of breakdown reporting based on patient characteristics reflect differences in willingness to report or differences in experiences. Because we included patients in an MSU, it is possible that breakdowns were related to medical care, surgical care, or both. We did not follow patients longitudinally and therefore only captured harm perceived by a patient at the time of the interview. It is possible that patients may have experienced harm later in their hospitalization or following discharge that was not measured. Lastly, we did not measure interrater reliability of the interview coding and therefore do not present the PECT as a validated instrument. These important questions should be targeted for future study.

 

 

CONCLUSION

When directly asked about their experiences, almost 4 out of 10 hospitalized patients reported a breakdown in their care, many of which were perceived to be harmful. Not all hospitals will have the resources to implement the intensive approach used in this study to elicit patient-perceived breakdowns. Therefore, further work is needed to develop sustainable methods to overcome patients’ reluctance to report breakdowns in care. Engaging patients’ families and friends may be a particularly fruitful strategy. We offer the PECT as a tool that hospitals could use to summarize a variety of sources of patient feedback such as complaints, responses to surveys, and consumer reviews. Hospitals that effectively encourage patients and their family members to speak up about perceived breakdowns will identify many opportunities to address patient concerns, potentially leading to improved patient safety and experience.

References

1. Weissman JS, Schneider EC, Weingart SN, et al. Comparing patient-reported hospital adverse events with medical record review: Do patients know something that hospitals do not? Ann Intern Med. 2008;149(2):100-108. PubMed
2. Weingart SN, Pagovich O, Sands DZ, et al. What can hospitalized patients tell us about adverse events? learning from patient-reported incidents. J Gen Intern Med. 2005;20(9):830-836. PubMed
3. Wetzels R, Wolters R, van Weel C, Wensing M. Mix of methods is needed to identify adverse events in general practice: A prospective observational study. BMC Fam Pract. 2008;9:35. PubMed
4. Friedman SM, Provan D, Moore S, Hanneman K. Errors, near misses and adverse events in the emergency department: What can patients tell us? CJEM. 2008;10(5):421-427. PubMed
5. Iedema R, Allen S, Britton K, Gallagher TH. What do patients and relatives know about problems and failures in care? BMJ Qual Saf. 2012;21(3):198-205. PubMed
6. Mazor KM, Roblin DW, Greene SM, et al. Toward patient-centered cancer care: Patient perceptions of problematic events, impact, and response. J Clin Oncol. 2012;30(15):1784-1790. PubMed
7. Frosch DL, May SG, Rendle KA, Tietbohl C, Elwyn G. Authoritarian physicians and patients’ fear of being labeled ‘difficult’ among key obstacles to shared decision making. Health Aff (Millwood). 2012;31(5):1030-1038. PubMed
8. Entwistle VA, McCaughan D, Watt IS, et al. Speaking up about safety concerns: Multi-setting qualitative study of patients’ views and experiences. Qual Saf Health Care. 2010;19(6):e33. PubMed
9. Tan M, Lang D. Effectiveness of nurse leader rounding and post-discharge telephone calls in patient satisfaction: A systematic review. JBI database of systematic reviews and implementation reports. 2015;13(7):154-176. PubMed
10. Garbutt J, Bose D, McCawley BA, Burroughs T, Medoff G. Soliciting patient complaints to improve performance. Jt Comm J Qual Saf. 2003;29(3):103-112. PubMed
11. Agoritsas T, Bovier PA, Perneger TV. Patient reports of undesirable events during hospitalization. J Gen Intern Med. 2005;20(10):922-928. PubMed
12. Weingart SN, Pagovich O, Sands DZ, et al. Patient-reported service quality on a medicine unit. Int J Qual Health Care. 2006;18(2):95-101. PubMed
13. Fisher KA, Ahmad S, Jackson M, Mazor KM. Surrogate decision makers’ perspectives on preventable breakdowns in care among critically ill patients: A qualitative study. Patient Educ Couns. 2016;99(10):1685-1693. PubMed
14. Halpern MT, Roussel AE, Treiman K, Nerz PA, Hatlie MJ, Sheridan S. Designing consumer reporting systems for patient safety events. Final Report (Prepared by RTI International and Consumers Advancing Patient Safety under Contract No. 290-06-00001-5). AHRQ Publication No. 11-0060-EF. Rockville, MD: Agency for Healthcare Research and Quality; 2011. 
15. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377-381. PubMed
16. Hsieh HF, Shannon SE. Three approaches to qualitative content analysis. Qual Health Res. 2005;15(9):1277-1288. PubMed
17. Kuzel AJ, Woolf SH, Gilchrist VJ, et al. Patient reports of preventable problems and harms in primary health care. Ann Fam Med. 2004;2(4):333-340. PubMed
18. Sokol-Hessner L, Folcarelli PH, Sands KE. Emotional harm from disrespect: The neglected preventable harm. BMJ Qual Saf. 2015;24(9):550-553. PubMed
19. Masso Guijarro P, Aranaz Andres JM, Mira JJ, Perdiguero E, Aibar C. Adverse events in hospitals: The patient’s point of view. Qual Saf Health Care. 2010;19(2):144-147. PubMed
20. Bardach NS, Lyndon A, Asteria-Penaloza R, Goldman LE, Lin GA, Dudley RA. From the closest observers of patient care: A thematic analysis of online narrative reviews of hospitals. BMJ Qual Saf. 2015. PubMed
21. Schneider EC, Ridgely MS, Quigley DD, et al. Developing and testing the health care safety hotline: A prototype consumer reporting system for patient safety events. Final Report (Prepared by RAND Corporation under contract HHSA2902010000171). Rockvelle, MD: Agency for Healthcare Research and Quality; May 2016. 
22. Shekelle PG, Pronovost PJ, Wachter RM, et al. The top patient safety strategies that can be encouraged for adoption now. Ann Intern Med. 2013;158(5 Pt 2):365-368. PubMed
23. Lawton R, O’Hara JK, Sheard L, et al. Can staff and patient perspectives on hospital safety predict harm-free care? an analysis of staff and patient survey data and routinely collected outcomes. BMJ Qual Saf. 2015;24(6):369-376. PubMed

Article PDF
Issue
Journal of Hospital Medicine 12 (8)
Topics
Page Number
603-609
Sections
Article PDF
Article PDF

There is growing recognition that patients and family members have critical insights into healthcare experiences. As consumers of healthcare, patient experience is the definitive gauge of whether healthcare is patient centered. In addition, patients may know things about their healthcare that the care team does not. Several studies have demonstrated that patients have knowledge of adverse events and medical errors that are not detected by other methods.1-5 For these reasons, systems designed to elicit patient perspectives of care and detect patient-perceived breakdowns in care could be used to improve healthcare safety and quality, including the patient experience.

Historically, hospitals have relied on patient-initiated reporting via complaints or legal action as the main source of information regarding patient-perceived breakdowns in care. However, many patients are hesitant to speak up about problems or uncertain about how to report concerns.6-8 As a result, healthcare systems often only learn of the most severe breakdowns in care from a subset of activated patients, thus underestimating how widespread patient-perceived breakdowns are.

To overcome these limitations of patient-initiated reporting, hospitals could conduct outreach to patients to actively identify and learn about patient-perceived breakdowns in care. Potential benefits of outreach to patients include more reliable detection of patient-perceived breakdowns in care, identification of a broader range of types of breakdowns commonly experienced by patients, and recognition of problems in real-time when there is more opportunity for redress. Indeed, some hospitals have adopted active outreach programs such as structured nurse manager rounding or postdischarge phone calls.9

It is possible that outreach will not overcome patients’ reluctance to speak up, or patients may not share serious or actionable breakdowns. The manner in which outreach is conducted is likely to influence the information patients are willing to share. Prior studies examining patient perspectives of healthcare have primarily taken a structured approach with close-ended questions or a focus on specific aspects of care.1,10,11 Limited data collected using an open-ended approach suggest patient-perceived breakdowns in care may be very common.2,12,13 However, the impact of such breakdowns on patients has not been well characterized.

In order to design systems that can optimally detect patient-perceived breakdowns in care, additional information is needed to understand whether patients will report breakdowns in response to outreach programs, what types of problems they will report, and how these problems impact them. Understanding such issues will allow healthcare systems to respond to calls by federal health agencies to develop mechanisms for patients to report concerns about breakdowns in care, thereby providing truly patient-centered care.14 Therefore, we undertook this study with the overall goal of describing what may be learned from an open-ended outreach approach that directly asks patients about problems they have encountered during hospitalization. Specifically, we aim to (1) describe the types of problems reported by patients in response to this outreach approach and (2) characterize patients’ perceptions of the impact of these events.

METHODS 

Setting

We conducted this study in 2 hospitals between June 2014 and February 2015. One participating hospital is a large, urban, tertiary care medical center serving a predominantly white (78%) patient population in Baltimore, Maryland. The second hospital is a large, inner city, tertiary care medical center serving a predominantly African-American (71%) patient population in Washington, DC.

Three medical-surgical units (MSUs) at each hospital participated. We selected MSUs because MSU patients interact with a variety of clinicians, often have long stays, and are at risk for adverse events. Hospitalists were part of the clinical care team in each of the participating units, serving either as the attending of record or by comanaging patients.

Patient Eligibility

Patients were potentially eligible if they were at least 18 years old, able to speak English or Spanish, and admitted to the hospital for more than 24 hours. Ineligibility criteria included the following: imminent discharge, observation (noninpatient) status, on hospice, on infection precautions (for inpatient interviews only), psychiatric or violence concerns, prisoner status, significant confusion, or inability to provide informed consent.

Eligible patients in each unit were randomized. Interviewers consecutively approached patients according to their random assignment. If a patient was not available, the interviewer proceeded to the next room. Interviewers returned to rooms of missed patients when possible. Recruitment in the unit ended when the recruitment target for that unit was achieved.

 

 

Interviewers

Five interviewers conducted interviews. One author (KS) provided interviewer training that included didactic instruction, observation, feedback, and modeling. Interviewers participated in weekly debriefing sessions. One interviewer speaks Spanish fluently and was able to conduct interviews in Spanish. Translator services were available for the other interviewers.

Interview Process

Interviews were conducted in person while the patients were hospitalized or via telephone 7 - 30 days postdischarge. A patient who had completed an interview while hospitalized was not eligible for a postdischarge telephone interview. Family members or friends present at the time of the interviews could also participate in addition to or in lieu of the patients with the patients’ assent. Interviewers obtained verbal, informed consent at the start of each interview.

The interview domains and sample questions were developed specifically for the current study and are listed in Table 1. The goal of the interview was to elicit the patient’s (or family member’s) perception of their care experiences and their perceptions of the consequences of any problems with their care. The interviewer sought to obtain sufficient detail to understand the patient’s concerns and to determine what, if any, action might be needed to remediate problems reported by patients. Interviewers captured patient responses by taking detailed notes on a case report form or by directly entering patient responses using a computer or iPad at the time of interview at the discretion of the interviewer.

We defined a patient-perceived breakdown as something that went wrong during the hospitalization according to the patient. If a patient-perceived breakdown in care was identified, the interviewer attempted to resolve the concern. Some breakdowns had occurred in the past, making further resolution impossible (eg, a long wait in the emergency department). Other breakdowns were active and addressable, such as the patient having clinical questions that had not been answered. In such cases, the interviewer attempted to address the patient’s concerns, typically by working with unit nursing staff. For patients interviewed postdischarge, the interviewer worked to resolve ongoing patient concerns with the assistance of the patient safety, quality, and compliance teams as needed. The interviewer provided a brief narrative summary of all interviews to unit nursing leadership within 24 hours. Positive comments were sent to leadership but not captured systematically for research purposes. Further details of the process of responding to patients’ concerns will be reported elsewhere. All data were entered into REDCap to facilitate data management and reporting.15

The MedStar Health Research Institute Institutional Review Board reviewed and approved this study.

Categorizing Patients’ Responses: The Patient Experience Coding Tool

Using directed content analysis,16 we deductively created the Patient Experience Coding Tool (PECT) in order to summarize the narrative information captured during the interviews and categorize patient-perceived breakdowns in care. First, we referred to our prior interviews of patients’ views on breakdowns in cancer care6 and surrogate decision-makers’ views on breakdowns in intensive care units13 to create the initial categories. We then applied the resultant framework to the interviews in the present study and refined the categories. This involved applying the categorization to an initial set of interviews to check the sufficiency of the coding categories. We clarified the scope of each category (ie, what types of events fit under each category) and created additional categories (eg, medication-related problems) to capture patient experiences that were not included in the initial framework.

We then coded each interview using the PECT. A minimum of 2 readers reviewed the narrative notes for each interview. The first reader provided an initial categorization; the second reader reviewed the narrative and confirmed or questioned the initial categorization to improve coding accuracy. If a reader was uncertain about the correct categorization, it was discussed by three readers until an agreement was achieved. Because facilities-related problems (eg, food or parking) fall outside the realm of provider-based hospital care, such comments were not the focus of the outreach efforts and were not consistently recorded. Therefore, they were not included in the PECT and are not reported here.

Analyses

We computed simple, descriptive statistics including the number and percentage of patients identifying at least one breakdown, as well as the number and percent reporting each type of breakdown. We also computed the number and percentage of patients reporting any harm and each type of harm. We computed the percentage of patients reporting at least 1 breakdown by hospital, type of interview (postdischarge vs inpatient), selected patient demographic characteristics (eg, gender, age, education, race), and interviewee (patient vs someone other than the patient interviewed or present during the interview) using the chi-square statistic to test the statistical significance of the resulting differences. All statistical analyses were performed using SPSS version 22.

 

 

RESULTS

A total of 979 outreach interviews were conducted. Of these, 349 were conducted via telephone postdischarge, and 630 were conducted in person during hospitalization. The average interview duration was 8.5 minutes for telephone interviews and 12.2 minutes for in-person interviews. Of the patients approached to participate, 67% completed an interview (61% in person, 83% via telephone). Patient characteristics are summarized in Table 2.

Overall, 386 of 979 interviewees (39.4%) believed they had experienced at least one breakdown in care. The types of patient-perceived breakdowns reported were categorized using the PECT and are summarized in Table 3 and the Figure. The most common concern involved information exchange. Approximately 1 in 10 patients (n = 105, 10.7%) felt that they had not received the information they needed when they needed it. Medication-related concerns were reported by 12.3% (n = 120) of interviewees and predominantly included concerns about what medications were being administered (5.7%) and inadequately treated pain (5.6%). Many of the patients expressing concerns about what medications were administered questioned why they were not receiving their outpatient medications or did not understand why a different medication was being administered, suggesting that many of these instances were related to breakdowns in communication as well. Other relatively common concerns were delays in the admissions process (reported by 9.2% of interviewees), poor team communication (reported by 6.6% of interviewees), healthcare providers with a rude or uncaring manner (reported by 6.3% of interviewees), and problems related to discharge (reported by 5.7% of interviewees).


Of the 386 interviewees who perceived a breakdown in care, 140 (36.3%) perceived harm associated with the event (Table 3). The most common harms were physical (eg, pain; n = 66) and emotional (eg, distress, worry; n = 60). In addition, patients reported instances of damage to relationships with providers (n = 28) resulting in a loss of trust, with participants citing breakdowns as a reason for not coming back to a particular hospital or provider. In other cases, patients believed that breakdowns in care resulted in the need for additional care or a prolonged hospital stay.

We found no difference between the 2 hospitals where the study was conducted in the percentage of interviewees reporting at least 1 breakdown (39.1% vs 39.9%, P = 0.80). We also found no difference between interview method, (ie, in person vs telephone; 40.6% vs 37.2%, respectively, P = 0.30), patient gender (40.6% and 38.8% for men and women, respectively, P = 0.57), race (41.0% and 36.8% for white and black or African-American, respectively, P = 0.20) or between interviewers (P = 0.37). We did identify differences in rates of reporting at least 1 breakdown in care related to age (45.4% of patients aged 60 years or younger vs 34.5% of patients older than 60 years, P < 0.001) and education (32.7% of patients with a high school education or less vs 46.8% of those with at least some college education, P < 0.001). Patients interviewed alone reported fewer breakdowns than if another person was present during the interview or was interviewed in lieu of the patient (37.8% vs 53.4%, P = 0.002). The rate of reporting breakdowns for patients interviewed alone in the hospital is very similar to the rates of those interviewed via telephone (37.8% vs 37.2%). For most types of breakdowns, there were no differences in reporting for in-person vs postdischarge interviews. Discharge-related problems were more frequently reported among patients interviewed postdischarge (8.9% postdischarge vs 4.0% in person, P = 0.002). Patients interviewed in person were more likely to report problems with information exchange compared to patients interviewed postdischarge (17.6% vs 13.5%, respectively; P = 0.09), although this did not reach statistical significance.

DISCUSSION

Through interviews with nearly 1000 patients, we have found that approximately 4 in 10 hospitalized patients believed they experienced a breakdown in care. Not only are patient-perceived breakdowns in care distressingly common, more than one-third of these events resulted in harm according to the patient. Patients reported a diverse range of breakdowns, including problems related to patient experience, as well as breakdowns in technical aspects of medical care. Collectively, these findings illustrate a striking need to identify and address these frequent and potentially harmful breakdowns.

Our findings are consistent with prior studies in which 20% to 50% of patients identified a problem during hospitalization. For example, Weingart et al. interviewed patients in a single general medical unit and found that 20% experienced an adverse event, near miss, or medical error, while nearly 40% experienced what was defined as a service quality incident.2,12 Of note, both our study and the study by Weingart et al. systematically elicited patients’ perspectives of breakdowns in care with explicit questions about problems or breakdowns in care.2,12 Because patients are often reluctant to speak up about problems in care,without such efforts to actively identify problems, providers and leaders are likely to be unaware of the majority of these concerns.6-8 These findings suggest that hospital-based providers should at least consider routinely asking patients about breakdowns in care to identify and respond to patients’ concerns.

Not only are patient-perceived breakdowns common, more than one-third of patients who experienced a breakdown considered it to be harmful. This suggests that our outreach approach identified predominantly nontrivial concerns. We adopted a broad definition of harm that includes emotional distress, damage to the relationship with providers, and life disruption. This differs from other studies examining patient reports of breakdowns in care, in which harm was restricted to physical injury.1,2 We consider this inclusive definition of harm to be a strength of the present study as it provides the most complete picture of the impact of such events on patients. This approach is supported by other studies demonstrating that patients place great emphasis on the psychological consequences of adverse events.17-19 Thus, it is clear from our work and other studies that nonphysical harm is important and warrants concerted efforts to address.

Patients in our study reported a variety of breakdowns, including breakdowns related to patient experience (eg, communication, relationship with providers) and technical aspects of healthcare delivery (eg, diagnosis, treatment). This is consistent with other studies examining patient perspectives of breakdowns in care. Weingart et al.found that hospitalized patients reported a broad range of problems, including adverse events, medical errors, communication breakdowns, and problems with food.2,12 This variety of events suggests a need for integration between the various hospital groups that handle patient-perceived breakdowns, including bedside providers, risk management, patient relations, patient advocates, and quality and safety groups, in order to provide a coordinated and effective response to the full spectrum of patient-perceived breakdowns in care.

Patients in our study were more likely to report breakdowns related to communication and relationships with providers than those related to technical aspects of care. Similarly, Kuzel et al.found that the most common problems cited by patients in the primary care setting were breakdowns in the clinician-patient relationship and access-related problems.17This is not surprising, as patients are likely to have more direct knowledge about communication and interpersonal relationships than about technical aspects of care.

We identified several factors associated with the likelihood of reporting a breakdown in care. Most strikingly, involving a friend or family member in the interview was strongly associated with reporting a breakdown. Other work has also suggested that patients’ friends and family members are an important source of information about safety concerns.20,21 In addition, several patient characteristics were associated with an increased likelihood of reporting a breakdown, including being younger and better educated. These findings highlight the importance of engaging patients’ friends and families in efforts to elicit patient concerns about healthcare, and they confirm recommendations for patients to bring a friend or family member to healthcare encounters.22 In addition, they illustrate the need to better understand how patient characteristics affect perceptions of breakdowns in care and their willingness to speak up, as this could inform efforts to target outreach to especially vulnerable patients.

A strength of this study is the number of interviews completed (almost 1000), which provides a diverse range of patient views and experiences, as evidenced by the demographic characteristics of participants. Interviews were conducted at two hospitals that differ substantially with regard to populations served, further enhancing the generalizability of our findings. Despite the large number of interviews and diverse patient characteristics, patients were drawn from only 3 units at 2 hospitals, which may limit generalizability.

We did not conduct medical record reviews to validate patients’ reports of problems, which may be viewed as a limitation. While such a comparison would be informative, the intent of the current study was to elicit patients’ perceptions of care, including aspects of care that are not typically captured in the medical record, such as communication. Other studies have demonstrated that patients’ reports of medical errors and adverse events tend to differ from providers’ reports of the same subjects.19,23 Therefore, we considered the patients’ perceptions of care to be a useful endpoint in and of itself. We did not determine the extent to which providers were already aware of patients’ concerns or whether they considered patients’ concerns valid. A related limitation is our inability to determine whether the differences we identified in the rates of breakdown reporting based on patient characteristics reflect differences in willingness to report or differences in experiences. Because we included patients in an MSU, it is possible that breakdowns were related to medical care, surgical care, or both. We did not follow patients longitudinally and therefore only captured harm perceived by a patient at the time of the interview. It is possible that patients may have experienced harm later in their hospitalization or following discharge that was not measured. Lastly, we did not measure interrater reliability of the interview coding and therefore do not present the PECT as a validated instrument. These important questions should be targeted for future study.

 

 

CONCLUSION

When directly asked about their experiences, almost 4 out of 10 hospitalized patients reported a breakdown in their care, many of which were perceived to be harmful. Not all hospitals will have the resources to implement the intensive approach used in this study to elicit patient-perceived breakdowns. Therefore, further work is needed to develop sustainable methods to overcome patients’ reluctance to report breakdowns in care. Engaging patients’ families and friends may be a particularly fruitful strategy. We offer the PECT as a tool that hospitals could use to summarize a variety of sources of patient feedback such as complaints, responses to surveys, and consumer reviews. Hospitals that effectively encourage patients and their family members to speak up about perceived breakdowns will identify many opportunities to address patient concerns, potentially leading to improved patient safety and experience.

There is growing recognition that patients and family members have critical insights into healthcare experiences. As consumers of healthcare, patient experience is the definitive gauge of whether healthcare is patient centered. In addition, patients may know things about their healthcare that the care team does not. Several studies have demonstrated that patients have knowledge of adverse events and medical errors that are not detected by other methods.1-5 For these reasons, systems designed to elicit patient perspectives of care and detect patient-perceived breakdowns in care could be used to improve healthcare safety and quality, including the patient experience.

Historically, hospitals have relied on patient-initiated reporting via complaints or legal action as the main source of information regarding patient-perceived breakdowns in care. However, many patients are hesitant to speak up about problems or uncertain about how to report concerns.6-8 As a result, healthcare systems often only learn of the most severe breakdowns in care from a subset of activated patients, thus underestimating how widespread patient-perceived breakdowns are.

To overcome these limitations of patient-initiated reporting, hospitals could conduct outreach to patients to actively identify and learn about patient-perceived breakdowns in care. Potential benefits of outreach to patients include more reliable detection of patient-perceived breakdowns in care, identification of a broader range of types of breakdowns commonly experienced by patients, and recognition of problems in real-time when there is more opportunity for redress. Indeed, some hospitals have adopted active outreach programs such as structured nurse manager rounding or postdischarge phone calls.9

It is possible that outreach will not overcome patients’ reluctance to speak up, or patients may not share serious or actionable breakdowns. The manner in which outreach is conducted is likely to influence the information patients are willing to share. Prior studies examining patient perspectives of healthcare have primarily taken a structured approach with close-ended questions or a focus on specific aspects of care.1,10,11 Limited data collected using an open-ended approach suggest patient-perceived breakdowns in care may be very common.2,12,13 However, the impact of such breakdowns on patients has not been well characterized.

In order to design systems that can optimally detect patient-perceived breakdowns in care, additional information is needed to understand whether patients will report breakdowns in response to outreach programs, what types of problems they will report, and how these problems impact them. Understanding such issues will allow healthcare systems to respond to calls by federal health agencies to develop mechanisms for patients to report concerns about breakdowns in care, thereby providing truly patient-centered care.14 Therefore, we undertook this study with the overall goal of describing what may be learned from an open-ended outreach approach that directly asks patients about problems they have encountered during hospitalization. Specifically, we aim to (1) describe the types of problems reported by patients in response to this outreach approach and (2) characterize patients’ perceptions of the impact of these events.

METHODS 

Setting

We conducted this study in 2 hospitals between June 2014 and February 2015. One participating hospital is a large, urban, tertiary care medical center serving a predominantly white (78%) patient population in Baltimore, Maryland. The second hospital is a large, inner city, tertiary care medical center serving a predominantly African-American (71%) patient population in Washington, DC.

Three medical-surgical units (MSUs) at each hospital participated. We selected MSUs because MSU patients interact with a variety of clinicians, often have long stays, and are at risk for adverse events. Hospitalists were part of the clinical care team in each of the participating units, serving either as the attending of record or by comanaging patients.

Patient Eligibility

Patients were potentially eligible if they were at least 18 years old, able to speak English or Spanish, and admitted to the hospital for more than 24 hours. Ineligibility criteria included the following: imminent discharge, observation (noninpatient) status, on hospice, on infection precautions (for inpatient interviews only), psychiatric or violence concerns, prisoner status, significant confusion, or inability to provide informed consent.

Eligible patients in each unit were randomized. Interviewers consecutively approached patients according to their random assignment. If a patient was not available, the interviewer proceeded to the next room. Interviewers returned to rooms of missed patients when possible. Recruitment in the unit ended when the recruitment target for that unit was achieved.

 

 

Interviewers

Five interviewers conducted interviews. One author (KS) provided interviewer training that included didactic instruction, observation, feedback, and modeling. Interviewers participated in weekly debriefing sessions. One interviewer speaks Spanish fluently and was able to conduct interviews in Spanish. Translator services were available for the other interviewers.

Interview Process

Interviews were conducted in person while the patients were hospitalized or via telephone 7 - 30 days postdischarge. A patient who had completed an interview while hospitalized was not eligible for a postdischarge telephone interview. Family members or friends present at the time of the interviews could also participate in addition to or in lieu of the patients with the patients’ assent. Interviewers obtained verbal, informed consent at the start of each interview.

The interview domains and sample questions were developed specifically for the current study and are listed in Table 1. The goal of the interview was to elicit the patient’s (or family member’s) perception of their care experiences and their perceptions of the consequences of any problems with their care. The interviewer sought to obtain sufficient detail to understand the patient’s concerns and to determine what, if any, action might be needed to remediate problems reported by patients. Interviewers captured patient responses by taking detailed notes on a case report form or by directly entering patient responses using a computer or iPad at the time of interview at the discretion of the interviewer.

We defined a patient-perceived breakdown as something that went wrong during the hospitalization according to the patient. If a patient-perceived breakdown in care was identified, the interviewer attempted to resolve the concern. Some breakdowns had occurred in the past, making further resolution impossible (eg, a long wait in the emergency department). Other breakdowns were active and addressable, such as the patient having clinical questions that had not been answered. In such cases, the interviewer attempted to address the patient’s concerns, typically by working with unit nursing staff. For patients interviewed postdischarge, the interviewer worked to resolve ongoing patient concerns with the assistance of the patient safety, quality, and compliance teams as needed. The interviewer provided a brief narrative summary of all interviews to unit nursing leadership within 24 hours. Positive comments were sent to leadership but not captured systematically for research purposes. Further details of the process of responding to patients’ concerns will be reported elsewhere. All data were entered into REDCap to facilitate data management and reporting.15

The MedStar Health Research Institute Institutional Review Board reviewed and approved this study.

Categorizing Patients’ Responses: The Patient Experience Coding Tool

Using directed content analysis,16 we deductively created the Patient Experience Coding Tool (PECT) in order to summarize the narrative information captured during the interviews and categorize patient-perceived breakdowns in care. First, we referred to our prior interviews of patients’ views on breakdowns in cancer care6 and surrogate decision-makers’ views on breakdowns in intensive care units13 to create the initial categories. We then applied the resultant framework to the interviews in the present study and refined the categories. This involved applying the categorization to an initial set of interviews to check the sufficiency of the coding categories. We clarified the scope of each category (ie, what types of events fit under each category) and created additional categories (eg, medication-related problems) to capture patient experiences that were not included in the initial framework.

We then coded each interview using the PECT. A minimum of 2 readers reviewed the narrative notes for each interview. The first reader provided an initial categorization; the second reader reviewed the narrative and confirmed or questioned the initial categorization to improve coding accuracy. If a reader was uncertain about the correct categorization, it was discussed by three readers until an agreement was achieved. Because facilities-related problems (eg, food or parking) fall outside the realm of provider-based hospital care, such comments were not the focus of the outreach efforts and were not consistently recorded. Therefore, they were not included in the PECT and are not reported here.

Analyses

We computed simple, descriptive statistics including the number and percentage of patients identifying at least one breakdown, as well as the number and percent reporting each type of breakdown. We also computed the number and percentage of patients reporting any harm and each type of harm. We computed the percentage of patients reporting at least 1 breakdown by hospital, type of interview (postdischarge vs inpatient), selected patient demographic characteristics (eg, gender, age, education, race), and interviewee (patient vs someone other than the patient interviewed or present during the interview) using the chi-square statistic to test the statistical significance of the resulting differences. All statistical analyses were performed using SPSS version 22.

 

 

RESULTS

A total of 979 outreach interviews were conducted. Of these, 349 were conducted via telephone postdischarge, and 630 were conducted in person during hospitalization. The average interview duration was 8.5 minutes for telephone interviews and 12.2 minutes for in-person interviews. Of the patients approached to participate, 67% completed an interview (61% in person, 83% via telephone). Patient characteristics are summarized in Table 2.

Overall, 386 of 979 interviewees (39.4%) believed they had experienced at least one breakdown in care. The types of patient-perceived breakdowns reported were categorized using the PECT and are summarized in Table 3 and the Figure. The most common concern involved information exchange. Approximately 1 in 10 patients (n = 105, 10.7%) felt that they had not received the information they needed when they needed it. Medication-related concerns were reported by 12.3% (n = 120) of interviewees and predominantly included concerns about what medications were being administered (5.7%) and inadequately treated pain (5.6%). Many of the patients expressing concerns about what medications were administered questioned why they were not receiving their outpatient medications or did not understand why a different medication was being administered, suggesting that many of these instances were related to breakdowns in communication as well. Other relatively common concerns were delays in the admissions process (reported by 9.2% of interviewees), poor team communication (reported by 6.6% of interviewees), healthcare providers with a rude or uncaring manner (reported by 6.3% of interviewees), and problems related to discharge (reported by 5.7% of interviewees).


Of the 386 interviewees who perceived a breakdown in care, 140 (36.3%) perceived harm associated with the event (Table 3). The most common harms were physical (eg, pain; n = 66) and emotional (eg, distress, worry; n = 60). In addition, patients reported instances of damage to relationships with providers (n = 28) resulting in a loss of trust, with participants citing breakdowns as a reason for not coming back to a particular hospital or provider. In other cases, patients believed that breakdowns in care resulted in the need for additional care or a prolonged hospital stay.

We found no difference between the 2 hospitals where the study was conducted in the percentage of interviewees reporting at least 1 breakdown (39.1% vs 39.9%, P = 0.80). We also found no difference between interview method, (ie, in person vs telephone; 40.6% vs 37.2%, respectively, P = 0.30), patient gender (40.6% and 38.8% for men and women, respectively, P = 0.57), race (41.0% and 36.8% for white and black or African-American, respectively, P = 0.20) or between interviewers (P = 0.37). We did identify differences in rates of reporting at least 1 breakdown in care related to age (45.4% of patients aged 60 years or younger vs 34.5% of patients older than 60 years, P < 0.001) and education (32.7% of patients with a high school education or less vs 46.8% of those with at least some college education, P < 0.001). Patients interviewed alone reported fewer breakdowns than if another person was present during the interview or was interviewed in lieu of the patient (37.8% vs 53.4%, P = 0.002). The rate of reporting breakdowns for patients interviewed alone in the hospital is very similar to the rates of those interviewed via telephone (37.8% vs 37.2%). For most types of breakdowns, there were no differences in reporting for in-person vs postdischarge interviews. Discharge-related problems were more frequently reported among patients interviewed postdischarge (8.9% postdischarge vs 4.0% in person, P = 0.002). Patients interviewed in person were more likely to report problems with information exchange compared to patients interviewed postdischarge (17.6% vs 13.5%, respectively; P = 0.09), although this did not reach statistical significance.

DISCUSSION

Through interviews with nearly 1000 patients, we have found that approximately 4 in 10 hospitalized patients believed they experienced a breakdown in care. Not only are patient-perceived breakdowns in care distressingly common, more than one-third of these events resulted in harm according to the patient. Patients reported a diverse range of breakdowns, including problems related to patient experience, as well as breakdowns in technical aspects of medical care. Collectively, these findings illustrate a striking need to identify and address these frequent and potentially harmful breakdowns.

Our findings are consistent with prior studies in which 20% to 50% of patients identified a problem during hospitalization. For example, Weingart et al. interviewed patients in a single general medical unit and found that 20% experienced an adverse event, near miss, or medical error, while nearly 40% experienced what was defined as a service quality incident.2,12 Of note, both our study and the study by Weingart et al. systematically elicited patients’ perspectives of breakdowns in care with explicit questions about problems or breakdowns in care.2,12 Because patients are often reluctant to speak up about problems in care,without such efforts to actively identify problems, providers and leaders are likely to be unaware of the majority of these concerns.6-8 These findings suggest that hospital-based providers should at least consider routinely asking patients about breakdowns in care to identify and respond to patients’ concerns.

Not only are patient-perceived breakdowns common, more than one-third of patients who experienced a breakdown considered it to be harmful. This suggests that our outreach approach identified predominantly nontrivial concerns. We adopted a broad definition of harm that includes emotional distress, damage to the relationship with providers, and life disruption. This differs from other studies examining patient reports of breakdowns in care, in which harm was restricted to physical injury.1,2 We consider this inclusive definition of harm to be a strength of the present study as it provides the most complete picture of the impact of such events on patients. This approach is supported by other studies demonstrating that patients place great emphasis on the psychological consequences of adverse events.17-19 Thus, it is clear from our work and other studies that nonphysical harm is important and warrants concerted efforts to address.

Patients in our study reported a variety of breakdowns, including breakdowns related to patient experience (eg, communication, relationship with providers) and technical aspects of healthcare delivery (eg, diagnosis, treatment). This is consistent with other studies examining patient perspectives of breakdowns in care. Weingart et al.found that hospitalized patients reported a broad range of problems, including adverse events, medical errors, communication breakdowns, and problems with food.2,12 This variety of events suggests a need for integration between the various hospital groups that handle patient-perceived breakdowns, including bedside providers, risk management, patient relations, patient advocates, and quality and safety groups, in order to provide a coordinated and effective response to the full spectrum of patient-perceived breakdowns in care.

Patients in our study were more likely to report breakdowns related to communication and relationships with providers than those related to technical aspects of care. Similarly, Kuzel et al.found that the most common problems cited by patients in the primary care setting were breakdowns in the clinician-patient relationship and access-related problems.17This is not surprising, as patients are likely to have more direct knowledge about communication and interpersonal relationships than about technical aspects of care.

We identified several factors associated with the likelihood of reporting a breakdown in care. Most strikingly, involving a friend or family member in the interview was strongly associated with reporting a breakdown. Other work has also suggested that patients’ friends and family members are an important source of information about safety concerns.20,21 In addition, several patient characteristics were associated with an increased likelihood of reporting a breakdown, including being younger and better educated. These findings highlight the importance of engaging patients’ friends and families in efforts to elicit patient concerns about healthcare, and they confirm recommendations for patients to bring a friend or family member to healthcare encounters.22 In addition, they illustrate the need to better understand how patient characteristics affect perceptions of breakdowns in care and their willingness to speak up, as this could inform efforts to target outreach to especially vulnerable patients.

A strength of this study is the number of interviews completed (almost 1000), which provides a diverse range of patient views and experiences, as evidenced by the demographic characteristics of participants. Interviews were conducted at two hospitals that differ substantially with regard to populations served, further enhancing the generalizability of our findings. Despite the large number of interviews and diverse patient characteristics, patients were drawn from only 3 units at 2 hospitals, which may limit generalizability.

We did not conduct medical record reviews to validate patients’ reports of problems, which may be viewed as a limitation. While such a comparison would be informative, the intent of the current study was to elicit patients’ perceptions of care, including aspects of care that are not typically captured in the medical record, such as communication. Other studies have demonstrated that patients’ reports of medical errors and adverse events tend to differ from providers’ reports of the same subjects.19,23 Therefore, we considered the patients’ perceptions of care to be a useful endpoint in and of itself. We did not determine the extent to which providers were already aware of patients’ concerns or whether they considered patients’ concerns valid. A related limitation is our inability to determine whether the differences we identified in the rates of breakdown reporting based on patient characteristics reflect differences in willingness to report or differences in experiences. Because we included patients in an MSU, it is possible that breakdowns were related to medical care, surgical care, or both. We did not follow patients longitudinally and therefore only captured harm perceived by a patient at the time of the interview. It is possible that patients may have experienced harm later in their hospitalization or following discharge that was not measured. Lastly, we did not measure interrater reliability of the interview coding and therefore do not present the PECT as a validated instrument. These important questions should be targeted for future study.

 

 

CONCLUSION

When directly asked about their experiences, almost 4 out of 10 hospitalized patients reported a breakdown in their care, many of which were perceived to be harmful. Not all hospitals will have the resources to implement the intensive approach used in this study to elicit patient-perceived breakdowns. Therefore, further work is needed to develop sustainable methods to overcome patients’ reluctance to report breakdowns in care. Engaging patients’ families and friends may be a particularly fruitful strategy. We offer the PECT as a tool that hospitals could use to summarize a variety of sources of patient feedback such as complaints, responses to surveys, and consumer reviews. Hospitals that effectively encourage patients and their family members to speak up about perceived breakdowns will identify many opportunities to address patient concerns, potentially leading to improved patient safety and experience.

References

1. Weissman JS, Schneider EC, Weingart SN, et al. Comparing patient-reported hospital adverse events with medical record review: Do patients know something that hospitals do not? Ann Intern Med. 2008;149(2):100-108. PubMed
2. Weingart SN, Pagovich O, Sands DZ, et al. What can hospitalized patients tell us about adverse events? learning from patient-reported incidents. J Gen Intern Med. 2005;20(9):830-836. PubMed
3. Wetzels R, Wolters R, van Weel C, Wensing M. Mix of methods is needed to identify adverse events in general practice: A prospective observational study. BMC Fam Pract. 2008;9:35. PubMed
4. Friedman SM, Provan D, Moore S, Hanneman K. Errors, near misses and adverse events in the emergency department: What can patients tell us? CJEM. 2008;10(5):421-427. PubMed
5. Iedema R, Allen S, Britton K, Gallagher TH. What do patients and relatives know about problems and failures in care? BMJ Qual Saf. 2012;21(3):198-205. PubMed
6. Mazor KM, Roblin DW, Greene SM, et al. Toward patient-centered cancer care: Patient perceptions of problematic events, impact, and response. J Clin Oncol. 2012;30(15):1784-1790. PubMed
7. Frosch DL, May SG, Rendle KA, Tietbohl C, Elwyn G. Authoritarian physicians and patients’ fear of being labeled ‘difficult’ among key obstacles to shared decision making. Health Aff (Millwood). 2012;31(5):1030-1038. PubMed
8. Entwistle VA, McCaughan D, Watt IS, et al. Speaking up about safety concerns: Multi-setting qualitative study of patients’ views and experiences. Qual Saf Health Care. 2010;19(6):e33. PubMed
9. Tan M, Lang D. Effectiveness of nurse leader rounding and post-discharge telephone calls in patient satisfaction: A systematic review. JBI database of systematic reviews and implementation reports. 2015;13(7):154-176. PubMed
10. Garbutt J, Bose D, McCawley BA, Burroughs T, Medoff G. Soliciting patient complaints to improve performance. Jt Comm J Qual Saf. 2003;29(3):103-112. PubMed
11. Agoritsas T, Bovier PA, Perneger TV. Patient reports of undesirable events during hospitalization. J Gen Intern Med. 2005;20(10):922-928. PubMed
12. Weingart SN, Pagovich O, Sands DZ, et al. Patient-reported service quality on a medicine unit. Int J Qual Health Care. 2006;18(2):95-101. PubMed
13. Fisher KA, Ahmad S, Jackson M, Mazor KM. Surrogate decision makers’ perspectives on preventable breakdowns in care among critically ill patients: A qualitative study. Patient Educ Couns. 2016;99(10):1685-1693. PubMed
14. Halpern MT, Roussel AE, Treiman K, Nerz PA, Hatlie MJ, Sheridan S. Designing consumer reporting systems for patient safety events. Final Report (Prepared by RTI International and Consumers Advancing Patient Safety under Contract No. 290-06-00001-5). AHRQ Publication No. 11-0060-EF. Rockville, MD: Agency for Healthcare Research and Quality; 2011. 
15. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377-381. PubMed
16. Hsieh HF, Shannon SE. Three approaches to qualitative content analysis. Qual Health Res. 2005;15(9):1277-1288. PubMed
17. Kuzel AJ, Woolf SH, Gilchrist VJ, et al. Patient reports of preventable problems and harms in primary health care. Ann Fam Med. 2004;2(4):333-340. PubMed
18. Sokol-Hessner L, Folcarelli PH, Sands KE. Emotional harm from disrespect: The neglected preventable harm. BMJ Qual Saf. 2015;24(9):550-553. PubMed
19. Masso Guijarro P, Aranaz Andres JM, Mira JJ, Perdiguero E, Aibar C. Adverse events in hospitals: The patient’s point of view. Qual Saf Health Care. 2010;19(2):144-147. PubMed
20. Bardach NS, Lyndon A, Asteria-Penaloza R, Goldman LE, Lin GA, Dudley RA. From the closest observers of patient care: A thematic analysis of online narrative reviews of hospitals. BMJ Qual Saf. 2015. PubMed
21. Schneider EC, Ridgely MS, Quigley DD, et al. Developing and testing the health care safety hotline: A prototype consumer reporting system for patient safety events. Final Report (Prepared by RAND Corporation under contract HHSA2902010000171). Rockvelle, MD: Agency for Healthcare Research and Quality; May 2016. 
22. Shekelle PG, Pronovost PJ, Wachter RM, et al. The top patient safety strategies that can be encouraged for adoption now. Ann Intern Med. 2013;158(5 Pt 2):365-368. PubMed
23. Lawton R, O’Hara JK, Sheard L, et al. Can staff and patient perspectives on hospital safety predict harm-free care? an analysis of staff and patient survey data and routinely collected outcomes. BMJ Qual Saf. 2015;24(6):369-376. PubMed

References

1. Weissman JS, Schneider EC, Weingart SN, et al. Comparing patient-reported hospital adverse events with medical record review: Do patients know something that hospitals do not? Ann Intern Med. 2008;149(2):100-108. PubMed
2. Weingart SN, Pagovich O, Sands DZ, et al. What can hospitalized patients tell us about adverse events? learning from patient-reported incidents. J Gen Intern Med. 2005;20(9):830-836. PubMed
3. Wetzels R, Wolters R, van Weel C, Wensing M. Mix of methods is needed to identify adverse events in general practice: A prospective observational study. BMC Fam Pract. 2008;9:35. PubMed
4. Friedman SM, Provan D, Moore S, Hanneman K. Errors, near misses and adverse events in the emergency department: What can patients tell us? CJEM. 2008;10(5):421-427. PubMed
5. Iedema R, Allen S, Britton K, Gallagher TH. What do patients and relatives know about problems and failures in care? BMJ Qual Saf. 2012;21(3):198-205. PubMed
6. Mazor KM, Roblin DW, Greene SM, et al. Toward patient-centered cancer care: Patient perceptions of problematic events, impact, and response. J Clin Oncol. 2012;30(15):1784-1790. PubMed
7. Frosch DL, May SG, Rendle KA, Tietbohl C, Elwyn G. Authoritarian physicians and patients’ fear of being labeled ‘difficult’ among key obstacles to shared decision making. Health Aff (Millwood). 2012;31(5):1030-1038. PubMed
8. Entwistle VA, McCaughan D, Watt IS, et al. Speaking up about safety concerns: Multi-setting qualitative study of patients’ views and experiences. Qual Saf Health Care. 2010;19(6):e33. PubMed
9. Tan M, Lang D. Effectiveness of nurse leader rounding and post-discharge telephone calls in patient satisfaction: A systematic review. JBI database of systematic reviews and implementation reports. 2015;13(7):154-176. PubMed
10. Garbutt J, Bose D, McCawley BA, Burroughs T, Medoff G. Soliciting patient complaints to improve performance. Jt Comm J Qual Saf. 2003;29(3):103-112. PubMed
11. Agoritsas T, Bovier PA, Perneger TV. Patient reports of undesirable events during hospitalization. J Gen Intern Med. 2005;20(10):922-928. PubMed
12. Weingart SN, Pagovich O, Sands DZ, et al. Patient-reported service quality on a medicine unit. Int J Qual Health Care. 2006;18(2):95-101. PubMed
13. Fisher KA, Ahmad S, Jackson M, Mazor KM. Surrogate decision makers’ perspectives on preventable breakdowns in care among critically ill patients: A qualitative study. Patient Educ Couns. 2016;99(10):1685-1693. PubMed
14. Halpern MT, Roussel AE, Treiman K, Nerz PA, Hatlie MJ, Sheridan S. Designing consumer reporting systems for patient safety events. Final Report (Prepared by RTI International and Consumers Advancing Patient Safety under Contract No. 290-06-00001-5). AHRQ Publication No. 11-0060-EF. Rockville, MD: Agency for Healthcare Research and Quality; 2011. 
15. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377-381. PubMed
16. Hsieh HF, Shannon SE. Three approaches to qualitative content analysis. Qual Health Res. 2005;15(9):1277-1288. PubMed
17. Kuzel AJ, Woolf SH, Gilchrist VJ, et al. Patient reports of preventable problems and harms in primary health care. Ann Fam Med. 2004;2(4):333-340. PubMed
18. Sokol-Hessner L, Folcarelli PH, Sands KE. Emotional harm from disrespect: The neglected preventable harm. BMJ Qual Saf. 2015;24(9):550-553. PubMed
19. Masso Guijarro P, Aranaz Andres JM, Mira JJ, Perdiguero E, Aibar C. Adverse events in hospitals: The patient’s point of view. Qual Saf Health Care. 2010;19(2):144-147. PubMed
20. Bardach NS, Lyndon A, Asteria-Penaloza R, Goldman LE, Lin GA, Dudley RA. From the closest observers of patient care: A thematic analysis of online narrative reviews of hospitals. BMJ Qual Saf. 2015. PubMed
21. Schneider EC, Ridgely MS, Quigley DD, et al. Developing and testing the health care safety hotline: A prototype consumer reporting system for patient safety events. Final Report (Prepared by RAND Corporation under contract HHSA2902010000171). Rockvelle, MD: Agency for Healthcare Research and Quality; May 2016. 
22. Shekelle PG, Pronovost PJ, Wachter RM, et al. The top patient safety strategies that can be encouraged for adoption now. Ann Intern Med. 2013;158(5 Pt 2):365-368. PubMed
23. Lawton R, O’Hara JK, Sheard L, et al. Can staff and patient perspectives on hospital safety predict harm-free care? an analysis of staff and patient survey data and routinely collected outcomes. BMJ Qual Saf. 2015;24(6):369-376. PubMed

Issue
Journal of Hospital Medicine 12 (8)
Issue
Journal of Hospital Medicine 12 (8)
Page Number
603-609
Page Number
603-609
Topics
Article Type
Display Headline
We Want to Know: Eliciting Hospitalized Patients’ Perspectives on Breakdowns in Care
Display Headline
We Want to Know: Eliciting Hospitalized Patients’ Perspectives on Breakdowns in Care
Sections
Article Source

© 2017 Society of Hospital Medicine

Disallow All Ads
Correspondence Location
Kimberly A Fisher, Meyers Primary Care Institute, 630 Plantation Street, Worcester, MA 016015; Telephone: 508-791-7392; Email: [email protected]
Content Gating
Open Access (article Unlocked/Open Access)
Alternative CME
Disqus Comments
Default
Use ProPublica
Article PDF Media